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Alms 
Metastasis is a complex multistep process and it is important to elucidate the 
underlying molecular mechanisms in this process. The proposed aim of this study will 
be to identify similarities and/or differences between uveal and cutaneous melanoma. 
Characteristics such as ploidy values and rates of proliferation of cells within the 
primary uveal melanoma will be compared with established clinical and histological 
prognostic criteria. A culture system for uveal melanomas will be developed to allow 
the in vitro study of karyotypic abnormalities. The expression of degradative enzymes 
such as tissue-type plasminogen activator, matrix metalloproteinase-2 and -9 (72 and 
92 kDa gelatinase respectively) will be studied in vitro using a combination of gelatin, 
casein and casein/plasminogen zymography; levels of plasminogen activator 
expression will be quantitated using a chromogenic assay specific for plasminogen 
activators. The expression of these enzymes will be compared with patient status. 
Further studies will be undertaken to derive cutaneous melanoma cell 
subpopulations having different experimental metastatic potentials in congenitally 
athymic nude mice. These cell lines will be analysed in vitro to determine the 
characteristics responsible for the alteration in experimental metastatic potential. The 
effect of host derived factors on melanoma cell cultures will be studied in vitro, 
particularly emphasis will be given to the cytokines TNFa and ll..-l. Their effect upon 
in vivo characteristics will be correlated with changes in melanoma associated 
markers in vitro. 
The role of the cytokines TNFa, TGF~ and IL-l in modulation of cutaneous 
melanoma gelatinase will be analysed to determine synergistic interactions between 
these factors. Comparable studies will be undertaken to determine similarities or 
differences in the control of these enzymes in uveal melanoma. These studies will 
determine the importance of the expression and modulation by host factors of 
gelatinase in the metastatic process. 
Summary 
Cutaneous and uveal melanomas display different patterns of metastatic spread in 
patients. This study has compared these two melanoma types and investigated 
parameters identifiable with the metastatic phenotype. A number of investigations 
were performed, and it was determined that most uveal melanomas were diploid and 
displayed high proliferation rates; high levels of plasminogen activator activity and the 
expression of the 92 kDa gelatinase were associated with tumors most likely to invade 
the sclera and cause metastatic disease. In addition, unique patterns of chromosomal 
alterations were associated with this tumor type. 
Further studies were undertaken using the cutaneous melanoma cell lines, A375 
and its related sub-line A375/NUPRl, which was derived from A375 following 
subcutaneous passage in nude mice. A375/NUPRI showed an increased 
"experimental" metastatic potential in congenitally athymic nude mice, but expressed 
similar levels of a number of melanoma associated markers: MHC class I and II and 
lCAM-l, and a similar proliferation rate in vitro. The 92 kDa gelatinase was found to 
be expressed by A375/NUPRl but not the parental A375 line. Doubling times for 
tumors implanted at subcutaneous and intradermal sites were also similar, as was the 
spontaneous metastatic potential for both cell lines. 
Modulation of these melanoma associated markers by TNFa. and ll...-l showed that 
whilst MHC expression was unaltered. proliferation rates were reduced and lCAM-1 
expression increased by both cytokines on both cell lines, IL-I having the greater 
effect. Induction of 92 kDa gelatinase was observed in both cell lines following 24 
hour incubation with TNFa., but only A375/NUPRI responded to IL-I stimulation. 
The alterations in A375 cell phenotype following TNFa. treatment did not alter the 
experimental metastatic potential of this cell line. 
In depth studies of 92 kDa gelatinase modulation identified synergy between 
TNFa. and TGF~; this was observed in melanoma celllines of both cutaneous and 
uveal origin. 
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CHAPTER 1 
AN INTRODUCTION TO CANCER INVASION 
AND METASTASIS 
1. 1. UVEAL MELANOMA. 
Uveal melanoma is a rare cancer (Deves et al., 1987), but it holds considerable 
interest because of the rapid and unexplained rise in incidence of the related but more 
common melanomas of the skin (Cutler and Young, 1975). Although uncommon in 
the context of general neoplasia, uveal melanomas (those located in the ciliary body 
and choroid), are the most common primary adult intraocular malignancy, they 
frequently metastasize, and approximately half of the patients die from their disease 
within 15 years of enucleation (Egan et al., 1988). Metastatic disease is responsible 
for virtually all tumor-related deaths. However tumor metastatic potential varies; 
some tumors have little or no metastatic capabilities whereas others metastasise 
readily. Once metastases intervene the prognosis is extremely poor with a median 
survival time of six months (Seddon et al., 1983). Despite recent advances in 
treatments, including many directed at preserving the eye, the overall prognosis has 
remained unaltered (Zimmerman and McLean, 1984). The lack of an economically 
acceptable culture system that permits the routine in vitro growth of uveal melanomas 
has hindered the study of the basic properties of this tumor type. Albert et al. (1984) 
reported a culture protocol for uveal melanomas involving the use of a fibroblast 
feeder layer and high concentrations of epidermal growth factor (10 J.lg/ml), this 
protocol was prohibitively expensive, we developed a less expensive short term 
culture protocol which to date has a 80% sucess rate, the established cells were 
verified as abnormal by cytogenetic analysis (Sisley et al., 1990). This has given us 
the ability to examine a number of different phenotypic and genotypic parameters 
associated with this tumor type with the aim of both investigating possible new 
prognostic indicators for this malignancy and studying the biology of this tumor type. 
Traditional prognostic indicators for uveal melanoma rely heavily on the assesment 
of the morphological and histological appearances of the tumor. The tumor location 
and size are of prognostic significance. Generally "posterior" uveal melanomas 
located anterior to the equator have a less favorable prognosis than ones located 
posteriorily (Shammas and Blocli, 1977). In addition, large tumors (tumor diameter 
1 
greater than 10 mm) have a less favorable prognosis than small tumors (Shammas 
and Blodi. 1977). Histologically. uveal melanomas may be classified as: spindle cell. 
epithelioid cell or mixed cell tumors. Pure spindle cell tumors generally do not 
metastasise as frequently as epithelioid tumors; the five year survival rate for these 
tumors is approximately 80 %. whereas epithelioid tumors have a survival rate of 
only 40 % (Paul et al., 1962). Calculation of the inverse standard deviation of the 
nucleolar area has been assessed as an indicator of survival (John et al .• 1977). More 
recently flow cytometry has been evaluated as a method of predicting patient survival; 
it has been demonstrated that the presence of a large aneuploid population of cells in 
the tumor may infer a poor prognosis (Meecham and Char, 1986). We have used this 
technique to investigate cell cycle kinetics in fresh uveal melanoma tissue (Rennie et 
al., 1989). 
1. 2. CUTANEOUS MELANOMA. 
The incidence of, and number of deaths due to, malignant cutaneous melanoma are 
rising at a rapid rate. Malignant melanoma accounts for less than 5 % of all cancers 
but it is among the most lethal because of its extremely high metastatic propensity. 
The incidence of cutaneous melanomas, particularly in the sun belt, is increasing 
(Glass and Hoover. 1989). Cutaneous melanoma shows a high frequency of 
metastases to the brain or central nervous system which result in clinical symptoms in 
up to 20 % of patients with melanoma (Amer et al., 1978; Akslen et al., 1987; Mc 
Cready and Balch. 1987). Additionally, skin metastases are observed in more than 
half of melanoma patients (Akslen et al ., 1987). 
1. 3. TUMOR PROGRESSION. 
Neoplasms are heterogeneous and contain sub-populations within them which 
have different metastatic propensities. It is thought that both naturally occuring and 
induced neoplasms may develop from a single transformed cell (Fialkow, 1979; 
Nowell, 1976; Vogel stein et al., 1985). During the course of disease the 
characteristics of the tumor change from a benign into a malignant phenotype. Studies 
by Foulds (1969; 1975) using murine mammary tumors led to the description of this 
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phenomena as 'neoplastic progression' which he defined as 'the acquisition of 
permanent, irreversable qualitative changes in one or more characteristics of a 
neoplasm'; the host influences tumor progression by introducing microenvironmental 
selection pressures (Prehn, 1976). Studies by Fidler and Hart (1981) provided 
evidence that tumors of unicellular origin are capable of developing subpopulations of 
cells with altered metastatic propensities within 6 weeks. This rapid process of tumor 
progression is considered to be due to both the genetic instability of tumor cells and 
the host imposed selection pressures which continually select for clones exhibiting an 
increased ability to grow. 
Analysis of tumor cell karyotypes has shown that cells exhibit increasingly altered 
karyotypes and ploidy values as they progress from benign to malignant neoplasms 
(Yunis, 1983; Nowell, 1989). Therefore as the tumor progresses it should exhibit an 
increased rate of genetic mutation since cellular homeostatic mechanisms are likely to 
become altered or inactivated. Experimental evidence for this was provided by Cifone 
and Fidler (1982) who showed that highly metastatic cells were both phenotypically 
and genotypically more unstable than non-metastatic cells. Furthermore. since tumors 
are composed of a number of subpopulations, which were phenotypically distinct, it 
is to be expected that these subpopulations will interact not only with the host but 
with each other. Miller et al. (1981) were able to show that subpopulations within 
mammary tumors could influence the growth characteristics, immunoreactivity and 
responsiveness to chemotherapy of each other. This idea was developed futher 
(Fidler and Kripke, 1980; Miller and Heppner, 1979) who showed that isolated 
clonal populations behaved differently in polyclonal combinations than in clonal 
isolation. This polyclonal stabilisation of tumor cell subpopulations within a tumor 
would create an equilibrium of these subpopulations, until a host selective pressure 
occured, at which time the clone most able to survive this pressure would eventually 
dominate the tumor and due to genetic instability, would diversify producing sub-
clones which would again reach an eqUilibrium until another selective pressure 
occured and the process was repeated, this is the idea behind Kerbel's clonal 
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dominance theory (Kerbel et al., 1988). If the tumor is continually experiencing 
selective pressures the rate of diversification will be higher than if it were not since 
the selection pressures remove the polyc1onal stabilisation, potentially resulting in 
greater genetic instability and metastatic potential. 
1. 4. CANCER METASTASIS. 
The main problem in cancer treatment is the prevention or destruction of 
metastases. In 1928 Ewing proposed that metastasis formation at regional and distant 
sites is primarily due to lymphatic and circulatory anatomy and the mechanical 
lodgement of malignant cells at the first barrier encountered. Therefore the sites of 
metastasis for a particular tumor are dependent upon its primary site, the properties of 
the surrounding tissues, the locations of mechanical barriers to the passage of 
malignant cells consequently lymph nodes and blood capillaries were considered 
important in determining the location of metastases. Thus, the distribution of 
metastases is related to the lymphatic and circulatory anatomy and to mechanical 
lodgement properties, this hypothesis is referred to as the anatomical-mechanical 
theory of metastasis. 
Two basic hypotheses have been proposed to explain patterns of hematogenous 
metastases (i) the one step or (ii) the multistep process. In a study by Bross et al. 
(1975) 4,278 autopsies were analysed for the pattern of metastases and the multi-step 
process was favoured, these authors suggest that the final site of metastasis involves a 
series of intermediate sites, typically the lung or liver, and subsequent metastatic 
spread occurs by the metastasis of metastases. The process of cancer metastasis 
consists of a series of sequential interrelated steps, each of which can be rate limiting, 
since a failure to complete any single step aborts the process (Poste and Fidler, 1979). 
Therefore the outcome of metastasis depends upon both the tumor cell phenotype and 
the host's reaction to the tumor cell. 
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Metastasis is complex and a scheme of events called "the metastatic cascade", has 
a number of components, these are listed below. 
1) The initial transforming event and growth of the neoplastic cells. 
2) Neovascularisation of the tumor leading to growth greater than 2 mm 
(Folkman, 1984). 
3) Local invasion of the host extracellular matrix by peripheral tumor cells. 
4) Escape of the tumor cell(s) from the primary tumor as either homo or 
heterotypic emboli or single cells, into either the lymphatic system or the vasculature. 
Heterotypic emboli may be formed by tumor cells interacting with lymphocytes. 
macrophages and/or platelets and may be formed either before escape or during 
haematogenous transit. 
5) Survival of the tumor cells in the circulation. 
6) Specific or non-specific arrest in the capillary beds of organs. 
7) Extravasation. 
8) Proliferation within the organ parenchyma completes the process. 
9)Subsequent metastasis of metastases is thought to occur in the same way. 
The formation of multicellular emboli is considered to be an important event in 
determining the site of arrest since passage through lymph nodes and capillaries will 
be increasingly difficult as emboli size increases. The ability of a tumor cell to undergo 
homotypic and heterotypic adhesion during their transport to a distant site is 
potentially important. In addition to homotypic adhesion of tumor cells (Fidler, 1973). 
heterotypic adhesion of circulating malignant cells with platelets (Gasic, 1984), 
lymphocytes (Fidler, 1975), and monocytes (Starkey et al., 1984) can modify blood-
borne arrest of cilculating tumor cells and lead to an increased number of metastases. 
However, this anatomical-mechanical hypothesis of cancer metastasis does not explain 
the unique organ colonisation patterns observed in some cancers, ocular melanoma 
amongst others (Nicolson, 1982). Zeidman and Buss, (1952) demonstrated that 
circulating tumor cells or their multicell emboli were not always arrested in the first 
capillary bed encountered, and that these cells could be deformed and released to 
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recirculate to other organs. Initial attempts to explain metastatic colonisation patterns 
that cannot be due to mechanical lodgement and anatomical considerations, were made 
by Paget (1889) who proposed a "seed and soil" hypothesis. This hypothesis 
proposes that the microenviroment of each organ (the soil) influences the implantation, 
invasion, survival and growth of particular tumor cells (the seeds). Obviously organ 
specific metastasis is dependent upon both tumor and host properties. It is highly 
likely that most malignant diseases spread by a combination of both of these 
mechanisms. In addition to these two theories another explanation for distant 
metastasis put forward by Bross and Blumenson (1976) suggests that organs become 
sequentially involved by a stepwise metastatic spread. Their concept of a metastatic 
cascade considers that metastasis occurs first to a "generalising site" and then further 
dissemination occurs to other sites, whilst this may be the situation in certain cancers 
(Bross and Blumenson, 1976), it may be that during the malignant progression of 
cancers they acquire the capability of colonising additional organ sites even in cancers 
that spread initially to only one distant site; these secondary tumors may therefore be 
composed of unique malignant cell subpopulations capable of metastasising to 
different specific sites (Nicolson, 1982; Nicolson and Poste, 1982). Alternatively, as 
the tumor progresses, the malignant cells may acquire additional properties that allow 
them to colonise many organ sites simultaneously (Nicolson, 1987). 
Since it is not ethical to investigate experimental cancer metastasis in patients, 
animals have been used to a large extent, particularly in mice and other rodents. Tarin 
et al. (1984) have studied site specific metastasis in humans by the introduction of 
peritoneovenous shunts for palliation of malignant ascites. Patients with malignant 
ascites had their ascitic fluid drained into the circulation via the jugular vein. In this 
study it was repOlted that in 15 of the 29 patients studied the shunts did not increase 
the risk of metastasis; in 8 patients, micrometastases were found in extra-abdominal 
organs, mainly the lungs, and in 7 patients, no evidence of tumor colonies could be 
detected other than in the abdomen. These negative fmding are supportive of the seed-
soil hypothesis. 
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1. 4. 2. Experimental Models of Metastasis. 
The development of animal models to study human malignant melanoma may be 
important in understanding of the biology of the disease, especially the metastatic 
properties, both from the point of improving therapeutic regimes and to further the 
understanding of both regional and site specific metastasis. The use of both congenital 
athymic 'nude' and/or 'SCID' (severe combined immunodeficiency) mice has proved 
popular since these immunologically deficient animals allow the growth of 
xenografted human tumor tissue. In nude mice successful growth of fresh tumor 
tissue is rare (Fogh et al., 1979; Neulat-Duga et al., 1984; Philips et al., 1989), 
however s.c. growth of cultured cell lines has been found to occur more frequently 
and occasionally metastasis is observed (Fogh et al., 1977; Sharkey and Fogh, 1979). 
Xenograft growth in nude mice was considered to be inhibited by residual natural 
immunity (Fidler, 1986) and young or immunosuppressed mice have been reported to 
be better hosts for tumor growth and metastasis (Ferrick et a/., 1989). Developing this 
idea, it would be logical that a mouse with a broader immune deficiency would be an 
improved vehicle for these studies, and the use of SCID mice has proved this 
hypothesis. The SCID mouse lacks both functional B- and T- cells due to 
multifunctional rearrangements of immunoglobulin and T-cell receptor genes (Bosma 
et al., 1983; Schuler et al., 1986;). Natural killer cells and macrophages are apparently 
unaffected by the autosomal recessive SCID mutation (Dorshkind et al., 1985; 
Czitrom et aI., 1985; Dorshkind et a/., 1984). Using the scm mouse it has been 
reported that both fresh tumor tissue (Bankert et a/., 1989) and cell lines (Reddy et a/., 
1987; Ghestie et a/., 1990) display improved growth, whilst fresh tumor tissue did 
not metastasise when injected subcutaneously. (Reddy et a/., 1987; Ghestie et a/., 
1990), if the tissue was dissociated a high frequency of spontaneous metastasis was 
observed (Hill et al., 1991). 
Many cancers show characteristic patterns of metastatic spread, and both uveal and 
cutaneous melanoma are no exception. Uveal melanoma shows a high incidence of 
metastasis to the liver (Nicolson, 1982) and cutaneous melanoma to the central 
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nervous system, liver and bowel (Nicolson, 1982). The relevance of experimental 
metastasis to the elucidation of the relative importance of the anatomical-mechanical 
and the seed-soil hypotheses is debatable and may depend upon the tumor system 
under examination and the method of administering the tumor cells. Intravenous 
injection of tumor cells, the experimental metastasis assay, measures only the terminal 
steps of metastasis, whereas, subcutaneous injection of tumor cells and measurement 
of subsequent spontaneous metastasis, although more time consuming, is perhaps a 
more appropriate assay for the metastatic process. 
The seed-soil hypothesis has been studied using organ-specific variant cell lines 
which have been selected from the parent population by showing alterations in their 
sites of metastasis (Nicolson, 1982). Whilst site specific metastasis has been 
explained by tumor cell immune system interactions (Reif, 1978), stimulation of 
proliferation due to organ specific factors (Sargent et al., 1988), or specific adhesion 
to a particular organ endothelium (Tohgo et al., 1986) are essential events in this 
process. Alternatively, adhesion, invasion and proliferation are inhibited at other sites 
within the body, thus the process is one of negative rather than positive selection. 
Bearing these factors in mind it is possible that by using a different species the 
investigator may introduce an error, that of possible mismatch between receptors and 
their ligands across a species barrier. 
1. 4. 3. Lymphatic Metastasis. 
During tumor cell invasion, tumor cells can easily penetrate small lymphatic 
vessels and be passively transported in the lymph to be trapped in the first draining 
lymph node, or they may bypass these regional lymph nodes to form distant nodal 
metastases ("skip metastases"); the lymphatic and vascular systems have numerous 
connections (Fischer and Fischer, 1966), which allow tumor cells to pass from one 
system to the other (Carr, 1983). The role of regional lymph nodes as temporary 
barriers to cell dissemination is an area of controversy (Black et al., 1971; Crile, 
1969). Removal of regional lymph nodes, which are considered to be the first site of 
metastasis, is thought to reduce the chance of tumor cells reaching the circulation and 
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hence spreading to distant organs. In melanoma there is evidence that some patients, 
those with intermediate thickness melanomas (1-4 mm), benefit from elective lymph 
node dissection (Balch et al., 1985). 
1. 4. 4. Vascular Metastasis. 
Although most solid tumors are highly vascular, these tumor vessels are not 
identical to normal vessels in mature tissues. This distinction between tumor and 
normal blood vessels includes differences in the cellular composition of tumor 
vasculature and the basement membrane structure leading to alterations in permeability 
and vessel stability. The vessels that grow in response to a tumor stimulus are 
different from normal capillaries in that they may contain only endothelial cells rather 
than endothelial cells and vascular pericytes; recent evidence indicates that pericytes act 
as a maturation signal that prevents endothelial cell proliferation (Orlidge and 
D'Amore, 1987). The mechanism for this effect involves the expression of activated 
transforming growth factor-I3, a inhibitor of endothelial cell proliferation (Antonelli-
Orlidge et al., 1989). 
As mentioned previously, a solid tumor is angiogenesis-dependent and as such 
there is a prerequisite that the tumor must produce factors which induce angiogenesis 
if it is to grow to a size greater than 2 mm (Folkman, 1984). Angiogenesis is a 
process dependent upon endothelial cell proliferation and migration and is controlled 
by a number of soluble factors and matrix components (Risau, 1990). Tumor cells are 
capable of using several different pathways for the induction of angiogenesis: 
(i) direct synthesis of angiogenic factors by the tumor cell (Klagsbrun et al., 
1986). 
(ii) Production of macrophage chemoattractants to cause migration of macrophages 
to the tumor site and. upon activation, the release of angiogenic activity (polverini and 
Leibovich,1984). 
(iii) Release of vascular permeability factors that cause leakage of of fibrinogen 
from the post capillary venules resulting in the build up of a fibrin gel causing the 
accumulation of a capillary bed due to endothelial migration (Dvorak, 1986). 
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(iv) two or more of the above acting in synergy. 
Endothelial cells produce a variety of extracellular matrix components which form 
a basement membrane. The quantity of basement membrane surrounding new tumor 
blood vessels is less than is found in normal blood vessels, whilst most of the 
basement membrane components are present in reduced quantity, Auspunk et al. 
(1981a and b) have reported that there are changes in the glycosaminoglycan species 
present in the membrane. Tumor vasculature has been reported to have an increased 
permeability relative to normal blood vessels (Underwood and Carr, 1972), which 
may potentiate tumor cell escape from the primary tumor, however, although escape 
from the primary tumor may not pose a major problem to successful metastasis, it may 
be that extravasation of the tumor cell into the organ parenchyma at a distant site 
represents the crucial importance of degradative enzyme expression, since at this stage 
the basement membrane may act as a major obstacle to tissue invasion. 
1. 4. 5. Ceil-Ceil/Matrix Adhesion In Metastasis. 
The ability of a tumor cell to detach from other tumor cells in the primary tumor, 
form homotypic and/or heterotypic emboli, adhere to and migrate through the 
endothelial cell layer and the basement membrane into the organ parenchyma are all 
mediated by cellular adhesion molecules. A number of different families of adhesion 
molecules exist which facilitate interactions between other cells and extracellular 
matrix components (For recent reviews: Albela and Buck, 1990; Lasky, 1991; 
Mecham, 1991; Humphries, 1990). Briefly, the major families of adhesion receptors 
are: 
(i) the integrins, are calcium dependent heterodimeric molecules assembled from a. 
and (3 subunits; 12 a. and 7(3 chains are currently known which are capable of 
mediating cell-cell and cell-matrix interactions. 
(ii) the immunoglobulin superfamily of receptors which are primarily involved in 
cell-cell interactions. 
(iii) the cadherins, a developmentally regulated family of calcium dependent 
receptors involved in cell-cell interactions. 
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(iv) the selectins or LOC-CAMs a family of receptors, containing lectin, EGF and 
komplement binding protein-like domains involved in endothelial leukocyte adhesion. 
(v) lymphocyte homing receptors. 
1. 5. EXTRACELLULAR MATRIX: COMPOSITION AND 
STRUCTURE. 
1. 5. 2. Interstitial Connective Tissue. 
Single tumor cells or groups of cells must separate from the primary tumor mass 
in order to form metastatic colonies at anatomically distant sites. As tumors progress 
toward malignancy, the surrounding extracellular matrix is slowly degraded and the 
strength of the adhesive interactions between tumor cells is diminished. As enzymatic 
destruction of the extracellular matrix continues (Goldfarb and Liotta, 1986), 
migratory tumor cells may effectively traverse tissue barriers, and increased interstitial 
pressures within the tumor may also facilitate tumor expansion into adjacent tissues 
and into blood vessels within the tumor. 
The components of these barriers will now be discussed, their physiological 
functions described and their relative resistances to degradation commented upon prior 
to a detailed description of two groups of enzymes thought to be important in tissue 
invasion. 
1. 5. 3. Collagen type I. 
Fourteen types of collagen have been reported to date (Mayne and Burgeson, 
1987~ van der Rest and Garrone, 1990). Collagen is the most abundant protein of the 
matrix and may account for up to 90% of the dermis, bone or submucosa. The 
collagens may be divided into two groups, the fibrillar collagens and the non-fibrillar 
collagens (Mayne and Burgeson, 1987). Fibrillar collagens consist of at least 5 major 
types, It II, m, V and XI (Miller and Gay, 1987). The triple helical form of type I 
collagen is the prevalent form and is a heterotrimer composed of two identical at (I) 
chains and an a2(I) chain. In addition to the heterotrimer form a homotrimer 
composed of a1(1) chains has been found to be synthesised by cells in culture (Mayne 
et ai., 1975) and in certain tumors (Moro and Smith, 1977).The chain sequence is 
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composed of a Gly-X-Y repeating triplet (where Xand Y represent amino acids) which 
forms a left handed helix. Each of the 3 chains revolves around a common central axis 
in a right handed superhelix (Mayne and Burgeson, 1987). 
The triple helical region of the fibrillar collagens is highly resistant to proteolysis. 
At neutral pH the major collagen degrading enzymes are the interstitial collagenases 
(MMP-l and 8) (Woessner, 1991). A collagenase is defined as an enzyme capable of 
cleaving the collagen triple helix at approximately the 3/4:1/4 locus between the NH2 
and COOH termini of the molecule. This releases two fragments the 3/4 (TCA) and the 
1/4 (TCB) components which are unstable at 370C and denature into gelatin (Barrett, 
1979); this gelatin is then further degraded by a number of enzymes (Werb, 1990). 
Interestingly, although there are many reports of interstitial collagenase correlating 
with the invasive ability of tumor cells (Woolley, 1984). Greater than 95 % of all 
interstitial collagens are found in a fiber structure which is resistant to degradation by 
interstitial collagenases (Weiss et al., 1980; Barrett, 1981). This structure is both 
highly stable and bound to proteoglycans, hyaluronate and other glycoproteins 
forming a structure extremely resistant to degradation. Barrett (1981) suggested that 
broad specificity enzymes like plasmin, elastase, stromelysin and cathepsins are in fact 
responsible for degrading the links between these fibers known as telopeptide regions. 
1. 5. 4. Collagen Type III. 
Collagen type ill has been reported to be found in association with collagen type I 
in distensive tissues, this type of collagen has a homo trimer al (III) (Chung and 
Miller, 1974). In vitro studies using mixtures of collagen types I and m have shown 
an inverse relationship between fibril size and the quantity of type m collagen present 
(Lapiere et al., 1977), suggesting a mechanism for controlling the size and properties 
of of the collagenous component of a fibrous stroma. 
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1. 5. 5. Collagen Type V. 
Collagen type V has been identified in a number of tissues but only as a minor 
component, it has been reported to have a number of structures, both homotrimeric 
and heterotrimeric: al(Vh a2(V), Cll(vh and Cll(V) Cl2(V) a3(V), the synthesis of 
which may be cell type or tissue specific, possibly reflecting its physiological role 
(Miller and Gay, 1987). Although isolated from placenta, it is now known to be 
widely distributed in pericellular zones (Martinez-Hernandez et al., 1982) in 
association with basal lamina (Martinez-Hernandez et al .• 1982) and may have the 
function of linking dissimilar connective tissues. Type V collagen molecules contain 
high amounts of noncollagenous sequences which make the molecule susceptible to 
nonspecific proteolysis. 
1. 5. 6. Flbronectin. 
Fibronectins are a family of closely related glycoproteins, the molecule is a virtual 
homodimer. disulphide-bonded close to the carboxy termini (Petersen et al .• 1989). 
Both chains have molecular weights of approximately 250 kDa, and are composed of 
a number of domains joined by flexible regions. Virtually all the carbohydrate (5 %) is 
present in the collagen binding domain. Differential slicing of the mRNA results in a 
large number of variants from a single gene (Petersen et al .• 1989; Hynes, 1985). the 
soluble forms of fibronectin found in the plasma and in the migration pathways of 
chick embryos (Ffrench-Constant et al .• 1988) appear to have distinctive splicing 
patterns which may influence their functional properties due to the presence or absence 
of specific domains. Fibronectin is both an important cell-binding extracellular matrix 
protein and is also important in the binding of other extracellular matrix components 
such as collagen (Engvall and Ruoslahti, 1977). glycosaminoglycans (Stathakis and 
Mosesson. 1977) and fibrinogen (Edsall et al .• 1947). Much of the work on the cell 
binding properties of fibronectin has involved the study of integrin receptor binding 
sequences in the molecule. Integrins are heterodimeric proteins consisting of an a and 
13 subunit (Review: Albela and Buck, 1990). The integrin receptors may form part of a 
transmembrane linkage between cytoskeletal and extracellular matrix components, 
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evidence for this hypothesis is that the intracellular domains of certain integrins have 
the ability to interact with the microfilament associated protein talin, and the 
extracellular domains interact with fibronectin and other extracellular matrix proteins 
(Horwitz et al., 1986). The presence of fibronectins as basement membrane proteins 
has been an area of debate, since it appears that embryonic or immature basement 
membranes are enriched in fibronectin, and this amount decreases with maturity 
(Gibson et ai., 1983; Abrahamson, 1986; Thiery et ai., 1985). The role of fibronectin 
in the modulation of cell migration is being elucidated and it has been demonstrated 
that both epidermal cell migration (Donaldson and Mahan, 1988) and mesenchymal 
cell migration (Thiery et ai.,1985; Woods and Couchman, 1988) can be promoted by 
fibronectin. 
1. 5. 7. The Basement Membrane. 
In the pathology of tumor invasion the basement membrane is regarded as a major 
barrier to the invasion of nonna! tissues by cancer cells (Burtin et a/., 1982; Liotta et 
a/., 1983), fragmentation of the basement membrane has been correlated with 
invasion, metastasis and prognosis (Daher et al., 1987). Following the early studies 
of Sylven and Bois (1960) there have been numerous reports of a correlation between 
invasive capacity and enzyme expression by cancer cells (Liotta et a/., 1980; Nakajima 
et a/., 1986; Niedbala et a/., 1987) and enzyme inhibitors (Cawston et a/., 1983; 
Halaka et at., 1983). Invasive capacity has been shown to increase with type IV 
collagenase (gelatinase) activity in some studies (Eisenbach et a/., 1985), in others it 
has not (Warburton et al., 1987). 
The basement membrane is a continuous quasi-elastic heteropolymeric mesh-like 
extracellular matrix containing laminin, type IV collagen, heparan sulfate 
proteoglycan, and other minor macromolecules which is produced by epithelial and 
endothelial cells. Thi'i membrane has many functions including cell and tissue 
support, compartmentalisation, providing an interactive surface for cellular regulation 
and molecular sieving (Farquhar, 1981), and many of these functions are dependent 
upon cell attachment to matrix determinants (Timpl, 1989). Heterogeneity of structure 
14 
and function occur in different tissues, in development (Form et ai., 1986), and in 
response to different physiological needs. 
The sheet-like structure, typically between 100-200 nm, is organised 
morphologically into three major zones: 
a) The lamina lucida externa or lamina rara which is an electron lucent region 20-
40 run wide located just below or adjacent to the epithelial or endothelial. 
b )The lamina densa or basal lamina is the middle layer, 20-100 nm wide, which is 
electron dense and contains a meshwork of fibrils. 
c) The lamina lucida interna is an electronlucent region of variable width located at 
the interface between the lamina densa and the underlying connective tissue. 
Epithelial and certain other basement membranes contain filaments (2-8 nm thick) 
which bind the epithelial tonofilament-desmosome complex to the lamina densa. On 
the opposite side of the basement membrane, anchoring fibers with a periodic binding 
pattern, smaller anchoring fibrils, and tubular microfilaments run between the lamina 
densa and the interstitial collagens of the connective tissue stroma. 
1. 5. 8. Collagen Type IV. 
The type IV collagen monomer is derived from three polypeptide chains [(xl (IV)z 
0.2 (IV)], and in contrast to the interstitial collagens is a flexible thread-like molecule 
about 400 nm in contour length and possesing a distinctive globular domain at its 
carboxy terminus. Interuptions in the human 0.1 (IV) and 0.2 (IV) triple helical 
domains coincide to produce 26 irregularly spaced sites that impart the increased 
flexibility to the molecule (Brazel et ai., 1988). The amino terminal 30 nm segment is 
referred to as the 7S domain (Timpl et al., 1981) and homologous COOH-terminal 
segments of the three chains (227-229 amino acid residues), which each possess six 
cysteines, form a disulphide-stabilised globular domain (Weber et al., 1988). Type IV 
collagen can self assemble into a stable three dimensional basement membrane 
network by association at the carboxy termini globules to form linear dimers (Timpl et 
al., 1981), association of four amino-terminal ends to form a 28 nm, end-overlapped 
(7S) domain leading to antiparallel dimeric and trimeric intermediates followed by the 
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stable tetramer structure (yurchenco and Funhmayr, 1986). Finally type IV collagen 
dimers self-interact through lateral association (Yurchenco and Furthmayr, 1984) to 
form the chicken wire structure associated with basement membrane collagen. Type 
IV collagen contains a cell attachment site in the triple helical region of the molecule 
(Timpl, 1989). Type N collagen, presumably due to the interuptions in the helical 
structure, is degraded by a number of proteinases at neutral pH which include 
sttomelysin-l (MMP-3), stromelysin-2 (MMP-lO), PUMP-l (MMP-7) 72 and 92 
kDa gelatinases (MMPs -2 and -9) and plasmin. 
1. 5. 9. Collagen Type VII. 
Type vn procollagen is a 450 nm long monomer with a carboxy-terminal globular 
domain that dime!izes through a disulpbide-linked, 60 nm overlapped, amino terminal 
interaction (Timpl, 1989). The carboxy-terminal domain is proteolytically cleaved after 
alignment of the dimers, which associate to form anchoring fibrils. In epithelial tissues 
these fibrils connect foci of basement membrane components called anchoring 
plaques, which are located within the stroma, to each other and to the lamina dens a of 
the basement membrane (Keene et a/., 1987). This network is thought to anchor the 
basement membrane to the stroma and to stabilise the stroma (Briggaman et a/., 
1971). The ability of type IV collagenase/gelatinase to cleave type VII collagen 
(Seltzer et a/., 1989), and in doing so weaken the integrity of the epidemal-dermal 
junction, could augment the invasive process. This may be the case with basal cell 
carcinoma invasion since the basement membrane integrity is found to be disrupted 
and loss of anchoring fibrils has been observed (Lane et a/., 1985). 
1. 5. 10. Lamlnln. 
Laminin is a glycoprotein found in the extracellular matrix which is known to 
mediate cell attachment, movement, differentiation, and growth (Reviews: Yurchenco 
and Schittny, 1990; Mecham, 1991; Mercurio and Shaw, 1991) 
Laminin is a flexible four-armed glycoprotein with a molecular weight of 
approximately 1000 kDa , it consists of three short arms (220 kDa) and one long arm 
(440 kDa) (Engel et a/., 1981), which are linked via disulphide bonds to form the 
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characteristic asymmetric cross-structure as seen by electron microscopy. Laminin 
posseses a number of sites which mediate its interactions with cells and other 
extracellular matrix molecules. During tumor metastasis it is necessary for tumor cells 
to cross the basement membrane; an important step in this process may be attachment 
to the basement membrane via cell-surface receptors for laminin. The first to be 
identified was a 65 to 70 kDa protein that bound to laminin with high affinity. The 
expression of this receptor was first found on tumor cells (Rao et ai., 1983; Malinoff 
and Wicha, 1983), and later on a wide variety of cell types (Reviews: Mercurio and 
Shaw, 1991; Mecham, 1991). An amino acid sequence which can act as a binding site 
for the 67 kDa receptor is present in the B 1 chain and has the peptide sequence 
YIGSR (Graf et al., 1987). Both the YIGSR sequence and another sequence, 
PDSRG, found in the same region, promote cell attachment, migration and melanoma 
colonisation of the lungs following tail vein injection (Kleinman et al., 1989). Thre~ 
other peptide sequences, VGVAPG, LGTIPG and IKV A V, have been shown to 
induce chemotaxis in the melanoma cell lines, A2058 (VGVAPG and LGTIPG) and 
B16FlO (IKVAV) (Mecham etal., 1989; Tashiro et al., 1989). The 67 kDa receptor 
may also bind to the carbohydrate side chains of the laminin molecule (Arumugham et 
al., 1986; Fujiwara et al., 1988). 
1. 6. TUMOR CELL INVASION. 
Tumor invasion may be considered as the primary step in a multistep process which, 
if successfully co:npleted, leads to the formation of metastases. During the metastatic 
cascade cellular invasion is important in at least three places: 
1) local invasion at the tumor-host interface, allowing enlargement of the tumor. 
2) Escape from the primary tumor into the vasculature or lymphatics 
(intravasation) 
3) Escape from the vasculature due to invasion at a secondary site (extravasation) 
The extracellular matrix, which is probably the commonest barrier to invasion, is 
comprised of the connective tissue stroma and the basement membrane. Tumor cell 
invasion of the adjacent host tissues may occur by a variety of mechanisms. The first 
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mechanism is dependent on proliferation rate, the actively growing tumor expands 
along the pathway of least resistance; the second mechanism is based on active 
locomotion of tumor cells through the host tissues. In addition to these two basic 
mechanisms, invasion is promoted by the degradation of the tissue through which it 
occurs. The invasive process has been divided into three sequential steps (Liotta, 
1985) (i) tumor cell attachment to the extracellular matrix components laminin and 
fibronectin (ii) lysis of matrix due to the production of hydrolytic enzymes by the 
tumor cells (iii) tumor cell locomotion into the region of lysis modified by proteolysis. 
Later studies have closely linked these three steps and shown the stimulation of 
degradative enzyme production following attachment to laminin (Turpeenniemi-
Hujanen et a/., 1986), and chemotaxis towards degraded extracellular matrix 
components (Tenanova and Lyall, 1986; Mundy et a/., 1981; Nakeshima et a/., 1986) 
and certain proteinases (Terranova et al., 1989). Furthermore, it is possible, if not 
probable, that tumor cells may escape from the primary tumor site during the 
angiogenic process, when extracellular matrix is being degraded and cellular migration 
is stimulated by a number of cytokines and growth factors. This controlled process 
involves the co-ordinated invasion and migration of endothelial cells and is proteinase 
dependent. The similarities between tumor invasion and angiogenesis are reviewed by 
Moscatelli and Rifkin (1988). 
Human cutan'!Ous melanoma invasion is thought to occur by repetitive cycles of 
active locomotiml followed by cessation of movement and proliferation (Suh and 
Weiss, 1984), although little is known about uveal melanoma invasion processes but 
Char et al. (1983) suggest that choroidal melanomas frequently grow rapidly after a 
period of relative Inactivity. 
In relation to the majority of the experimental work presented in this thesis, 
enzymes thought to be involved in the invasive component of the metastatic cascade 
will be discussed in detail. Due to the diversity of the components of the basement 
membrane and the interstitial matrix which may act as barriers to invasion, the 
invading tumor cell may require the expression of an array of degradative enzymes, 
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some highly specific and some with broader substrate specificities, rather than merely 
the expression of a single multifunctional enzyme. Likewise the expression of both 
membrane bound and secreted proteinases may be essential for invasion of certain 
tissues but not for others. A specific set of enzymes may be required for the 
degradation of different tissues, each of which has a unique composition of 
extracellular matrix components. 
1. 7. DEGRADATIVE ENZYMES. 
The enzymes which are typically associated with matrix hydrolysis are proteases 
and glycosidases (Goldfarb and Liotta, 1986). Proteases have been classified into 
exopeptidases (peptidases) and endopeptidases (proteinases) (Review: McDonald, 
1985). Exopeptidases are active upon the amino and carboxy termini of proteins in 
contrast to proteinases which cleave within the protein chain. Exopeptidases are 
classified as amino-, carboxy-, dipeptidyl-, tripeptidyl-, peptidyl di-, tri-, omega-
peptidases. Their direct importance in extracellular matrix invasion is debatable, but 
they are thought to modify peptide regulatory factors involved in tumor growth and 
angiogenesis. They have not been shown to directly degrade the macromolecular 
matrix structure. The enzymes which are primarily involved in degradation of the 
extracellular matrix macromolecules are the proteinases. This group of enzymes has 
been detected at intracellular, cell surface and extracellular locations. Intracellular 
enzymes are frequently found in lysosomes, and these enzymes are active against 
proteins taken up during endocytosis, extracellular enzymes have been detected in 
either soluble or vesicle associated forms. 
There are cWTently four categories of proteinases determined by the catalytic 
mechanism of the active site: aspartic and cysteine proteinases, typically active at acid 
pH, and serine and metalloproteinases, active at neutral and slightly alkaline pH 
(Review: McDonald, 1985). Proteinases are involved in a variety of physiological and 
pathological processes (Table. 1. 1). 
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Table 1. 1. 
Functions of proteinases in physiological processes. 
Emigration of inflammatory cells out of blood vessels, through the basement 
membrane and underlying connective tissue. 
Migration and proliferation of microvascular endothelial cells and fibroblasts during 
neovascularisation. 
Editing of excess matrix components during rapid connective tissue synthesis and 
assembly. 
Removal of obsolete matrix components from migration, signalling and assembly 
pathways. 
Breakdown of connective tissue components coupled to synthesis during tissue 
expansion and growth. 
Destruction of extracellular matrix during inflammation, activation of connective tissue 
cells, and fibrosis. 
Taken from Werb, 1990. 
Some of these actions may have relevance to tumor growth and invasion, for 
example stimulation of endothelial cell migration may augment neovascularisation of 
the tumor and hence increase the growth of the tumor. 
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1. 8. PROTEINASES IN INVASION AND METASTASIS. 
The increased proteolytic activity of malignant cells was noted by Fisher in 1925, 
and its correlation with neoplastic transformation has been extensively studied 
(Reviews: Mullins and Rohrlich, 1983; Dano et al., 1985; Goldfarb and Liotta, 1986). 
Elevated levels of a number of proteinases have been correlated with tumor 
invasiveness. These include plasminogen activators, interstitial collagenase, type IV 
collagenase, cathepsins, and proteoglycanases (Review: Tryggvason et al., 1987). 
Recent studies propose that the following factors are important in the invasive process: 
(i) the localisation of the enzyme at the cell surface, (ii) the synergistic action of two or 
more proteinases working in concert and (iii) the balance of enzyme to inhibitor 
expression. The fIrst of these two concepts will be discussed here and the third will be 
illustrated in the section concerning tissue inhibitors of metalloproteinases (TIMPs). 
Evidence for the fIrst concept was presented by Chen et al. (1984) who grew 
transformed chicken embryo fibroblasts and mouse BALB/c 3T3 cells on radiolabelled 
fibronectin covalently linked to the surface of a gelatin fIlm. The fibronectin was 
found to be degraded only at the points of cell-matrix contact This degradation could 
be inhibited by 1, 10-phenanthroline but not by a number of other proteinase 
inhibitors, subsequently a fibronectin-degrading metalloproteinase was identified in 
membrane fractions from these cells (Chen and Chen, 1987). Additional evidence was 
obtained by Sas et al. (1986), who observed that when a number of tumor cell lines 
were grown on glass coverslips coated with purifIed fIbronectin, laminin. or type IV 
collagen, degradation of the substratum began at the sites of initial cell contact and was 
restricted to the paths of cellular migration. Similar studies by Jones and DeClerk 
(1980) showed that lIT 1080 human fIbrosarcoma cells degraded the extracellular 
matrix produced by rat smooth muscle cells in a similar cell associated manner. In 
addition this group showed that when this extracellular matrix was floated in the 
medium above the cells. no degradation occurred. Studies involving the degradation 
of basement membrane using human breast cancer cells seeded onto endothelial cell-
derived matrix, showed that they degraded both the glycoprotein and collagen 
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components. However, the conditioned medium had no degradative ability 
presumably due to either a catalytic ability of the cell surface or inactivation due to 
inhibitor binding once released from the cell surface (Yee and Shiu, 1986). Further 
studies on invasion using HT 1080 cells showed that during invasion of a 
reconstituted basement membrane, clearing was observed only in the vicinity of 
invading pseudopodia (Kramer et al., 1986). Binding sites for a number of 
degradative enzymes have been identified on the cell surface, urokinase-type 
plasminogen activator (UK) is a prominent example of this phenomena. Following the 
identification of a high affinity cell-surface receptor for UK (Vassalli et al., 1985; 
Stoppelli et al., 1985), this receptor was found on a number of tumor cell types 
(Stoppelli et al., 1986). The receptor allows UK to bind to the cell surface via an 
amino-terminal domain which has partial sequence homology with epidermal growth 
factor (Stoppelli et al., 1985). Tissue-type plasminogen activator (tPA) also has a 
binding site on cultured fibroblasts (Hoal et al., 1983), platelets (Vaughan et al., 
1989) and human umbilical vein endothelial cells (Hajjar et al., 1987). Recently tPA 
has been shown to bind to the man nose receptor which is expressed on macrophages 
and liver sinusoidal cells (Otter et al., 1991), however it is not known if the enzyme 
retains activity when bound as is the case for the UK receptor. 
The cell surface may play an important role in degradation by (i) protecting the 
enzyme from inhibitors due to steric hindrance, (ii) causing bound enzyme to be more 
readily activated and have a higher specific activity than soluble enzymes, (iii) acting 
as a catalyst by bringing the enzyme and its substrate into close proximity and (iv) 
localising the degradative event so as to concentrate upon a small area and tunnel 
through the matrix. 
. 
In contrast the role of secreted enzyme may be equally important since these 
molecules may (i) cause a generalised lysis of large areas of matrix, (ii) bind to 
inhibitors present in the microenviroment in doing so stabilise the enzyme and remove 
inhibitors from the immediate vicinity of the tumor, (iii) locally activate cytokines or 
growth factors (iii) act as chemotactic agents or growth promoting factors in their own 
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right and (iv) bind to the surface of other cells, causing them to gain an altered cellular 
phenotype. 
Metastatic tumor cells produce a variety of degradative enzymes that weaken or 
destroy extracellular matrix molecules (Tryggvason et ai., 1987). In addition to 
enzymes produced by the tumor cells, an advancing front of invasive tumor cells can 
also induce secretion of hydrolytic enzymes from adjacent non-tumor tissue. 
Extracellular matrix destruction at the tumor periphery may be facilitated by 
degradative enzymes produced by host cells, such as neutrophils and monocytes, that 
are attracted to the tumor site (Gabbert, 1985). Tumor angiogenesis may further 
promote matrix degradation because the migrating endothelial cells (Kalebic et a/., 
1982) and co-migrating mast cells (Dabbous et a/., 1986) modify the extracellular 
matrix via the production of hydrolytic enzymes or by the deposition of new matrix 
molecules (Risau and Lemmon, 1988). The extracellular matrix components 
potentially representing barriers to tumor invasion and the proteinases capable of 
degrading them are shown in table 1. 2. 
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Table 1. 2. 
Proteinase susceptibility of selected extracellular matrix proteins. 
Matrix protein 
Interstitial connective tissue 
Collagen type I 
Collagen type ill 
Collagen type V 
Fibronectin 
Elastin 
Basement membrane 
Collagen type IV 
Collagen type VII 
Heparan sulphate proteoglycan 
Laminin 
Denatured collagen (Gelatin) 
Adapted from Werb. 1990. 
MMP Matrix metalloproteinase 
Proteinases 
MMP-l, MMP-8, Cathepsins B and L 
MMP-I, MMP-3, MMP-8, MMP-lO, 
plasmin 
MMP-2,MMP-3,MMP-9.MMP-IO 
MMP-2, MMP-3. MMP-7, MMP-I0. 
Cathepsin G, UK, Plasmin, PMN 
elastase, macrophage elastase, cathepsin 
o 
PMN elastase. macrophage elastase, 
MMP-2. MMP-3 and cathepsin D 
MMP-2. MMP-3. MMP-7, MMP-9, 
MMP-lO, plasmin 
MMP-l,MMP-2 
Mast cell chymase, PMN elastase 
Plasmin, MMP-3 and PMN elastase 
MMP-l, MMP-2. MMP-3. MMP-7, 
MMP-9, MMP-lO, Cathepsins Band L, 
PMN elastase 
In respect to the experimental investigations performed for this thesis two groups 
of enzymes will be introduced in additional detail. these are the metallproteinase family 
also known as the matrixins and the plasminogen activators. tissue-type plasminogen 
activator and urokinase-type plasminogen activator. 
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1. 9. 1. METALLOPROTEINASES AND THEIR NATURAL 
TISSUE INHIBITORS. 
1. 9. 2. Metalloprotelnases. 
Metalloproteinases are a group of enzymes which are involved in both normal 
remodelling processes such as embryonic development, post partum involution of the 
uterus, bone and growth plate remodelling, ovulation, and wound healing and in 
pathological processes including rheumatoid arthritis, tumor invasion and 
periodontitis (Mullins and Rohrlich, 1983). 
Recently, the matrix metalloproteinases, which are commonly referred to as the 
collagenase gene family have had a systematic series of names proposed for them, the 
family has been tentatively renamed the matrixins. The matrixins have been previously 
named on the ability of an enzyme to degrade a single substrate e. g. type IV 
collagenase, collagenase etc, however "type IV collagenase" has the ability to degrade 
a number of substrates. 
The enzymes present in the matrix in family have a number of properties which 
characterise them: 
(i) Dependence on zinc at the catalytic site (Whitham et al., 1986; McKerrow, 
1987; Jongeneel et al., 1989). 
(ii) Secretion in a zymogen form. 
(iii) Activation of the zymogens by proteinases or organomercurials (Review: Van 
Wart and Birkedal-Hansen, 1990). 
(iv) Cleavage of the enzyme during activation which results in a loss of 
approximately 10 kDa (Review: Van Wart and Birkedal-Hansen, 1990). 
(v) homology in the cDNA with interstitial collagenase (Reviews: Docherty and 
Murphy, 1990; Matrisian. 1990). 
(vi) Cleavage of extracellular matrix components by the enzyme. 
(vi) Enzyme activity inhibited by TIMP (Review: Woessner, 1991). 
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The matrixins are systematically named as matrix metalloproteinase n, where n is a 
number, this is typically abbreviated to MMP-l, MMP-2 etc. The matrixin family of 
enzymes is rapidly expanding, however, many matrixins have been characterised in 
only a single laboratory and await confirmation or sequence data. Three such enzymes 
are MMP-4 (Azzo and Woessner, 1986), MMP-6 (Nakano and Scott, 1987) and 
Stromelysin-3 (Basset et al., 1990). The nomenclature, previous names, molecular 
weights of the respective enzymes and the natural substrates of the matrixins (matrix 
metalloproteinases) is shown in table 1. 3. 
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Table 1. 3. 
Nomenclature and natural substrates of the matrix metalloproteinasesa. 
Groups Enzyme names Molecular mass Matrix substrates 
(kDa) 
I Interstitial 52 Deduced Collagen types I, II, 
collagenase III,VII, X 
MMP-1 (57/52) Latent Gelatins 
(EC 3. 4. 24. 7) 
Vertebrate (48)/42 Active 
collagenase 
Fibroblast 24 Modified 
collagenase 
Neutrophil 53 Deduced Collagens I, II, III 
collagenase 
MMP-8 85 Latent 
65 Active 
II 72·kDa 72 Deduced Gelatin type I 
gelatinase 
MMP-2 72 Latent Collagens, IV, V, 
VII,X 
Type IV collagenase 66 Active Fibronectin, elastin 
92·kDa 80 Deduced Gelatins I, V 
gelatinase 
MMP-9 92 Secreted Collagens IV, V 
Type V collagenase 84 Active 
aThis table presents recommended names for the matrixins, together with synonyms. 
The molecular weights are those deduced from eDNA (minus the signal peptide) and 
those of the secreted form (variably glycosylated) and active form (or forms). Minor 
forms are in parentheses. Taken from Woessner, 1991. 
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Table 1. 3 continued. 
Nomenclature and natural substrates of the matrix metalloproteinasesa. 
Group Enzyme names Molecular mass Matrix substrates 
(kDa) 
III Stromelysin 52 Deduced Proteoglycan, link 
protein 
MMP-3 (60)/57 Secreted Fibronectin,laminin 
(EC 3. 4. 24. 17) 
Transin (50)/48 Active Gelatins I, III, IV, 
V 
Proteoglycanase 28 Active Collagens Ill, IV, 
V, IX 
Procollagenase Procollagen 
activator peptides 
Activates 
procollagenase 
Collagenase Weak elastin 
activator protein digestion 
Stromelysin.2 53 Deduced Gelatins I, III, IV, 
V 
MMP-I0 53 Secreted Weak on collagens 
nr, IV, V 
Transin-2 47 Active Activates 
28 Active procollagenase 
Fibronectin 
Uterine 28 Deduced Gelatins I, III, IV, 
metalloproteinase V 
MMP-7 28 Secreted Proteoglycan 
Fibronectin 
Pump-l (21 )/19 Active Activates 
procollagenase 
aThis table presents recommended names for the matrixins, together with synonyms. 
The molecular weights are those deduced from cDNA (minus the signal peptide) and 
those of the secreted form (variably glycosylated) and active form (or forms). Minor 
forms are in parentheses. Taken from Woessner, 1991. 
28 
The matrix metalloproteinases are frequently compared using structural criteria and 
have been divided into a number of domains. MMP-9, the largest matrixin, has 7 
domains (Table 1. 4). The other members have fewer domains, the smallest matrix 
metalloproteinase, MMP-7, having only four domains. The domains are typically: 
(i) a signal peptide of between 17 and 29 amino acids. 
(ii) a propeptide sequence of between 77 and 87 amino acids which is cleaved 
from the enzyme during activation. 
(iii) an amino-terminal latent proteinase typically either 112 or 113 amino acids. 
(iv) a domain with homology to the gelatin binding region of fibronectin present 
only in gelatinase species. 
(v) a putative zinc binding region of between 50 and 60 amino acids. 
(vi) a domain, with homology to a 54 amino acid segment of the a2 (V) collagen 
chain present in o~y the 92 kDa gelatinase. 
(vii) a carboxy-terminal hemopexin-lik:e domain which is typically between 202 
and 213 amino acids and thought to be involved in determining substrate specificity 
(Clark and Cawston. 1989). 
The distribution of these domains in the human enzymes of the matrixin family is 
shown in table 1. 4. 
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Table 1. 4. 
Domain structure of matrixins of human origin. 
The number of amino acids is shown within each domain. Where domains are left 
blank this indicates that the domain is absent in the enzyme. 
MMP Signal Pro- Active Fibro-
peptide peptide enzyme nectin 
9 
2 
1 
3 
7 
19 
29 
19 
17 
17 
87 
80 
80 
82 
77 
Adapted from Woessner, 1991. 
112 
112 
112 
112 
113 
30 
176 
175 
Zinc 
50 
50 
50 
53 
60 
a.2(V) Hemo-
collagen pexin 
53 210 
202 
209 
213 
· 1. 9. 3. Activation of Metalloprotelnases. 
As mentioned earlier the matrixins are secreted in a latent fonn and activated in situ 
by physiological mechanisms which are at present unclear. Two amino acid 
sequences, one in the propeptide (p71 R {; G V IN P D V /L NG) and the other in the 
zinc binding region (V/yl96 A A H E I.JI/F G H S/A LIM G) are highly conserved in 
all 11 enzymes for which the cDNA sequences are available. These two sequences are 
thought to form the "cysteine switch". The current hypotheses put forward to explain 
the activation process involves the "cysteine switch". Activators of the matrixins may 
be separated into four groups (i) proteases (trypsin, autolysis), (ii) conformational 
perturbants (SDS, NaSCN), (iii) reversible sulfhydryl-group modifiers (Hg(II), 
organomercurials), and (iv) irreversible sulfhydryl-group modifiers (oxidants, 
alkylating agents). The high level of conservation of these sequences lead Van-Wart 
and Birkedal-Hansen (1990) to suggest that latency of the matrixins was due to 
complex formation between the propeptide cysteine and the active-site zinc atom and 
that this represents a previously unknown mechanism for the latency of this family of 
enzymes. The complex is thought to both block the active site and exclude water from 
the coordination sphere of the zinc atom. Water has been found to be essential for the 
catalytic activity of zinc hydrolases and is thought to act as a fourth ligand (Vallee and 
Auld, 1990). It is likely that all modes of activation of the matrixin zymogens involve 
diSSociation of this complex and and the replacement of the cysteine ligand by water. 
1. 9. 4. Gelatlnases and Tumor Invasion and Metastasis. 
There is a large body of literature correlating the expression of proteinases with 
tumor invasion a.'ld metastasis. Proteinases such as gelatinases act in synergy with 
interstitial collagenase in the degradation of collagen types I, II and III. Interstitial 
collagenase cleaves these collagens to 3/4 and 1/4 collagen fragments (McCroskery et 
al., 1975; Yamanashi et al., 1973), which are denatured to gelatin at body temperature 
and become susceptible to gelatinolytic proteinases (Netherey and O'Grady, 1989; 
Zucker et al., 1987). The synergistic action of these two groups of enzymes appears 
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to play an important role in the penetration of the connective tissue surrounding the 
tumor. 
The 72 and 92 kDa gelatinases have been reported to share many common features 
including close substrate specificities (Mackay et al., 1990; Murphy et al., 1991). 
Recent studies by Murphy et al., (1991) have determined the relative activities of the 
two gelatinase species against several substrates. The 92 kDa gelatinase was found to 
have a higher activity than 72 kDa gelatinase when type IV collagen was the substrate, 
however, the 72 kDa gelatinase exhibited higher activities against elastin and 
proteoglycan. A study performed by Mackay et al. (1990) using 64 and 92 kDa 
gelatinases purified from tumor conditioned medium demonstrated these enzymes had 
little or no ability to degrade native type IV collagen under conditions reported to 
preserve the tertiary structure of type IV collagen and that degradation of collagen 
types IV and V occurred at the telopeptide region and these workers suggest that these 
enzymes are not true type IV collagenases. 
There are a number of studies which have correlated expression of interstitial 
collagenase and/or gelatinase and the malignant potential of in vitro cultured tumor 
cells (Ballin et al., 1988; Liotta et al., 1980; Nakajima et al., 1987; Yamagata et al., 
1988; Yamagata et al., 1989). Collagenase activity has been correlated with the grade 
of histological differentiation of tumor tissue (Van Der Stappen et al., 1990), extent of 
host tissue invasion (Wid and Frick, 1979) and invasion of lymphatics and veins in 
vivo (Kubochi et al., 1986) by tumor cells. In addition it has been proposed that 
secretion of a 92 kDa species of gelatinase (possibly MMP-9) by carcinoma or 
oncogene transfected cells correlates with increased metastatic potential (Ballin et al., 
1988; Bernhard et aI., 1990; Wilhelm et al., 1989; Yamagata et al., 1988; Yamagata et 
al., 1989). 
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1. 9. 5. Regulation of Metalloprotelnase Production. 
Both the 72 kDa and 92 kDa gelatinase genes contain 13 exons which coincide 
(Huhtala et al., 1990; Huhtala et al., 1991). Whilst the genes for interstitial 
collagenase (Collier et al., 1988), rat stromelysin-l and 2 (transin-l and 2) (Matrisian 
et al., 1986; Breathnach et al., 1987) and 92 kDa gelatinase (Huh tala et al., 1991) are 
of similar size (approx 7-8 kb), the gene for 72 kDa gelatinase is about 27 kb (Huhtala 
et al., 1990). The interstitial collagenase and stromelysin genes contain 10 exons 
(Collier et al., 1988; Matrisian et al., 1986; Breathnach et al., 1987),the exons present 
in these genes correspond with those present in the type IV collagenase genes. The 92 
kDa gelatinase promoter is closely related to those of human interstitial collagenase 
and human stromelysin. The TATA-like sequence (TTAAA) is present in the same 
region in both the human stromelysin (Quinones et al., 1989) and 92 kDa gelatinase 
promoters (Huhtala et al., 1991). Rat (Matrisian et al., 1986) and rabbit (Fini et al., 
1987) stromelysin and human interstitial collagenase (Collier et al., 1988) however 
contain true TATA boxes at these locations (Fini et al., 1987), but the 72 kDa 
gelatinase does not contain a TATA box. In addition the TPA responsive elements 
(TRE) located at -79 to -73 are present in the promoters of human 92 kDa gelatinase, 
rat stromelysin, and both rabbit and human interstitial collagenase but not in the 
human 72 kDa gelatinase promoter. In contrast the 72 kDa gelatinase promoter 
contains two GC consensus sequences (GC boxes), for binding the transcription 
factor Spl, which are not found in the other metalloproteinase promoter sequences 
studied to date. One GC box starts at -89 and the other at -69. 92 kDa gelatinase 
contains only one GC box at -533 to -527. Funhermore, the 72 kDa gelatinase 
promoter contains a potential binding site for the transcription factor AP-2. All 
metalloproteinase promoters studied to date have lacked the presence of a CAA T box. 
Curiously the sequence between positions -131 to -90 in the 92 kDa gelatinase 
promoter consists of alternating C and A residues. In common with the stromelysin. 
urokinase, elastase, interstitial collagenase and c-myc genes (Kerr et al., 1990) there is 
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a FOS-binding sequence (GNNTI'GGNGN) in the promoter of the 92 kDa gelatinase; 
this sequence is not found in the 72 kDa gelatinase promoter. 
1. 9. 6. Oncogene Induction and Adenovirus E1 A Repression 
of Metalloprotelnase Gene Expression. 
Initial studies by Thorgeirsson et al. (1985) showed that ras oncogene transfection 
induced the metastatic phenotype and an increase in type IV collagenolytic activity in 
NIH/3T3 fibroblasts. In further studies by this group, Ballin et al. (1988) 
demonstrated that ras transfection induced a 92 kDa gelatinase in NIH/3T3 fibroblasts 
which is thought to be responsible for the increase in collagenolytic activity. 
Comparable studies by Collier et al. (1988) showed induction of a 65 kDa enzyme 
capable of degrading gelatin and type IV collagen from human bronchial epithelial 
cells transfected with ras. However, more recent studies (Ballin et al., 1991) using N-
nitrosomethylurea induced rat mammary carcinomas found no direct relationship with 
between levels of ras expression and neoplastic changes. The levels of ras expression 
were examined in both primary tumors, metastases and metastatic and nonmetastatic 
tumors and no consistent differences were found. 
In a series of co-transfection experiments Garbisa et al. (1987) correlated type IV 
collagenolytic activity with metastatic ability in rat embryo fibroblasts transformed 
with either c-Ha-ras alone or co-tranfected with c-Ha-ras plus v-myc, and in those co-
transfected with c-Ha-ras and EIA. Cells transfected with c-Ha-ras alone or in 
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combination with v-myc displayed high spontaneous metastatic ability, however, 
When co-transfected with Ad-2 EtA the cells although still highly tumorigenic were 
nonmetastatic and did not express type IV collagenase. 
Related studies by Frisch et al. (1990) demonstrated that following stable 
transfection of HT 1080 with Adenovirus EIA the expression of a number of 
proteinases including 72 kDa type IV collagenase, interstitial collagenase and 
urokinase was repressed, and correlated with decreased invasion of reconstituted 
basement membrane in vitro and a reduction in metastatic potential in vivo. In addition 
phorbol ester tumor promoter induction of interstitial collagenase was found to be 
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blocked in the EIA transfected lIT 1080 cells. Transient transfection ofHT 1080 with 
plasmids containing the 5' flanking regions of either interstitial collagenase or type N 
collagenase linked to the chloramphenicol acetyl transferase (CAT) coding sequenc~ 
demonstrated that gene transcription was repressed, this repression was investigated 
using a TP A responsive element (TRE) driven thymidine kinase promoter and found 
to be due to inhibition of the activator protein-l (AP-l) transcription pathway; this 
effect was not due to repression of the c-jun gene which was found by this group to 
be hypersensitive to TPA induction. TPA modulation occurs via a TRE (Angel et al., 
1987). AP-l, binds to this element. AP-l is the protein complex fonned by the c-jun 
and c-fos oncogene products, JUN is the DNA binding component of this complex, 
the binding of which is enhanced by FOS (Angel et al., 1987; Lee et al., 1987; 
Bohmann et al., 1987; Angel et al., 1988; Chiu et al., 1988; Curran and Franza, 
1988). In contrast, De Groot et al. (1991) demonstrated that in three different cell 
types: P19, JEG-3 and HeLa, EIA induced activity of jun/AP-land that binding of 
junj AP-l to a TRE is induced when E lA is expressed. 
Conca et al. (1991) demonstrated that, using mutant IL-l (Arg127-Gly), 
expression of the immediate early genes c-fos, c-jun and junB following stimulation 
with ll..-1 was not sufficient to lead to the expression of TRE containing genes. The 
PEA3 binding (c-ets) transcription factor which binds immediately upstream of AP-l 
(Gutman and Wasylyk, 1990; Wasylyk et al., 1990) could be regulated by IL-l and 
lead to transcription, alternatively junB has been reported to be capable of negative 
regulation (Chiu et al., 1989). 
Collagenase gene expression is modulated by IL-l (Stephenson et al., 1987), TP A 
(Stephenson et al'., 1987) and TNFa (Dayer et al., 1985). IL-l has been reported to 
induce c-fos, c-myc (Lin and Vilcek, 1987), and c-jun (Conca et al., 1989) expression 
in human foreskin fibroblasts, and ll..-1 together with TNFa could trigger expression 
by similar mechanisms to TP A. 
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1. 9. 7. PEA3 and AP-1 Binding Sites In the Collagenase 
Promoter. 
AP-l has been shown to regulate highly expressed genes present in transformed 
cells such as stromelysin, c-fos and collagenase (reviews: Herrlich and Ponta, 1989; 
Imler and Wasylyk, 1989), NF-lCB (a transcription factor expressed by B cells and 
activated T-cells and involved in regulation of immunoglobulin kappa light chain and 
IL-2a-receptor, (Sen and Baltimore, 1986a; Nabel and Baltimore, 1987» (Leonardo 
and Baltimore, 1989) and PEA3 (Wasylyk, 1989). PEA3, a factor which binds to the 
polyoma virus enhancer (Martin et al., 1988) is induced by serum, TPA and the non-
nuclear oncogenes v-src, Py middle T, Ha-ras, v-mos and v-raf (Wasylyk, 1989). 
Gutman and Wasylyk, (1990) demonstrated that PEA3 binds to the collagenase 
promoter and acts synergistically with AP-l to achieve maximal induction of 
transcription by TPA and several oncogenes. Angel et al. (1987a and b) reported that 
collagenase contains a TPA-responsive element that binds AP-l. Analysis of deletion 
mutants of the collagenase promoter determined the existence of additional inducible 
elements upstream of the AP-l site (Angel et al., 1987a; Schontal et al., 1988), 
Gutman and Wasylyk (1990) showed that the PEA3 and AP-l motifs participate in the 
response of the collagenase promoter to TPA stimulation, thereby delimiting a TPA 
and oncogene responsive unit (TORU). AP-l is essential to confer inducibility, but 
maximal levels of expression can only be obtained with the co-operation of PEA3. 
Ptashne (1988) proposed that two eukaryotic activators can work synergistically, not 
by direct contact, but because they touch a third protein (promiscuous cooperativity). 
NF-lCB may be regulated by similar factors to AP-l suggesting that these factors are 
the nUclear targets of a common pathway. A number of different types of TORU are 
thought to exist: (i) simple. formed by AP-l or NF-lCB alone. (ii) Composite, formed 
by two or more interacting elements. Collagenase promoter is an example of the 
second type formed by AP-l and PEA3. 
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1. 9. 8. Tissue Inhibitors of Metalloprotelnases. 
The activity of the matrixins in tissues is regulated by a family of inhibitors, the 
TIMP family (Cawston, 1986), this family is composed of at least three members, 
TIMP-l (Sellers et al., 1977), TIMP-2 (Stetler-Stevenson et al., 1989) and LIMP 
(Cawston et al., 1990). Another inhibitor IMP is identical to TIMP-2 (Herron et al., 
1986; Stetler-Stevenson et aI., 1989). 
TIMP-l is a glycosylated protein of Me 28,500 that inhibits all activated members 
of the matrixin family. There are 12 highly conserved cysteine residues which form 6 
disulphide bonds, producing the characteristic double domain structure of the 
molecule (Williamson et al., 1990). TIMP-2 is a 21 kDa nonglycosylated protein 
which is about 40% homologous with TIMP-l, however the 6 disulphide bonds are 
conserved as are other important residues, which has lead to the suggestion that they 
may act in a similar manner (Williamson et aI., 1990). 
MMP-9 is secreted as a complex of zymogen with TIMP-l (Wilhelm et al., 1989) 
and MMP-2 is found as a complex with TIMP-2 in the conditioned medium of the 
human melanoma cell line A2038 and bovine aortic endothelial cells, this time as a 
27.5 kDa protein (DeClerk et al., 1989). Both TIMP-l and TIMP-2 bind at a site other 
than the active site and upon activation, both the MMP-2 and MMP-9 can be inhibited 
by binding a second molecule of TIMP-l or TIMP-2 (Goldberg et al., 1989). 
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1. 9. 9. TIMP's and Invasion and Metastasis. 
Further evidence for the role of matrix metalloproteinases in tumor invasion has 
come from studies involving TIMPs. Matrix degradation is thought to occur only 
when activated enzyme levels exceed the levels of inhibitor expression and 
availability. Initial studies demonstrated that both natural and recombinant TIMP-l 
inhibited invasion of the human amniotic membrane and metastasis as determined by 
lung colonisation of the B16 melanoma following tail vein injection (Mignatti et al .• 
1986; Schultz et al .• 1988). amnion invasion by the sarcoma cell line M5076 was 
decreased by adding excess TIMP-l (Thorgeirsson et al .• 1982). rTIMP-l has also 
been shown to reduce lung colonisation by c-Ha-ras-transfected rat embryo fibroblasts 
in nude mice (Alvarez et al., 1990). Studies by Kokha et al. (1989) using antisense 
strand constructs to decrease the level ofTIMP-l mRNA and hence the level ofTIMP-
1 protein so shifting the enzyme to inhibitor ratio towards active enzyme resulted in 
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enhancement of the invasive phenotype. Recent studies by DeClerk et al. (1991) 
reported that rTIMP-2 inhibited invasion of smooth muscle cell multilayers by HT-
1080 cells and ras-transformed rat embryo fibroblasts. Degradation of glycoprotein 
and collagen components of these matrices was also inhibited by rTIMP-2. In addition 
Albini et al. (1991) have reported that exogenous TIMP-2 inhibits invasion in the 
Membrane Invasion Culture System assay. 
1. 10. 1. PLASMINOGEN ACTIVATORS AND PLASMIN. 
Two forms of plasminogen activator have been identified, tissue-type plasminogen 
activator (tPA) and urokinase-type plasminogen activator (UK). These two PAs are 
products from different genes and may be distinguished by a number of biological, 
molecular biological and immunological factors. 
Tissue type plasminogen activator is synthesised as a 72 kDa single chain 
polypeptide that is proteolytically cleaved into a double chain form by a variety of 
proteinases. including plasmin, tissue kallikrein and activated factor X (Ichinose et al., 
1984). Two-chain tPA contains a heavy (40 kDa) and a light (30 kDa) chain linked by 
a single interchain disulfide bond. The heavy chain contains two "kringle regions" a 
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"finger region" which resembles a domain found in fibronectin, a domain with 
homology with epidermal growth factor (Gerard et aI., 1986); the light chain contains 
the active site (Rilken and Groeneveld, 198). The single and two chain forms of tPA 
are equally effective in activating plasminogen (Rijken et al., 1982). The enzymatic 
activity oftPAis greatly enhanced in the presence of fibrin (Ranby, 1982; Hoylaerts et 
al., 1982). It is the formation of a trimolecular complex of fibrin, plasminogen and 
tPA which results in the activation of plasminogen to plasmin (Collen, 1987). tPA is 
directly inhibited by the plasminogen activator inhibitors 1 and 2 (Blasi et al., 1987; 
Medcalf et al., 1988). 
UK and related plasminogen activators compose the second major class of PA, 
urokinase-type PAs. The enzyme is synthesised and secreted as a single chain 
glycoprotein. Single chain UK must undergo a proteolytic cleavage to yield a 
disulphide linked two chain form which displays a high level of activity in comparison 
with the single chain form (Pannell and Grewich, 1987). The two-chain species (54 
kDa) has a similar catalytic domain to t-PA (Gerard et al., 1986), only one kringle 
domain (Gerard et al., 1986) and no finger domain (Collen and Lijnen, 1986). 
Urokinase has a cell binding region (Fibbi et al., 1986; AppeUa et al., 1987) in the 
amino terminus consisting of 18-32 amino acids (Appell a et al., 1987). 
PlaSminogen activators of both higher and lower molecular weights have been 
reported A low molecular weight species (31-33 kDa) of urokinase was sequenced by 
Steffens et al. (1982), which was found to be the product of proteolysis and was 
unable to bind to the cell surface receptor (Vassali et al., 1985); a 110 kDa species has 
been reported to be the product of tP A binding to an inhibitor (Dano et aI., 1985) and 
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a 105 kDa species expressed by thymocytes is possibly a stable enzyme-receptor 
complex (Fulton and Hart, 1980; Fulton and Han, 1981). 
PlaSminogen is a 90 kDa single chain glycoprotein produced in the liver (Raum et 
al., 1980). The native form of plasminogen has an amino-terminal glutamic acid 
which is converted to lysine following digestion by plasmin (Saskela, 1985). Binding 
of plasmin to fibrin and extracellular matrix components has important implications for 
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enzyme activity. Binding of plasminogen to fibrin produces marked stimulation of the 
activation by tP A (Takada et al .• 1989). Binding to the extracellular matrix is saturable 
and reversible (Knudsen et al .• 1986); matrix bound plasminogen is a good substrate 
for activation by tPA or UK. The plasmin formed whilst bound to the matrix is 
protected from the inhibitor (X.2-antiplasmin (Knudsen et aI .• 1986). 
Plasmin is a trypsin like serine protease which is activated following the 
proteolytic cleavage of plasminogen at the Arg 560-Val561 peptide bond (Robbins et 
al .• 1967). In addition to its role in fibrinolysis (Astrup. 1978). plasmin is able to 
degrade a number of extracellular matrix proteins. such as fibronectin. laminin. 
collagen types m. and IV. gelatin and cartilage proteoglycans (Review: Werb. 1990) 
and to activate latent enzymes such as metalloproteinases (Mignatti et al .• 1986). 
1. 10. 2. Plasminogen Activators In Invasion and Metastasis. 
PlaSminogen activators/plasmin have been repeatedly linked with both neoplastic 
growth and tumor cell invasion (Markus. 1988). The activation of plasminogen is 
potentially able to produce large scale extracellular proteolytic activity. since the 
zymogen plasminogen is found at high concentrations (211M) in the body fluids and 
plasmin has a broad range of substrates both protein and proteoglycan in nature; 
proteoglycan degradation involving hydrolysis of the protein portion of the molecule 
(Liotta et al .• 1981). The role of plasminogen activators in matrix invasion is 
potentially three fold: (i) they represent proteinases which convert plasminogen to 
plaSmin, which has a broad range of matrix substrates, (ii) plasmin thus produced can 
act as a catalyst in the activation latent enzymes and (iii) plasmin can act in synergy 
with other active proteinases both to clear protected substrates allowing specific 
enzymes access to their substrates. Studies using HT 1080 showed that inhibition of 
PA activity not only inhibited the lysis of plasmin-sensitive glycoproteins but also 
plaSmin resistant substrates such as elastin and interstitial collagen, highlighting the 
importance of plasmin in the turnover of a number of extracellular matrix components 
(Bogenmann and Jones, 1983; Bergman et al., 1986; Heisel et al., 1983). This 
indirect effect of plasmin on matrix components is perhaps best understood in the 
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activation of interstitial collagenase and subsequent collagen degradation (Paranjpe et 
al., 1980). Furthermore B16 melanoma cell invasion of the amnion basement 
membrane in vitro was blocked by inhibitors of plasmin and collagenase and 
antibodies to collagenase and UK (Mignatti et al., 1986). Involvement of plasminogen 
activators in metastasis has been demonstrated using epidermal carcinoma cells in a 
chick embryo chorioallantoic membrane model of metastasis. The invasion of the 
carcinoma cells through the allantoic membrane and subsequent metastasis to the 
embryonic lung was blocked following injection of antibodies against human 
urokinase into the blood stream of the embryo (Ossowski, and Reich, 1983). Further 
in vivo studies were performed by Ossowski (1988) who showed a requirement for 
plasminogen activators in both amnion invasion and intravasation. Although 
uncommon, UK production has been recently been associated with human melanomas 
which were also shown to produce tPA. Matrix degradation by UK expressing cell 
lines was shown to be mediated by UK rather than tP A. These cell lines were also 
spontaneously metastatic to the lung following s.c. growth (Quax et al., 1991). 
1. 11. Tumor-Host Interactions During Metastasis. 
Malignant tumor tissues frequently contain high proteinase activities, which may 
be dependent upon either tumor derived proteinases or host derived proteinases. The 
level of proteinase activity is dependent upon the balance of enzyme to inhibitor, an 
excess of enzyme compared to inhibitor results in active enzyme conversely an excess 
of inhibitor would lead to an absence of active enzyme. Tumor tissues frequently 
contain host cells, usually fibroblasts, macrophages and monocytes. All these types of 
cells have been reported to be able to express a number of proteinases and inhibitors. 
It is therefore conceivable that in some cases the host cells themselves may playa 
significant role in the degradation of the extracellular matrix during tumor invasion, 
either due to endogenous host cell proteinase or inhibitor expression, stimulation of 
tumor cell proteinase or inhibitor expression due to either soluble intercellular 
communication mediated by cytokines or growth factors or by the expression of 
specific extracellular matrix components capable of affecting tumor cell phenotype. 
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Alternatively tumor cells may stimulate host cell proteinase or inhibitor expression by 
similar mechanisms. The total enzyme: inhibitor balance of both tumor and host cells 
needs to be further established. 
1. 11. 2. Interactions Between Tumor Cells and Leukocytes. 
Polymorphonuclear neutrophils (PMNs) are the most abundant form of circulating 
white blood cell and may play an important role in regulating the viability and 
invasiveness of circulating tumor cells. The effects of PMN s on tumor cells are varied; 
some reduce experimental metastatic potential (Glaves, 1983) whilst others may 
potentiate experimental metastasis (Aeed et al., 1988). PMNs have been shown to 
increase the attachment of rat hepatocarcinoma cells to endothelial cells suggesting that 
they possibly increase the rate at which arrest and extravasation takes place (Orr and 
Warner, 1987). Current scenarios envisage that this phenomena may be due to ICAM-
1: LFA-l interactions which may facilitate metastatic spread to lymph nodes due to 
tumor cell: host cell adhesion and subsequent lymphocyte homing carrying bound 
tumor cells to the regional lymph nodes. 
Intercellular adhesion molecule 1 (lCAM-l) is frequently found on cells of the 
melanocytic lineage, malignantly transformed cells showing a higher incidence of 
expression (Johnson et al., 1989; Natali et al., 1990). The expression of ICAM-l in 
primary lesions from stage 1 melanoma patients has been shown to correlate with 
tumor thickness (Johnson et al., 1989; Natali et al., 1990), which is itself an indicator 
of prognosis. The frequency of expression is higher in metastases than in primary 
lesions, which may indicate a selective process, or alternatively because of the 
modulatory effects of various cytokines, possibly due to immunocyte derived 
cytokines (Matsui et al., 1987; Pober et al., 1986; Dustin et al., 1986; Rothlein et al., 
1986; Dustin et al., 1988; Maio et al., 1988). The high frequency of ICAM-l 
expression in metastases is interesting, since lCAM-l has been shown to be a ligand 
for lymphocyte function antigen-l (LFA-l) in T cell mediated cytotoxicity (Makgoba 
et al., 1988). However, LFA-l, LFA-3 and lCAM-l were reported not to be the 
major adhesion ligands for LAK cell mediated lysis on a series of target tumor cell 
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lines, none of which were melanoma cell lines (Quillet-Mary et al., 1991). Current 
scenarios envisage that this phenomena may be a differentiation dependent event 
reflecting the stage of differentiation of the melanocytes from which the melanoma 
cells originated. Alternatively it may be that ICAM-l: LFA-l interactions facilitate 
metastatic spread to lymph nodes due to tumor cell: host cell adhesion and subsequent 
lymphocyte homing carrying bound tumor cells to the regional lymph nodes. In 
addition, cytokines produced by tumor cells may act to modulate tumor and host cell 
behaviour; for example, recent work has shown that human melanoma cells produce 
IL-l which stimulates their own ICAM-l expression and affects adhesion to 
endothelial cells, This cytokine may also alter leukocyte cell behavior (Burrows et al. 
1991). 
1. 12. CYTOKINES. 
1. 12. 2. Tumor Necrosis Factor Alpha. 
Tumor necrosis factor/cachectin (TNFa) is a polypeptide hormone with a broad 
range of biological activities (Beutler and Cerami, 1987). Initially described as a 
component of the serum of endotoxin-treated mice with the ability to cause necrosis of 
some transplantable tumors (Carswell et al., 1975) it was later found to be capable of 
having a cytostatic or cytocidal effect upon some tumor cells (Williamson et ai" 
1983). In physiological situations it has now been found to be a mediator in the 
processes of host defence, immunity and tissue homeostasis, and is important in the 
pathogenesis of infection, tissue injury and inflammation (Tracey et al., 1989). Tumor 
necrosis factor and cachectin were found to be identical (Caput et ai" 1986; Pennica et 
al., 1985). Active TNFa is composed of 3 subunits, each of which is a 157 amino 
acid peptide (17 kDa). Cleavage of the molecule at the cell surface is thought to be 
essential for the secretion of the molecule. TNFa and the related molecule (30 % 
homology) lymphotoxin (TNFP) bind to the same receptor and share several 
biological activities. TNFa is synthesised by a number of different cell types, 
including monocytes/macrophages, lymphocytes, natural killer cells, glomerular 
mesangial cells, tstrocytes and microglial cells of the brain, and kupffer cells of the 
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liver (Tracey et al., 1989). TNFa does not exist in a stored fonn but is synthesised de 
novo following cell activation. The biosynthesis of TNFa is tightly regulated by 
transcriptional and post-transcriptional mechanisms (Beutler et al., 1986). However, 
Beutler et al. (1986) demonstrated that macrophages contain a pool of TNFa mRNA 
that is not expressed as protein. 
Perhaps the most relevant activities, to this study, ofTNFa are the role it plays in 
inflammation, tissue remodelling and cytotoxicity. TNFa has been shown to be 
involved in the release of other cytokines such as IL-l (Nawroth et al., 1986) and 
TGF~ (pober and Cotran, 1990). IL-l and TNFa have the ability to alter endothelial 
cell phenotype, and activation of these cells results in vascular leakiness by causing a 
structural reorganisation of the endothelial cell layer (Brett et al., 1989). TNFa causes 
increased expression of intercellular adhesion molecules (ICAMs) (Munro et al., 
1989), and the de novo expression of endothelial leukocyte adhesion molecule-l 
(Bevilacqua et al., 1988), together with an increase in the expression of a number of 
other adhesion molecules such as inducible cell adhesion molecule or vascular cell 
adhesion molecule (Osborn et aI., 1989). In addition TNFa. acting in concert with IL-
l and IFNy, alters the proteinase to inhibitor balance, resulting in the degradation of 
basement membrane proteins by endothelial cells (Stolpen et al., 1986). TNFa may 
also be involved more deeply in tissue remodeling since it stimulates bone (Bertolini et 
ai., 1986) and cartilage (Saklatvala, 1986) resorption and inhibits the synthesis of 
proteoglycans (Saklatvala, 1986). Furthermore, TNFa can act as a growth factor, by 
stimulating fibroblast and mesenchymal cell proliferation (Vilcek et aI., 1986) directly, 
and indirectly by stimulating the production of other cytokines that mediate cell 
proliferation and matrix production (Tracey et al., 1989). TNFa may increase the 
mitogenic ,effect of epidermal growth factor by increasing the expression of the cell 
surface receptors for this cytokine (Palombella et al., 1987), and is capable of 
promoting neovascularisation (Frater-Schroder et al., 1987). 
The TNFa receptor is a protein of molecular mass 300 kDa (Creasy et al., 1987) 
composed of two different subunits (Urban et al., 1986). Two different types of 
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TNFa receptor may exist (Imamura et al., 1987), a myeloid cell-type receptor and an 
epithelial cell type receptor (Hohmann et al.. 1989; Yonehara et al .• 1989). Soluble 
forms of the TNFa receptor have been detected in urine (Engelmann et al .• 1990) and 
in sera of cancer patients (Schall et al., 1990). which may be a 'shed' form of the cell 
receptor which could compete with the cell surface receptor in the binding of TNFa 
thus acting as an inhibitor . 
. 1. 12. 3. Transforming Growth Factor Beta. 
The transforming growth factor-(3 family is composed of a minimum of five 
members showing a high degree of homology (Review: Massague. 1988). 
Transforming growth factor (3 is a multifunctional. hormone-like peptide that controls 
cell proliferation and differentiation in several cell lines (Sporn et al.. 1986; Massague. 
1987; Lyons and Moses, 1990). TGF (3 has been found to be expressed by a wide 
variety of cell types (Derynk et al., 1985) and has been detected at high levels in 
platelets (Assoian et al., 1983) and in bone (Seyedin et al., 1985). It is considered to 
, 
be an important factor in embryogenesis. wound healing. and bone remodeling and 
, 
has been shown to induce a tumorigenic phenotype in mesenchymal cells when they 
are co-stimulated with epidermal growth factor (Roberts et al., 1981). The effects of 
TGF-(3 are cell-type specific, it is mitogenic for fibroblasts (Leof et al .• 1986) but 
inhibits the growth of keratinocytes and endothelial cells (Muller et al .• 1987; 
Pietenpol et al., 1990) via the suppression of c-myc expression (Shipley et al., 1985) 
or dephosphorylation of the retinoblastoma gene product (Laiho et al., 1990). TGF-(3 
stimulates wound healing processes (Sporn et al., 1986; Mustoe et al., 1987; Pierce et 
al., 1989), and in vitro it has been shown to increase the synthesis of extracellular 
matrix components, namely, fibronectin (Ignotz et al., 1987; Nickoloff et al., 1988; 
Wikner et al., 1988). type I collagen (Ignotz et al .• 1987) and proteoglycan (Edwards 
et al., 1987) in mesenchymal and epithelial cells. TGF-p is known to inhibit the 
expression proteinases involved in degradation of the extracellular matrix. such as 
plasminogen activators (Laiho et al., 1986), interstitial collagenase (Overall et al., 
1989). stromelysin (Matrisian et al., 1986; Kerr et al., 1988). cathepsin L (Chiang 
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and Nilsen-Hamilton, 1986) and elastase (Redini et al., 1988), and to modulate the 
action of growth factor-induced expression of interstitial collagenase (Edwards et al., 
1987) and stromelysin (Kerr et al., 1990), possibly due to Fos binding (Kerr et al., 
1990). In contrast, TGF-f3 has been reported to increase synthesis of 72 kDa type N 
collagenase in gingival fibroblasts (Overall et al., 1989; Overall et al., 1991) and in 
primary cultures of rat bone cells (Overall et al., 1989) and both the 72 kDa and 92 
kDa type IV collagenase in keratinocytes (Salo et al., 1991) and fibrosarcoma cells 
(Kubota et al., 1991). Furthermore, TGF-f3 has been shown to decrease the level of 
proteinase activity by increasing the expression of TIMP-l (Overall et al., 1989; 
Edwards et al., 1987) and plasminogen activator inhibitor-l (Overall et al., 1989; 
Kubota et al., 1991). 
1. 12. 4. Interleukln 1. 
Interleukin 1 (IL-1) is a pluripotent peptide hormone which is produced by a 
variety of cell types including macrophages (Gery et al., 1972; Blyden and 
Handschumacher, 1977; Lachman et al., 1977; March et al., 1985), lymphoid (Scala 
et al., 1984; Matsushima et al., 1985) and non-lymphoid cells (Sauder et al., 1982; 
Fontana et al., 1982). Two molecular species ofIL-l are known, IL-la and /3 (March 
et al., 1985); IL-l/3 is preferentially produced by human cells and the two species 
share 26% homology and have similar activities operating via the same receptor 
(Maeger, 1990). 
IL-l is both involved in the generation of antigen specific immune responses 
(Mizel, 1989), inflammation and in pathological conditions of excess connective tissue 
degradation, including rheumatoid arthtitis (Henderson et al., 1987). In vitro, IL-l 
stimulated cells synthesise a number of proteinases capable of degrading extracellular 
matrix such as, 92 kDa gelatinase (Wilhelm et al., 1989), plasminogen activators 
(Mochan et al .• 1986) and stromelysin (Quinones et al., 1989). 
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1. 13. CYTOKINE INDUCED TRANSCRIPTION FACTORS. 
Changes in the transcriptional expression of genes in eukaryotic cells in response 
to peptide regulatory factors are mediated through DNA sequences called enhancers 
and promoters. These contain multiple binding sites for sequence-specific DNA-
binding proteins. The occupation of cis-acting elements by trans-acting factors 
determines the transcritional activity of both constitutive and inducible genes.The 
action of certain cytokines has been linked with the modulation of specific DNA-
binding proteins. 
1. 13. 2. Interleukln-1. 
Shirakawa et a/. (1988) and Osborn et a/. (1989) found that IL-1 treatment of 
70Z/3 cells, YT cells or several T -cell lines would induce the activation of NF-lCB, a 
DNA binding protein with specificity for an ll-base pair sequence found in the 
regulatory elements of the genes for the 1C immunoglobulin light chain (Review: 
Lenardo and Baltimore, 1989). IL-1 has also been reported to induce the AP-1 
transcription factor (Muegge et a/., 1989). 
1. 13. 3. Tumor Necrosis Factor a. 
TNFa has been shown to induce the transcription factor AP-1 (Brenner et a/., 
1989) and a NF-lCB-like DNA binding protein (Lowenthal et a/., 1989; Osborn et a/., 
1989). Induction of NF-lCB binding is independent of new protein synthesis and 
involves dissociation ofNF-lCB from a cytosolic complex with an inhibitor (I-lCB) and 
subsequent translocation from the cytoplasm into the nucleus (Baeuerle and Baltimore, 
1988a; 1988b). TNFa stimulates the genes for the transcription factors c-fos (Haliday 
et a/., 1991) and c-jun (Brenner et a/., 1989; Haliday et a/., 1991), and decreases the 
expression of c-myc in HL-60 cells (Robinson-Benion et a/., 1991). 
1. 13.4. Transforming Growth Factor (3. 
Compartively little is known about the tertiary messengers which are regulated by 
TGF(3, although recent work by Robinson-Benion et a/. (1991), found a 
downregulation of c-myc associated with cellular responses to both TGF(3 and TNFa 
treatments. 
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CHAPTER 2 
MATERIALS AND METHODS 
CHAPTER 2. 
MATERIALS AND METHODS. 
2. 1. MATERIALS. 
2. 1. 1. General Laboratory Equipment and Reagents. 
Chemicals. 
All chemicals used in the preparation of solutions, buffers or stains were obtained 
from FSA Laboratory Supplies (Laboratory Grade) unless otherwise stated. 
Glassware. 
Detergent washed pyrex glassware was rinsed in de-ionized water and dried in a hot 
air oven at 800 C followed by sterilisation at 1600 C for 2 hours. 
Plastics and Disposable Equipment. 
Plastic and disposable equipment was purchased from the suppliers listed below: 
Item Supplier 
Bijoux, 10m1 and 30m1 centrifuge tubes S terilin Ltd. 
Disposable filters Schleicher and Schuell. 
10m! and Iml plastic pipettes and 
tissue culture flasks. Costar. 
Syringes and needles, Falcon bottles, 
Flexible microtitre assay plates and 
Tissue culture plates Becton Dickenson Ltd. 
Pico Provials Canberra Packard Ltd. 
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LP3 plastic tubes Luckham Ltd. 
Filter pad Skatron. 
Phosphate Buffered Saline. 
Phosphate Buffered Saline tablets, purchased from Oxoid Ltd., were prepared as 
directed, prior to sterilisation by autoclaving at 15lb/sq in for 15 mins. 
Scintillation Liquid. 
Scintillation liquid was purchased from Merk Ltd. as a stock solution and stored at 
room temperature. 
3 H·Thymldlne. 
3H-Thymidine was purchased from Amersham International Ltd. as a stock solution 
with an activity of 37 MBq/ml and was stored at 4°C. 
Water. 
De-ionized water for rinsing glassware was obtained by passing tap water through an 
Elgastat de-ionizer resulting in a specific conductivity of> 1Q60 hm/cm3. 
Distilled water for all other purposes was purified to a specific conductivity of 5mS by 
reverse osmosis using a Milli-Ro 6 Plus system (Millipore (UK) Ltd.). This distilled 
water was then sterilised by autoclaving at 15 lb/sq in for 15 mins, and for the 
remainder of this study termed simply water. 
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2. 1. 2. Tissue Culture Reagents. 
Stock Solutions, Buffers and Supplements. 
EDT A used to remove adherent tumour cell lines from plastic bottles was 
purchased from BDH made to 0.02 % (W/v) in PBS, autoclaved at 10 lb/sq in for 
10 min and stored at 40C. 
Fetal calf serum, (FCS), purchased from Northumbria Biologicals Ltd. was stored 
at -20°C in 50 ml aliquots. All FCS used throughout this work was heat inactivated at 
56°C for one hour and stored at -200 C until use. 
Fungizone, was purchased from Gibco Chemical Co. was divided into 1 ml 
aliquots and stored at -20°C until use. 
Glucose, purchased from Sigma Chemical Co. and dissolved in sterile water at a 
concentration of 200 gil and stored at -200 C until use. 
L-Glutamine, purchased from Flow Laboratories Ltd., as a 200mM solution and 
was stored at -200 C in 1 ml aliquots. 
New born calf serum, (NBCS), purchased from Life Technologies Ltd.was 
stored at -20°C in 50 ml aliquots. All NBCS used throughout this work was heat 
inactivated at 560 C for one hour and stored at -200 C until used. 
Non-essential amino acids, (NEAA) were purchased from Life Technologies 
Ltd. and stored at 4°C until use. 
PeniCillin, purchased from Glaxo Laboratories Ltd. and dissolved in sterile distilled 
water at a concentration of 100,000 U/ml prior to storage in 2 m1 aliquots at -200 C 
until use. 
so 
Streptomycin, purchased from Glaxo Laboratories Ltd. and dissolved in sterile 
distilled water at a concentration of 100 U/ml prior to storage in 2 m1 aliquots at -200 C 
until use. 
SOdium bicarbonate solution, fmal concentration of 7.5% (w/v) in water and 
sterilised by autoclaving at 10 lb/sq in for 10 min and stored at 40 C until use. 
Thioglycollate broth tablets, purchased from Oxoid Ltd., were prepared as per 
instructions and sterilised by autoclaving at 15 lb/sq in for 18 mins before storage at 
room temperature. 
Trypan blue powder was prepared to a 0.1 % (w/v) solution in PBS, residual, 
undissolved powder was removed by fIltration before sterilisation by autoclaving at 15 
lb/sq in for 15 mins and storage at room temperature. 
Trypsin, purchased from Life Technologies Ltd. as a sterile 2.5 % (v/v) (xlO) 
solution, was diluted to a 0.25 % (v/v) solution with sterile PBS, aliquoted and 
stored frozen at -200 C. 
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Media. 
RPMI 1640 medium, purchased from Life Technologies Ltd. as a 1 x concentrate 
without glutamine, 10 m1 of lrglutamine (200 mM) was added immediately prior to 
use. 
Dulbecco's medium, purchased from Life Technologies Ltd. as 10 x concentrate, 
was prepared as follows: 
Dulbecco's (10 x) 
Water 
Sodium Bicarbonate 
NEAA 
1M NaOH 
lrglutamine 
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50m! 
405m1 
25m! 
5ml 
5ml 
10ml 
Posterior uveal melanoma medium, was composed of the following: Hams Fl2 
basal medium containing I-glutamine. purchased from Sigma chemical Co. Ltd as a Ix 
media was supplemented as follows: 
Hams F12 500 rnl 
FCS 25 rnl 
Donor horse serum 75 rn1 
Glucose 6 rnl of 200 gil stock 
EGF 60 J.1l of 100 J.1g1rnl stock 
Penicillin 0.6 rnl 
Streptomycin 0.6 rnl 
Fungizone 6 rn1 
All media was stored at 40 C until use. 
Sterility Check. 
The sterility of each batch of media was checked before use. 1rnl of medium was used 
to innoculate each of two universals of thioglycollate broth. whereupon they were 
incubated for 1 week at 32 and 370 C respectively after which time the media was 
considered sterile if the broth had remained clear. 
Mycoplasma Test. 
Cell lines were tested for contamination with a mycoplasma tissue culture rapid 
detection system (Laboratory Impex Ltd.) on a regular basis. 
53 
2. 1. 3. Electrophoresis Reagents. 
All reagents were of electrophoresis grade and once prepared were kept at 40C in 
the dark for not longer than 4 weeks, reagents such as ammonium persulphate were 
prepared fresh daily. Water used for electrophoresis applications was of the purest 
grade available. 
2. 1. 4. Cytoklnes and Growth factors. 
Recombinant human interleukin 1 alpha (IL-l a) was a generous gift of 
NIBSC with specific activity of 1xIOS U/mg and Hoffman La Roche with specific 
activity of 2-3x108 U/mg. Dilution with RPMI 1640 medium, 2 % (v/v) BSA to 
lxl06 U/ml occurred prior to storage at -80°C. 
Recombinant human interleukin 2 (IL-2) was a generous gift from the Glaxo 
Institute for Molecular Biology, Geneva, Switzerland with a specific activity of 1.6 x 
106 U/mg and was reconstituted in RPM! 1640 and 0.2 % BSA prior to storage at -
800 c. 
Recombinant human interleukin 4 (IL-4) was generous gift from Sandoz 
Pharmaceuticals Ltd. Basel, Switzerland and was reconstituted in PBS prior to 
storage at - 8()oC. 
Recombinant human interleukin 6 (IL-6) was a generous gift from ICI 
Pharmaceuticals with a specific activity of 4.1x107 U/mg and was reconstituted in 
PBS prior to storage at - 800C. 
Recombinant human interferon alpha (IFNa) was a generous gift from 
Wellcome Foundation Ltd., Beckenham, Kent, England. It was supplied at 6xl07 
U/mg and made up to 1xIOS U/ml in PBS containing 1 % BSA prior to storage at -
800 C. 
Recombinant human interferon gamma (IFNy) was a generous gift from Dr. 
O. R. Adolf, Boehringer-mannheim, Vienna. Purified protein (>99 %, <2.5 EU/mg 
by L.A.L.) derived from Escherichia coli was supplied lyophilised with a specific 
activity of 2xl0' IU/mg. Reconstitution with sterile 0.9 % (w/v) NaCI and dilution to 
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1x106 IU/ml with RPMI 1640, 0.2 % (V/v) BSA, occurred immediately before 
storage in aliquots at -80oC. 
Recombinant human tumor necrosis factor-alpha (TNFa) was a generous 
gift from Strangeways Laboratory, Cambridge. The specific activity was 2.7x108 
U/mg. Dilution with RPMI, 0.2 % (V/v) BSA to lx107 or 1x106 U/ml occurred 
immediately before storage in aliquots at -800 C. Alternatively, recombinant human 
Tumor necrosis factor alpha was a gift from Boehringer-Mannheim, specific activity 
of6x1Q7 U/mg. 
Recombinant human transforming growth factor beta 2 (TGF132)was a 
generous gift from Sandoz pharmaceutical division, Basel, Switzerland with a 
specific activity of 2.8xl04 U/mg 
Epidermal growth factor (EGF) was a generous gift from ICI and was 
reconstituted in water to give a stock solution of 1 mg/ml, aliquotted and stored at -
800C until use. 
Insulin like growth factor 1 (IGF 1) was purchased from Kabi Pharmacia and 
was reconstituted in PBS to give a stock solution of 100 Jlg/ml, aliquotted and stored 
at - 800C until use. 
Insulin like growth factor 2 (IGF 2) was purchased from Kabi Pharmacia and 
reconstituted in 0.5 % acetic acid to give a stock solution of 100 Jlg/ml, aliquotted 
and stored at - 80 Oc until use. 
Platelet derived growth factor (PDGF) was purchased from British 
Biotechnology and was reconstituted in 4 mM HCl + 1 mg/ml BSA to give a stock 
solution of 2 Jlg/ml which was aliquotted and stored at -800c until use. 
Acidic fibroblast growth factor (aFGF) was purchased from British 
Biotechnology with a specific activity of 1-5x107 U/mg and was reconstituted in PBS 
+ 0.1 % BSA, aliquotted and stored at -800C until use. 
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2. 1. 5. Antibodies. 
FITC. Fluorescein-isothiocyanate (FITC)-conjugated goat anti-mouse F(ab'h 
antibodies was purchased from Caltag Laboratories Inc. 100 J.ll of 1/60 dilutions were 
used in MoAb staining tests as determined by titration assays. 
lILA·DR. The monoclonal antibody against class II MIlC antigens was purchased 
from Dakopatts, Denmark, and stored at 4°C. Aliquots of 5 JlI were used in MoAb 
staining tests as determined by titration assays. 
ICAM·l. The monoclonal antibody against lCAM-1 was a generous gift of Dr. 
Nancy Hogg, Imperial Cancer Research Fund Laboratories. 20 JlI aliquots were used 
in MoAb staining tests as determined by titration assays. Aliquots were stored at -
80°C. 
IL·la. Sheep anti IL-1ex polyclonal antibody was a generous gift from NIBSC and 
was aliquotted and stored at· 800c. 
TNFex Goat anti TNFex polyclonal was a generous gift from NIDSC and was 
aliquotted and stored at - 800C. 
W6/32. The monoclonal antibody against class I MHC antigens was a generous gift 
of Dr. Keith Gelsthorpe, Blood Transfusion Centre, Sheffield After titration, aliquots 
of 10 JlI were used in MoAb staining tests. Aliquots were stored at -BOoC. 
2. 1. 6. Maintenance of the Nude Mouse Colony. 
Male and female, 4 to 6 week old, athymic Balb/c nude mice were bred and 
maintained under sterile conditions. Animals were maintained under the guide lines of 
the Home Office. All protocols were reviewed and approved by the Home Office .. 
Mice were fed sterilised rodent chow and tap water ad libitum. 
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_2. 2. METHODS: IN VIVO PROCEDURES . 
. 2. 2. 1. Preparation of Cells for Subcutaneous and 
Intradermal InJection. 
Subconfluent cultures were detached using 0.02 % EDTA, resuspended in 
Dulbecco's medium containing 10 % FCS, centrifuged at 400 g for 6 minutes and 
then resuspended in ice-cold PBS. Cell counts were done using a hemocytometer. 
Cell cultures were used that were >95 % viable as determined by trypan blue 
exclusion. Cells were diluted such that the required number of cells were present in 
100 Jll of ice-cold PBS. Cells were placed on ice until use. 
2. 2. 2. Experimental Metastasis Assay. 
Subconfluent cultures were detached using 0.02 % EDTA, resuspended in 
Dulbecco's medium containing 10 % FCS, centrifuged at 400 g for 6 minutes and 
then resuspended in ice-cold PBS. Cell counts were done using a hemocytometer. 
Cell cultures were used that were >95 % viable as determined by trypan blue 
exclusion. Cells were adjusted to a final concentration of 1x10? cells/ml by the 
addition of ice-cold PBS; mice received 1 x 1 06 viable cells in 0.1 ml in to the lateral tail 
vein. Animals were killed 12 weeks post innoculation by cervical dislocation 
following etherisation and subjected to gross necropsies. Lungs were either fixed in 
neutral buffered formal saline and the extent of lung colonisation determined or 
establishment of cell cultures was attempted. 
2. 2. 3. Spontaneous Metastasis Assay. 
Subconfluent cultures were prepared as described above except that cells were 
titrated prior to subcutaneous injection such that the final number injected was in the 
range lx106-1xl04 in a volume of 0.1 mI. Tumors were resected when they reached 
approximately 0.8 cm2, the wound was sealed either with clips or sutured, invasion of 
the body wall was rare. The animals were then observed for greater than 12 weeks to 
detennine if spontaneous metastasis had occured. Animals were killed by cervical 
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dislocation following etherisation and subjected to gross necropsies. Lungs and 
abdominal organs were visually examined for the presence of tumors. Tumors, if 
detected, were established in vitro as cell cultures 
. 2. 2. 4. In Vivo Growth Kinetic Calculations. 
To determine in vivo growth kinetics, tumors were measured weekly at 
orthogonal angles. Mean tumor diameter was calculated: 
Mean tumor diameter= / (X) (y) 
where X and Y are the diameters (mm) of two orthogonal measurements. 
Doubling time was calculated according to the following equation (Welch et al., 
1991): 
DT = 0·1 (be - to) 
where tx-to is the difference in time (in days) between tumor measurements, and 
diarnx is the mean diameter of the tumor at time= x 
2. 3. IN VITRO PROCEDURES • 
. 2. 3. 1. Cutaneous Melanoma Tissue Culture. 
Human cutaneous melanoma cell lines A37S, DX3, SK23 and LTS.l were a 
generous gift from Dr I. R. Hart (Imperial Cancer Research Fund, London). Cells 
were routinely grown in vented tissue culture flasks (Costar, Cambridge, MA, 
U.S.A) in Dulbecco's medium (Gibco, Paisley, Scotland) supplemented with 10 % 
FCS (Sera-lab, Sussex, England) and no antibiotics at 370 C in a humidified 
incubator (5 % CO2 and 95 % air). 
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2. 3. 2. Establishment of Nude Mouse Metastatic Lesions In 
Vitro. 
Tumor tissue derived from growth in nude mice was processed as follows: the 
tissue was excised; if the tissue was from either a subcutaneous or intradermal tumor, 
it was cut free of the surrounding host tissue, and divided into a number of aliquots; 
typically three, one aliquot was immediately snap frozen in liquid nitrogen vapour, 
another was formalin fIxed and the remaining tissue was placed in sterile PBS prior to 
transport to the tissue culture laboratory. Lung derived colonies were treated in a 
similar manner, however, the quantity of tumor tissue was typically much smaller, 
and in consequence, storage in nitrogen vapour and formalin fIxation was infrequent. 
The lungs as a whole were washed in sterile PBS prior to transport, in PBS, to the 
laboratory. Tumor tissue derived from subcutaneous or intradermal lesions was 
mechanically disaggregated into fragments of Imm3 with scalpels, and seeded onto 75 
cm2 vented tissue culture flasks in Dulbecco's medium containing 20 % FCS and 
antibiotics (streptomycin, penicillin and fungizone). 
Discrete lung lesions were dissected from the lung tissue by a variety of 
techniques. Dependent upon the size of the tumor colony, the neoplasm was excised 
with either a scalpel or picked off with the aid of a sterile needle. Disaggregation of 
. 
the nodule was achieved either by mincing, as described previously, if the tumor was 
relatively large, or by gentle rubbing of the nodule against the growth surface of a 12 
well tissue culture treated plate. Culture were established in Dulbecco's medium 
containing 20 % FCS and antibiotics at 370 C in a humidified incubator (5 % CO2 
and 95 % air). 
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2. 3. 3. Establishment and maintenance of Posterior Uveal 
Melanoma Cell LInes In vitro. 
Human posterior uveal melanoma cell lines were established from fresh biopsy 
tissue as short term cultures. After enucleation. the globe was bisected and samples 
of tumor tissue removed and placed in growth medium. The tumor tissue was minced 
into fragments of Imm3• and digested using a cocktail containing collagenase type II 
(0.025 %). pronase E (0.05 %) and dithiotbreitol (0.5 J.1M) (Sigma. Poole. England) 
for 2 hours at 370 C. The tumor cell suspension was washed twice with growth 
medium and pelleted by centrifugation at 400 g for 6 minutes. The washed cell 
suspension was seeded onto 75 cm2 vented tissue culture flasks in posterior uveal 
melanoma medium and cultured at 370 C in a humidified incubator in an atmosphere 
of 5 % CO2 and 95 % air. 
2. 3. 4. Cytogenetic Analysis of Melanoma Cell Cultures. 
Cell cultures were harvested after 1 to 6 weeks in culture by the addition of 0.05 
mg/ml colcemid for four hours. treated with 0.0375 M KCL for 15 minutes, spun 
down and and fixed immediately with 3: 1 methanol: acetic acid in water. 
Chromosome preparations were made using cold wet slides. Slides were G banded 
using trypsin and stained with Leishmans. Where a single abnormal or extra 
chromosome was observed or a missing chromosome was seen in only two cells. they 
were considered non-clonal and excluded 
2. 3. 5. Coating of Tissue Culture Surfaces with Collagen type 
I. 
Collagen (Sigma Chemical Co.) was added to sterile filtered 0.1 M acetic acid to 
obtain a 0.01 % collagen solution and stirred at room temperature until dissolved, 
typically 3 hours. Culture vessels were coated at concentrations of 5. 10, and 15 
J.l.g/cm2 and allowed to dry for 48 hours at 370 C. The culture surface was rinsed with 
PBS prior to the addition of cells and/or medium. 
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2. 3. 6. Coating of Tissue Culture Surfaces with Collagen type 
IV. 
Collagen (Sigma Chemical Co.) was reconstituted to a concentration of 2 mglml in 
filter sterilised 0.25 % acetic acid and allowed to dissolve overnight with gentle 
stirring at 40 C. Culture vessels were coated at concentrations of 5. 10, and 15 
Jlglcm2 and allowed to dry overnight at 370 C. The culture surface was rinsed with 
PBS prior to the addition of cells and/or medium. 
2. 3. 7. Coating of Tissue Culture Surfaces with Flbronectln. 
Fibronectin (Sigma Chemical Co.) was reconstituted with ice cold sterile water to 
a concentration of 1 mglm1 and allowed to dissolve for 30 minutes at room 
temperature. The fibronectin was diluted with sterile PBS to a final concentration of 1 
mg/ml and used to coat culture vessels at final concentrations of 1, 5, and 10 Jlglcm2 
and allowed to dry at room temperature for 1 hour . 
. 2. 3. 8. Coating of Tissue Culture Surfaces with Lamlnln. 
The laminin (Sigma Chemical Co.) was thawed slowly at 40 C to avoid the 
formation of a gel. Laminin was diluted in PBS to a concentration of 1 mglml and 
used to coat the culture vessel surface at concentrations of 1, 2.5, and 5 Jlglcm2 and 
allowed to dry at room temperature for 1 hour prior to the addition of cells or 
medium. 
2. 3. 9. Collection of Serum Free Melanoma Cell Conditioned 
Medium. 
Human cutaneous and posterior uveal melanoma cells were seeded at a 
concentration of 2xl05 cells/well in 12 well tissue culture plates and cultured either 
overnight or for three days respectively in their usual growth medium. The serum 
containing medium was removed and the cells washed three times with PBS for one 
hour at 370 C and then further cultured in 1ml of serum free medium in the presence or 
absence of cytokines or growth factors; for posterior uveal melanoma cultures serum 
free medium contained neither serum, antibiotics nor EOF. Cell cultures were 
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examined microscopically at both the beginning and the end of the experiment, to 
detennine if the cytokines or growth factors under investigation were affecting the 
cellular morphology, culture appearance, or having a cytotoxic effect on the melanoma 
cell cultures. The serum free culture supernatants were collected and centrifuged at 
15000 g for 5 minutes to pellet any non-adherent cells or cell debris. The supernatants 
were then aliquotted and stored at -800C. As a control the medium which the cytokine 
was reconstituted in was placed in an empty well and incubated under identical 
conditions as the experimental wells, this medium was used as a blank in all 
subsequent analyses . 
. 2. 3. 10. Preparation of Cell Lysates. .i 
Celllysates were prepared by a modification of the method of Murphy et al. 
(1989). Cell extracts in Triton X-100 (Sigma, Poole, England) were prepared to 
examine total cellular enzyme activities. Cell cultures were treated in an identical 
manner, however after removal of the conditioned medium. the cells, lx1()6 per 100 
~l of lysis buffer. were solubilised at 40 C for 30 minutes using lysis buffer (0.1 % 
Triton X-100, 5 mM CaCl2 in 50 mM Tris-HCI buffer pH 7.4), scraped with a 
rubber policeman. and stored at -800C after centrifugation at 15000 g for 5 minutes. 
2. 3. 11. Triton X-114 Phase Separation of Membrane 
Proteins. 
Separation of integral membrane proteins was attempted using the method of 
Bordier (1981). Cell extracts in Triton X -114 (Sigma, Poole. England) were prepared 
as for Triton X-l00 cell extracts, however the cells were incubated in a salted ice bath 
for 30 minutes rather than at 40 C in lysis buffer containing Triton X-114 not Triton 
X-100. The cell lysate. typically 100~, was layered on a 150 ~ cushion of 6 % (w/v) 
sucrose. 10 mM Tris-HCI. pH 7.4. 150 mM NaCI. and 0.06 % Triton X-114 placed 
at the bottom of a 1.5 rnl conical eppendorf tube. The clear sample was incubated for 5 
minutes at 370C. causing clouding of the solution. The tube was centrifuged for 5 
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minutes at 400 g at room temperature in a swinging bucket rotor. Following 
centrifugation the detergent phase was identified as a pellet at the base of the tube. The 
separation was then repeated, following addition of of 0.5 % Triton X-114 to the 
aqueous phase. After dissolution of the Triton X-114 by placement in a salted ice bath 
for 15 minutes the mixture was again overlayed on the sucrose cushion used 
previously and incubated for 5 minutes at 370C and centrifuged as described 
previously. 
The final separation, to extract any remaining lipophilic proteins from the 
remaining aqueous phase, involved rinsing with 2 % Triton X -114 in a separate tube 
without a sucrose cushion. The detergent phase of this extraction was discarded. 
Finally buffer or Triton X-114 was added to the respective detergent and aqueous 
phases to ensure equal volumes, salt and surfactant concentrations. As a control, 
ovalbumin (1 mg/ml), a hydrophilic protein, was extracted in a parallel tube and its 
presence in the detergent and aqueous phases monitored by coomassie brilliant blue R 
250 staining of the gel. 
2. 3. 12. Antibody Inhibition of Cytoklne Mediated Effects. 
To determine the specificity of the cytokine mediated effects on gelatinase 
expression TNFa and IL-1a were preincubated with neutralising antisera to the 
respective cytokines. One neutralising unit of antisera will neutralise 10 units of 
cytokine. Preincubation, of 100 Units of TNFa and IL-1a, with 11 neutralising units 
and 110 neutralising units of specific antiserum for 1 hour at 40C was used to used to 
confirm the role of these cytokines in the biological effects previously demonstrated. 
Controls were the medium which the cytokine was reconstituted in as a blank, 
cytokine alone as a positive control and antisera alone as a negative control. The 
resulting conditioned medium was analysed by zymography for the presence of gelatin 
degradation. 
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2. 3. 13. Concentration of Melanoma Cell Conditioned 
Medium. 
Melanoma cell conditioned medium was concentrated using either Amicon 
centricom centrifugal concentrators or if the volume was greater than 15 m1 with an 
Amicon stirred cell, both membrane types had molecular weight cut off values of 10 
kDa. The conditioned medium was concentrated by following the manufacturers 
instructions. 
2. 3. 14. Zymography. 
Identification of gelatinolytic enzymes expressed by human cutaneous and human 
posterior uveal melanoma cells was performed by electrophoresis of conditioned 
medium or cell lysate in a gelatin containing SDS polyacrylamide gel, followed by 
washing of the gel in a 2 % solution of Triton X-100, incubation in a buffer 
appropriate for enzyme activity for 48 hours and finally staining with either amido 
black 10 B or coomassie brilliant blue R 250, based on the method of Heussen and 
Dowdle (1980). Electrophoresis was carried out by the method of Laemmli (1970) in 
polyacrylamide gels containing Img/ml gelatin. In some experiments casein 
hydrolysate was incorporated into SDS containing polyacrylamide gels. 
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Preliminary experiments determined that degassing of the gels was not required 
for consistently reproducible results and the following gel recipes were used. 
Polyacrylamide resolving mini gel slabs measuring 0.75 x 85 x 45 mm were cast from 
a mixture prepared from stock solutions as follows: 
(i) Acrylamide (29 %) and bisacrylamide (1 %) in water 875 !AI 
(ii) 1.5 M Tris-HCl, pH 8.8, containing 0.4 % SDS 
(iii) Gelatin: 1 % in water 
(iv) Ammonium persulphate: 100 mg/ml in water 
(v)TEMED 
(vi) Water 1400 III 
Volume used for the resolving gel was 3 mI. 
The resolving gels were carefully overlaid with 100 !AI of butanol and allowed to 
polymerise at room temperature. When polymerisation was complete, the butanol was 
removed by washing with water, typically three times, the glass plates were carefully 
dried with blotting paper and a stacking gel with castellated sample wells was cast on 
top of the resolving gel from the following mixture of stock solutions: 
(i) Acrylamide (30 %) and bisacrylamide (1 %) in water 
(ii) 0.5 M Tris-HCI, pH 6.8, containing 0.4 % SDS 
(iii) Ammonium persulphate: 100 mg/ml 
(iv)TEMED 
(v) Water 1730 III 
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Volume used for the stacking gel was 2 mI. 
800 ml of Running buffer (0.25 M Tris, 0.2 M glycine, pH 8.5, 0.1 % SDS) was 
addded to the top and bottom reservoirs of a Biorad Mini Protean II electrophoresis 
tank and 20 J.1l of a mixture of 100 J.11 sample plus 33 J.11 of non-reducing sample 
buffer (0.5 M Tris-HCI, pH 6.8, 10 % SDS, 32 % glycerol, 0.1 % bromophenol 
blue) was loaded in the sample wells. 
Electrophoresis was performed at room temperature at a constant voltage of 200 
V. When the tracking dye front had reached the bottom of the gel (after 36 minutes) 
the gel was removed from its cassette and shaken gently at room temperature for 1 
hour in 50 ml of 2 % Triton X-I 00, and then rinsed three times in 50 ml of 50 mM 
Tris-HCl pH 7.4, containing 200 mM NaCl and 5 mM CaC12 for 5 minutes and 
incubated for 48 hours at 370 C in 50 ml of the same buffer. Gels were fixed and 
stained for 15 minutes in either a solution of 0.1 % amido black or coomassie brilliant 
blue R 250 in 30 % methanol and 10 % acetic acid in H20 and destained in an 
identical solution containing no stain. Gelatinolytic enzymes were detected as 
transparent bands on the blue background of the stained gel (reagents from 
BDH,.Poole, England). 
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Alternatively resolving gels would contain an identical concentration of casein 
hydrolysate in place of gelatin and would be treated in the same manner to determine 
the presence of caseinolytic enzymes. Plasminogen activators could be detected in a 
similar manner, however the gel recipe had the following modifications: 
(i) Acrylamide (30 %) and bisacrylamide (0.8 %) in water 1060 ~l 
(ii) 1.5 M Tris-HCl, pH 8.8, containing 0.4 % SDS 780 JlI 
(iii) Casein 2 % in 0.375 M Tris-HCI, 0.1 % SDS, pH 8.8 350~1 
(iv) Plasminogen: 1mg/ml 
in 0.375 M Tris-HCl, 0.1 % SDS. pH 8.8 20.5 JlI 
(v) Ammonium persulphate: 100 mg/ml in water 30~1 
(vi)TEMED 
(vii) Water 1230 ~l 
Control gels did not contain plasminogen. the volume was made up with 0.375 M 
Tris-HCI. 0.1 % SDS. pH 8.8 buffer. Gels were treated in an identical manner but 
Were incubated in 0.1 M Tris-HCl, pH 8.1 for 48 hours. Differences in band position 
between casein and casein/plasminogen gels could be used to identify plasminogen 
dependent lysis of casein. Reduced molecular weight markers were used to estimate 
apparent molecular weight values for bands of substrate degradation on all types of 
Sustrate gels. 
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The molecular weight marker solution was composed as follows: 
(i) phosphorylase b 300 ~l of a stock solution of 0.5 mg 
reconstituted in 300 J.Ll of 50 % glycerol. 
(ii) bovine serum albumin 
in 500 ~1 of 50 % glycerol. 
(iii) ovalbumin 
in 100 ~l of 50 % glycerol. 
(iv) carbonic anhydrase 
in 100 ~l of 50 % glycerol. 
(v) 60 J.Ll of 50 % glycerol. 
1O~1 of a stock solution of 25 mg reconstituted 
10J.Ll of a stock solution of 5 mg reconstituted 
10 ~1 of a stock solution of 5 mg reconstituted 
(vi) 125 J.Ll of reducing sample buffer 
This gives a fmal protein concentration of 1 mg/ml. 
Reduced standards were boiled for 5 minutes with reducing sample buffer (0.5 M 
Tris-HeI, pH 6.8, 10 % SDS, 32 % glycerol, 0.1 % bromophenol blue containing 2.5 
% mercaptoethanol), 20 J.1l of the reduced standard solution were run on each gel. For 
each sample analysed control serum free medium was run in parallel to ensure that 
bands of degradation were not due to medium contaminants . 
. 2. 3. 15. Activation of Latent Metalloprotelnases using p-
APMA. 
Activation of latent metalloproteinases was achieved using a modification of 
Stetler-Stevenson et al. (1989). Stock solutions of 10 roM para-
aminophenylmercuric acetate (p-APMA) (Sigma, Poole, England) in 0.05 M NaOH 
were prepared fresh daily. Conditioned medium was incubated with a final 
concentration of 1 mM p-APMA for varying times (0-24 h) at 37oC. Control tubes 
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contained the same volume of 0.05 M NaOH as the experimental tubes. Following 
incubation with p-APMA samples and controls were analysed by zymography. 
2. 3. 16. Use of Proteinase Inhibitors. 
Proteinase inhibitors were prepared fresh daily and used as follows: 
(i) Ethylenediaminetetraacetic Acid (EDTA): a stock solution of 100 mM EDTA in 
water was prepared. 5 ml of this solution was added to 40 ml of incubation buffer; the 
pH of the buffer was determined and adjusted to its original pH, the fmal volume was 
adjusted to 50 ml with water. Control gels were incubated in incubation buffer alone. 
(ii) 1, 10 Phenanthroline: a stock solution of 100 mM 1, 10 phenanthroline in 
dimethyl sulphoxide (DMSO) was prepared. 5 ml of this solution was added to 45 ml 
of incubation buffer; and no alteration of pH was observed. Control gels were 
incubated in (i) 50 ml of buffer containing 5 ml of DMSO and (ii) incubation buffer 
alone. 
(iii) Phenylmethylsulfonyl Fluoride (PMSF): a stock solution of 10 mM PMSF in 
isopropanol was prepared. 10 ml of this solution was added to 40 ml of incubation 
buffer, no alteration of pH was observed. Control gels were incubated in (i) 50 ml of 
buffer containing of 10 m1 of isopropanol and (ii) incubation buffer alone. 
(iv) trans-Epoxysuccinyl-L-Ieucylamido-(4-guanidino)butane (E-64): a stock 
solution of 10 mM E-64 in DMSO was prepared 10 ml of this solution was added to 
40 ml of incubation buffer, no alteration of pH was observed. Control gels were 
incubated in (i) 50 ml of buffer containing 10 ml of DMSO and (ii) incubation buffer 
alone. 
(v) N-Ethylmaleimide (Net-Mal): a stock solution of 100 mM N-ethyl maleimide • 
in DMSO was prepared, 10 ml of this solution was added to 40 ml of incubation 
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buffer, no alteration of pH was observed. Control gels were incubated in (i) 50 ml of 
buffer containing 10 ml of DMSO and (ii) incubation buffer alone. 
2. 3. 17. Plasminogen Activator Activity Determination. 
The activity of UK and tP A in conditioned media collected from melanoma cell 
cultures was determined using the chromogenic assay of Leprince et al. (1989). This 
coupled enzyme reaction is reponed to be capable of distinguishing between UK and 
tPA activity, since tPA activity requires the presence of soluble fibrinogen fragments 
for activity (Lee et al., 1988). Step 1 of the assay allows plasmin to be generated from 
plaSminogen due to the action of plaminogen activators, which are active at pH 8.5, 
the pH is decreased to 7.5 in step 2, thereby inhibiting the activity of plasminogen 
activators but promoting the activity of plasmin. Step 2 of the assay allows detection 
of plasmin due to cleavage of the synthetic substrate N aCBZ-I-Lysine thiobenzyl 
ester (Sigma Chemical Co.). The cleaved substrate then acts upon 5,5'-Dithiobis-(2-
nitrobenzoic Acid) (DTNB) (Sigma Chemical Co.) to produce a yellow colour. the 
intensity of which is dependent upon the quantity of DTNB cleaved, which may be 
measured using a spectrophotometer. 
A solution containing 5 J.Ll of sample, 5 J.Ll of 0.4 mg/ml plasminogen (Kabi 
Vitrum), reconstituted in assay buffer (0.1 M Tris-Glycine buffer, pH 8.5 containing 
0.5 mg/ml bovine serum albumin (Sigma, Poole, England» and where appropriate, to 
measure tPA activity, 10 J.LI of fibrinogen fragments (0.5 mg/ml in assay buffer) 
(American diagnostics) was made up to 30 ml with assay buffer and the plates 
incubated for 2 hours at 370 C (Step 1).270 J.LI of a reagent mixture containing 100 
Parts 0.2 M sodium phosphate/sodium chloride pH 7.5, 1 part each of 0.1 % Triton 
X-IOO in water, 22 roM DTNB in 50 roM sodium phosphate (Sigma, Poole, 
England) and 20 mM N aCBZ-I-Lysine thiobenzyl ester in water (Sigma, Poole, 
England) was added to each well and the reaction allowed to proceed for 4 hours at 
370 C (Step 2). Optical density was measured at 405 nm in a Titenek multiscan 
microplate spectrophotometer. 
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Fig. 2. 1. Arrangement of samples for the simultaneous measurement of UK and tPA 
activity on a 96 well plate. 
l 10 111 of fibrinogen fragments 
1 2 3 4 
o 0 0 0 
A B 
5 
o 
_L ___ .A.:N~Q:- SAMPLE 
B-A: TOTAL PA ACTIVITY 
C-A: UK ACTIVITY 
B-C: tPA ACTIVITY 
5u.l of plasminogen 
678 
o 0 0 
C 
15 mIU UK 
9 
o 
Seven samples were measured on the same 96 well plate. 5 ~l of sample is added 
to each of the wells 1-9. The first three wells (A) receive no plasminogen and measure 
plasminogen independent lysis of the substrate due to other proteases present in the 
conditioned medium. The first 6 wells receive fibrinogen fragments and are used for 
the determination of total PA (tPA and UK) activity (B-A). The last six wells receive 
no fibrinogen fragments and the values of wells 7 to 9 (C) minus the values of wells 1 
to 3 (A) represents endogenous UK activity (C-A). TPA activity is the difference 
between total PA activity and UK activity (B-C). The bottom row receives no sample 
(1 to 6) and is used to determine spontaneous hydrolysis of the substrate or 5 mIU of 
UK Which is used as an internal control between plates. 
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PA activities are the mean value of triplicate sample determinations deduced from 
a standard curve titration using UK and tP A standards assayed in triplicate. All 
measurements of standards and samples were perfonned such that PA determinations 
were in the linear range of the standard curve. All reagents were from BDH Chemical 
Co Ltd, Poole, England) unless otherwise stated. Storage of UK and tPA standards, 
plaSminogen, fibrinogen fragments, DTNB and N aCBZ-I-Lysine thiobenzyl ester 
was at -800C prior to assay. All buffers were prepared fresh on the day of use. 
Control wells were set up to measure plasminogen independent lysis of the substrate 
(no plasminogen added) and spontaneous lysis (5 III of assay buffer instead of 
sample). 
2. 3. 18. Proliferation Assays. 
Melanoma cells were seeded onto flat-bottomed 96 well plates in 200 III of 
Dulbecco's medium containing 10 % FCS at a concentration of 4xl04 cells/well, and 
allowed to equilibrate for 24 hours at 370 C in an atmosphere of 5 % CO2 and 95 % 
air. Following two 1 hour washes with PBS at 370C, the cells were incubated in 
serum free medium containing cytokines, either used alone or in combination, for 24 
hours in the conditions described previously. After this initial incubation, the cultures 
were pulsed with 0.5 IlCi 3H-thymidine/well for 4 hours. Cellular 3H-thymidine 
incorporation was determined following the addition of 100 III of concentrated 
trypsin/well for 20 minutes; and harvesting of this suspension onto filter paper using 
a Skatron cell harvester (Skatton, Suffolk, England). The dried filter papers, each 
corresponding to a single well, were counted in scintillation fluid, using a 
betaspecttophotometer (Canberra Packard Ltd., Bedfordshire, England). 
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.2. 3. 19. Flow Cytometrlc Analysis of Cutaneous Melanoma 
Cell Cycle Kinetics. 
The cell cycle kinetics of cutaneous melanoma cell cultures maintained in vitro 
was detennined using a DNA analysis kit (Becton Dickinson Ltd., Oxford, England). 
Alterations in cell cycle kinetics due to cytokine treatment was studied by the 
following method; the cells were detached from their growth surface using 0.02 % 
EDTA, centrifuged at 400 g for 6 minutes to pellet the cells. To a pellet of lxl06 cells, 
300 ~ of solution A (trypsin in citrate stabilizing buffer) was added and incubated for 
15 minutes at room temperature with continous agitation. Step 2 involved the addition 
of 200 ~1 of solution B (trypsin inhibitor and Ribonuclease A in citrate stabilizing 
buffer) and incubation for a further 15 minutes. The samples were then centrifuged at 
400 g for 6 minutes and stained with 200 ~1 of solution C (propidium iodide and 
spermine tetrahydrochloride in citrate stabilizing buffer) for 30 minutes at room 
temperature. The cell cycle was analysed using an orthocyte benchtop flow cytometer 
attached to a PC computer and the % of cells in G<YQ .. S and G2fM phases of the cell 
cycle was determined. The Go/G 1 peak channel number and the coefficient of 
variation (C. Y.) of this peak were recorded and used to produce histograms. Samples 
with a C.Y. greater than 10 channels were considered to be of poor quality due to 
inadequate cellular or DNA staining. 
2. 3. 20. Flow Cytometrlc Analysis of Posterior Uveal 
Melanoma Cell Cycle Kinetics. 
After enucleation, the globe was bisected and samples of tumor tissue removed 
and placed in growth medium. The tumor tissue was minced into fragments of 1 mm3 
and digested using a cocktail containing collagenase type II (0.025 %), pronase E 
(0.05 %) and dithiothreitol (0.5 ~M) (Sigma, Poole, England) for 2 hours at 370 C. 
The tumor cell suspension was washed twice with growth medium by centrifugation 
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at 400 g for 6 minutes and following a final wash in ice-cold PBS the suspension was 
held on ice at 40 C. 
Cell suspensions were filtered through a 50 Jl.lIl mesh to remove cell clumps prior 
to DNA staining with the intercallating fluorochrome, propidium iodide (PI) (Sigma 
Chemical Co Ltd, UK). Staining was as follows, 0.2 % Triton X-1OO was used to 
permeabilise cell membranes (100 ~V106 cells) and DNA was stained with 20 ~g!m1 
PI for 15 minutes at room temperature. 
Cell suspensions were analysed using a FACS 420 flow cytometer with an 
accessory Consort 30 computer (Beckton Dickinson [UK] Ltd) using a 488 nm 
excitation laser wavelength, and measuring the emission fluorescence of PI through a 
530 nm band pass filter. A minimum of 10,000 cells were analysed for each sample. 
The intensity of the fluorescence was considered proportional to their DNA content. 
Cell cycle measurements were made using the planimetric method of Chrisman et al . 
(1974) and Dean (1980) asuming that GoIG .. S, and G2fM phase cells adopt 
binomial distributions. 
The ploidy of the sample was calculated, with normal lymphocytes forming the 
diploid standard, using the equation: 
ploidy index= QolQl peak channel (tumour cells) 
GcYGl peak channel (normal cells) 
Diploid cells therefore have an index of one and tetraploid cells have an index of 
two in accordance with the convention on nomenclature for DNA cytometry 
(Hiddeman et aI., 1984). The qUality of the sample was assessed by the coefficient of 
variation (CV) of the GoPl peak. 
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2. 3. 21. Flow Cytometrlc Immunostalnlng. 
Following completion of the experimental protocol, the cells were harvested and 
centrifuged in Dulbecco's medium cotaining 10 % FCS at 400 g for 6 minutes. The 
pellet was resuspended in PBS and aliquots of lx106 cells were placed in LP3 tubes, 
pelleted by centifugation at 400 g for 6 minutes and stained using specific monoclonal 
antisera as follows. The cell pellet was incubated with an excess of monoclonal 
antibody (MoAb) (W6/32, 10 ~l; m..A-DR, 5 ~ and ICAM-l, 20 ~l, as determined 
by titration assays) at 40 C for 30 minutes then washed with PBS containing 1 % FCS 
(PBS-FCS) The PBS was removed and the cells incubated with 100 ~l (1/60 diluted 
according to titration assays) of fluorescein-isothiocyanate (FITC)-conjugated goat 
anti-mouse F(ab')2 antibodies at 4°C for 30 mins after thorough mixing. This 
incubation was terminated by washing with PBS-FCS, and the cells were 
resuspended and fixed in 1 % paraformaldehyde and analysed with an orthocyte 
benchtop flow cytometer attached to a PC computer (Ortho Diagnostic Systems Ltd). 
Background fluorescence was assessed by including a control with no primary MoAb 
added. Mean fluoresence intensity was given as channel number on a linear scale from 
1 to 256. 
2. 4. NAMES AND ADDRESSES OF SUPPLIERS. 
Amersham International Ltd. 
UK Sales Office, Lincoln Place, Green End, Aylesbury, Bucks. HP20 2TP. 
Becton Dickinson Ltd. 
Between Towns Road, Cowley, Oxford OX4 3LY. 
Biological Industries Ltd. 
56 Telford Road, Cumbemauld, Glasgow G67 2AX. 
Blood Transfusion Service. 
Langley Road, Sheffield. 
Boehringer Mannheim. 
Boehringer mannheim, Bender & Co., Vienna, Austria. 
75 
Bradsure Biologicals. 
65 Park Lane, Sutton bonington, Loughborough, Leicestershire LE12 5NQ. 
British Biotechnology Ltd. 
Brook House, Waltington Road, Cowley, Oxford OX4 5LY. 
Caltag Laboratories Inc. 
436 Rozzi Place, South San Francisco, California, 94080, USA. 
Costar. 
205 Broadway, Cambridge, MA 02139, USA. 
DAKO Ltd. 
16 Manor Courtyard, Hughenden Avenue, High Wycombe, Bucks. HP31 5RE. 
Dynatech Laboratories Ltd. 
Caux Road, Billingshurst, Sussex RH14 9SJ. 
ECACC. 
PHLS Centre for Applied Microbiology & Research, Porton Down, Salisbury, SP4 
OJO. 
Fisons Scientific Equipment • 
Bishop Meadow Road, Loughborough, Leicestershire LEll )RG. 
Glaxo Institute for Molecular Biology S.A. 
Route des Acacias 46, 1211 Geneva 24, Switzerland. 
Imperial Cancer Research Fund Laboratories. 
P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX. 
Laboratory Impex Ltd. 
111-113 Walde grave Road, Teddington, Middlesex TWll SLL. 
Life Technologies Ltd. 
P.O. Box 35, Washington Road, Abbotsinch Industrial Estate, Paisley PA3 4EP. 
N .I.B.S.C. 
National Institute For Biological Standards and Control (NIBSC), Blanche 
Lane,South Mimms, Potters Bar, Hertfordshire EN6 3QG. 
76 
Merck Ltd. 
Fourways, Carlyon Road Industrial Estate, Atherstone, Warwickshire CV9 1nl. 
Northumbria Biologicals Ltd. (NBL). 
South Nelson Industrial Estate, Cramlington, Northumberland NE23 9HL. 
Nycomed Ltd. 
Nycomed House, 2111 Coventry Road, Sheldon, Binningham, B26 3EA. 
Ortho Diagnostic Systems Ltd. 
Enterprise House, Station Road, Loudwater, High Wycombe, Bucks, HPlO 9UF. 
Seralab Ltd. 
Crawley Down, Sussex RHlO 4FF. 
Sigma Chemical Co. Ltd. 
Fancy Road, Poole, Dorset BH17 7NH. 
Skatron. 
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CHAPTER 3 
INTRODUCTION: THE USE OF ANIMALS IN 
THE DETERMINATION OF THE METASTATIC 
PHENOTYPE. 
3. 1. INTRODUCTION: THE USE OF ANIMALS IN THE 
DETERMINATION OF THE METASTATIC PHENOTYPE. 
Despite significant improvements in early diagnosis, surgical techniques, general 
patient care, and local and systemic adjuvant therapies, most deaths from cancer are 
due to metastases that are resistant to conventional therapies (Fidler, 1978; Fidler et 
al., 1978; Fidler, 1984; Fidler and Balch, 1987; Fidler and Hart, 1982; Sugarbaker, 
1985). The metastatic foci can be located either in lymph nodes and visceral organs 
distant to the primary tumor or in various regions of the tumor's primary tissue, 
producing a clinical state which is difficult to treat 
The isolation of tumor cells with enhanced metastatic potential, in an animal 
model, from a primary tumor has been possible by selection either in vivo or in vitro. 
FollOwing implantation of the cells subcutaneously (s. c.), intra-dennally (i. d.), intra-
muscularly (i. m.) or intravenously (i. v.) into mice, cells may be derived from 
metastatic lesions which have an increased metastatic propensity compared with the 
j 
original cell inoculum. This procedure has been successfully used to establish a 
number of tumor cell lines with increased metastatic capacity (Fidler, 1973; Fidler, 
1978; Poste, 1982; Talmadge and Fidler, 1982; Raz and Hart, 1980; Brunson and 
Nicolson, 1978). More recently attention has focussed on the development of 
spontaneously metastatic tumor models, rather than those which involve i. v. injection 
of tumor cells to produce "experimental metastasis". This fonn of metastasis whilst 
more clinically relevant is less frequently observed. There are however a number of 
reports of spontaneously metastatic human melanoma cell lines in nude mice (CornU et 
al., 1989; Iliopoulos et al., 1989; Fodstad et al., 1988; Ishikawa, et al., 1988). 
An alternative approach has been to select cells for the enhanced expression of a 
phenotype believed to be important in determining the metastasis of a tumor cell. The 
cells are then tested in an appropriate host to determine their metastatic potential (Hart, 
1979; Poste et al., 1980; Sloane and Honn, 1984). 
Clinical studies in cancer patients and in experimental rodent tumor models have 
shown that certain tumors produce metastasis to specific organs independent of 
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vascular anatomy. rate of blood flow. and number of cells delivered to each organ. 
The dissemination of radiolabelled melanoma cells in experimental rodent systems 
demonstrates that tumor cells reach the microvasculature of many organs (Fidler. 
1970; Price et al., 1986; Fidler et al., 1977; Hart et al., 1981), however, growth does 
not occur in all the organs encountered. Extravasation into organ parenchyma and 
proliferation of the tumor cells occurs only at specific body sites. and the presence of 
viable tumor cells within a particular organ is not indicative of successful growth and 
formation of a metastatic lesion (Nicolson, 1988; Horak et al., 1986; Naito et al .• 
1987; Fidler and Talmadge, 1986). 
The attempts to understand the mechanisms that regulate the pattern of site specific 
metastasis began in 1889, when Paget analysed over 735 autopsy records of women 
with breast cancer, and suggested that the non random pattern of metastases was not 
due to chance but, rather, that certain tumor cells (the "seed") had a specific affinity 
for growth in certain organs (the "soil"). Metastasis resulted when the seed could 
grow in the soil. Experimental evidence for the "soil and seed" hypothesis was 
obtained using the B16 murine melanoma cell line (Hart, 1982; Hart and Fidler, 
1981). Tumor growth developed in the lungs, and was shown to be present in 
fragments of pulmonary or ovarian tissue but not in renal tissue. Experiments with 
organ derived soluble growth factors indicate that soil factors can have profound 
effects on certain tumor cell subpopulations (Nicolson, 1988). 
An appropriate model for studies of human cancer metastasis must fulfill two 
,I 
requirements: the cells must be metastatic, and they must grow in the relevant organ 
environment The first report of the successful growth of human tumor xenografts in 
athymic nude mice (Rygaard and Povlseen, 1969), has been followed by numerous 
studies which have used this procedure to assess the metastatic properties of human 
tumors. Unfortunately, many highly malignant tumors fail to form metastases when 
grafted into nude mice (Fidler and Nicolson, 1987; Sordat et al., 1982), and this has 
seriously restricted the use of xenografts in studying human metastasis. 
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The aim of the present study was to assess the tumorigenicity and spontaneous 
metastatic potential in nude mice of a series of established long term human cutaneous 
melanoma cell lines and short term cultured uveal melanoma cell lines, or fresh uveal 
melanoma tissue implants. In addition, tail vein injection of cutaneous melanoma cell 
lines was used to determine their lung colonising ability, which was used as a measure 
of "experimental" metastatic potential. Tumors developing following s. c. or i. d. 
injection were excised, and the animals observed for greater than 12 weeks to allow 
the development of occult metastases to a detectable size. Animals were killed and 
subjected to autopsy at times greater than 12 weeks. Tumor growth occuring at 
secondary body sites following s. c. or i. d injection were considered to be examples 
of spontaneous metastasis, portions of the tumor tissue were snap frozen in liquid 
nitrogen, formalin fIxed or recultured, if sufficient quantity of tissue was available. In 
Some cases, mice with s. c. or i. d. tumors were killed and autopsied immediately 
rather than allowing possible occult metastases to develop. 
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3. 2. RESULTS. 
3. 2. 1. Uveal Melanoma Tumorigenesis In Nude Mice 
Following Subcutaneous and Intradermal InJection. 
Uveal melanoma tissue fragments and short tenn cell lines were assessed for their 
ability to grow either subcutaneously or intradennally in nude mice. Following tumor 
resection the bulk of the tumor was either stored or disaggregated as described above 
(Materials and Methods) and used for in vitro studies. In some cases a portion of the 
tumor was used for in vivo innoculation, and tissue fragments implanted within 2 
hours of receiving the tumor. 
Cell lines were grown to approximately 70 % confluency, washed with PBS and 
detached from their growth surface with EDT A. The cell suspension was washed with 
Hams F12 medium, followed by PBS, and cells were finally resuspended at a 
concentration of 3.5x106· Ix 107 cells/m1; 0.1 m1 was typically injected. 
Results of uveal melanoma tissue implantation and cell line injection are given in tables 
3. 1. and 3. 2. respectively. Tissue fragments from 24 uveal melanomas were 
implanted, 22 subcutaneously and 2 intradennally. Tumor take was low with 6 out of 
24 (25 %) (MEL20, 23, 40, 50, 52 and 62) showing tumor growth. Four uveal 
melanoma cell lines were injected subcutaneously of which one grew (MEL23), 
results are shown in table 3. 2. The characteristics of the primary tumors are compared 
with sucessful tumor growth in table 3. 3. Tumors which grew in nude mice 
displayed low 1.9 % and 3.8 % proliferation rates, as measured by flow cytometric 
analysis, there appeared to be an association with cell type, ploidy and the location of 
the tumor within the eye prior to removal. Mixed and epithelioid cell tumors accounted 
for all six tumors which sucessfully grew, five and one respectively. Tumors having 
diploid, diploid with an aneuploid subpopulation and diploid with a tetraploid 
subpopulation accounted for all tumor growth, these represented three, two and one 
tumors respectively. Analysis of the site of the primary tumor showed a correlation 
with tumors arising from choroid (3) or involving both the choroid and ciliary body 
(3). All tumors implanted were initially of a large size (greater than 15 nun diameter 
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and 5 mm depth) when removed from the eye. Upon autopsy one tumor was found to 
have spontaneously metastasised to the liver and spleen (MEL52), no pulmonary or 
skin metastases were detected. The characteristics of this tumor were assessed, it was 
a diploid tumor having an aneuploid subpopulation,of mixed cell type, and involved 
both the choroid and ciliary body. The patient is alive with no detectable metastatic 
disease. 
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Table 3. 1. 
Tumorigenic potential of uveal melanoma tissue implanted subcutaneously in nude 
mice. 
T~ Tumor takeb/number of Duration of experiment 
mice implanted (Months) 
MEL2()c 3/3 12 
MEL21 0(1, 11.14 
MEL22 0/1 8 
MEL23d 1(1, 3 
MElJO 0/3 7 
MEL31 0/1 13 
MElJ7 011 10 
MEL38 0/1 15 
MEIAO 111 13 
MElA8 0/4 12 
MEIA9 0(1, 12 
MELSO 1(1, 14 
MELS1 011 11 
MELS2e l/3g 14 
MELS3 0(1, 9 
MELS4 0/2 8 
MELS6 0/1 12 
MELS7 0/4 10 
MELS9 0(1, 9 
MEL61 0(1, 12 
MEL62e•f m 9 
MEL63 0/1 8 
MEL64f 0(1, 6 
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a Following tumor resection the bulk of the tumor was either stored or dis aggregated 
as described above (Materials and Methods) and used for in vitro studies. In some 
cases a portion of the tumor was used for in vivo innoculation, and tissue fragments 
were passed through a gauge needle to disaggregate them and implanted within 2 
hours of receiving the tumor. 
b Tumor take was detected as vertical growth of a tumor nodule at the site of 
implantation. 
c This tumor achieved 3 successful in vivo passages. 
d This tumor achieved 2 successful in vivo passages. 
e This tumor achieved 1 successful in vivo passage. 
f Intradermal injections. 
g Spontaneous metastases detected in the liver and spleen. 
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Table 3. 2. 
Tumorigenic potential of uveal melanoma cell lines injected subcutaneously in nude 
mice. 
Tum0r8-
MEL17 PI 
MEL18Pl 
MEL23P3 
MEL37bP6 
Tumor takeb/number of 
mice injected 
0/2 
0/2 
lIlc 
0/1 
Duration of experiment 
(Months) 
2 
13 
12 
10 
a Cell lines were grown to approximately 70 % confluency, washed with PBS and 
detached from their growth surface with EDT A. The cell suspension was washed with 
Hams F12 medium. followed by PBS, and cells were finally resuspended at a 
concentration of 3.5x 106· lx107 cells/ml; 0.1 m1 was typically injected. 
b Tumor take was considered positive if vertical growth occurred at the site of 
injection was detected. 
c This tumor achieved 2 successful in vivo passages. 
" 
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Table 3. 3. 
Comparison of tumor tissue displaying vertical growth in nude mice with the 
characteristics of the primary tumor. 
Cell Typea Mixed 
5/1¢ 
Locationb Choroid 
3/13 
PloidyC Diploid 
3/15 
Epithelioid 
113 
Choroid and Ciliary 
Diploid! 
Aneuploid 
216 
body 
3110 
Diploid! 
Tetraploid 
111 
Spindle 
0/2 
Ciliary body 
OIl 
Aneuploid 
0/0 
~ As determined by the histological criteria of McLean et al. }983 
As detennined by histological analysis following enucleation of the eye. 
c Ploidy values were calculated using the method of Rennie et al. 1989, data was not 
available for two tumors. 
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· 3. 2. 2. Derivation of the A375/NUPR1 Melanoma Cell Line 
from the A375 Melanoma by Subcutaneous Passage In Nude 
Mice. 
The human melanoma cell line A375/NUPRl was derived from the parental A375 
melanoma cell line following tumor growth in a Balb/c nude mouse and established as 
a long term cell culture as follows. Subcutaneous injection of lxl05 A375 cells into 
the right flank of a Balb/c nude mouse resulted in the development of a tumor, which 
was resected, minced into fragments of 1 mm3, and disaggregated using a cocktail 
containing collagenase type II (0.025 %), pronase E (0.05 %) and dithiothreitol (0.5 
JlM) for 2 hours at 370 C. The tumor cell suspension was washed twice with growth 
medium and the suspension seeded onto a 75 cm2 vented tissue culture flask in 
Dulbecco's medium supplemented with 20 % fetal calf serum and antibiotics at 370 C 
in a humidified incubator (5 % CO2 and 95 % air). Tumor growth was observed from 
both explants and single cells. The tumor cell line was confirmed as abnormal by 
cytogenetic analysis and verified as mycoplasma free using a nucleic acid 
hybridisation kit. The tumor cell line A375/NUPRl was shown to be related to A375 
by cytogenetic analysis but had an altered karyotype (shown in fig. 3. 1). This subline 
was used subsequently in in vitro experiments to establish its phenotype in relation to 
cytokine response and gelatinolytic activity. 
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Figure 3. l. 
Cytogenetic analysis of A375 and A375/NUPRl. 
A375 
Lab. No 
2 
8 
13 
" 
I. 
. - . 
--
.. 
I. 20 21 
CH .'1 
...... -
to II 12 
18 17 I. 
• 
22 x y 
Karyotypes of A375 and A375/NUPRl demonstrating that the same ploidy and 
structural rearrangement are common to both. 
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Figure 3. 1. continued 
Cytogenetic analysis of A375 and A375/NUPR1. 
A375/NUPRl 
Lab No Karyotype 
8 
13 1~ 10 
• 
19 20 
9 10 II 
18 
21 x 
Karyotypes of A375 and A375/NUPRl demonstrating that the same ploidy and 
structural rearrangement are common to both. 
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3. 2. 3. In Vivo Growth Characteristics of A375 and 
A375/NUPR1 MelanomaCell Lines In Nude Mice. 
Subconfluent cultures were prepared as described above except that cells were 
titrated prior to subcutaneous injection such that the final number injected was in the 
range lxl04-1x106 in a volume of 0.1 m1 of ice cold PBS. 
To determine in vivo growth kinetics. tumors were measured weekly at orthogonal 
angles. The mean tumor diameter and doubling time were calculated as described in 
materials and methods. 
Experiment 1. 
To determine the tumor growth rate, lxl06 cells were injected subcutaneously into 
groups of up to 3 Balb/c nude mice and the tumors measured at weekly intervals. 
Growth was rapid, with mean doubling times of 6.3 ± 3.1 days and 3.9 ± 0 days for 
A375 and A375/NUPRl respectively. However, when the number of tumor cells 
injected was decreased to Sxl05 the mean doubling times decreased to 7.7 ± 2.7 days 
and 7.6 ± 2.5 days for A375 and A37S/NUPRl respectively (Table 3. 4). An 
injection of greater than lxl05 tumor cells was required for tumor take and. no 
significant difference in tumor take rate was observed between the two cell lines. 
Experiment 2. 
The experiment was repeated, however, the number of cells injected was in the 
range lxlOS-lxl06. Tumor doubling times were calculated as previously described 
and are shown in table 3. 4. When lxl06 cells were injected subcutaneously into 
groups of upto 3 Balb/c nude mice the mean doubling times were 3.0 and 3.5 ± 0.5 
days for A37S and A37SlNUPRl respectively. However, when lower cell numbers 
were injected the mean doubling times remained of a similar magnitude, in contrast to 
the previous experiment, where they increased approximately two fold. Furthermore, 
tumor take was at a higher frequency with lx105 cells effectively producing a tumor. 
The duration of the second experiment was 28 days in contrast to 49 days for the first 
experiment. The reasons for these differences are at present unknown. 
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Table 3. 4. 
Growth potentials of A375 and A375/NUPR1 human malignant melanoma cells in 
nude mice following subcutaneous injection: Experiments 1 and 2. 
Number of cells Number of mice Tumor doubling Number of mice Number of 
injected/cell line with s. c. timea (Days) showing spontaneous 
Tumor spontaneous metastasesc 
growth/number metastasis/numb 
injected er injectedb 
h106 A375 313 (1/1) 6.3 ± 3.1 (3.0) None (None) Na (Na) 
1x106 313 (3/3) 3.9±0 None (None) Na (Na) 
A375/NUPR1 (3.5 ± 0.5) 
5x105 A375 213(213) 7.7 ± 2.7 1/3 (None) 2 (L) (Na) 
(4.8 ± 1.4) 
5x105 213 (313) 7.6 ± 2.5 2/3 (None) 1,1 (L) (Na) 
A37S/NUPR1 (3.2 ± 0.2) 
2.Sx10S A375 0/3 (ND) Na Na Na 
2.5xlOS 013 (ND) Na Na Na 
A375/NUPR1 
h10S A375 0/3 (213) Na (3.5 ± 0.1) Na(None) Na(Na) 
h10S 013(313) Na (3.1 ± 0.3) Na(None) Na (Na) 
A375/NUPR1 
5x104 A375 0/2 (ND) Na Na Na 
5x104 0/2 (ND) Na Na Na 
A375/NUPR1 
Results of experiment 2 are shown in brackets 
a Mean value ± standard deviation. 
b Mice were subjected to autopsy at the time of tumor resection, and the extent of 
Spontaneous metastasis was determined. 
c The number of spontaneous metastases present in the skin (S), lungs (L) and 
abdominal organs (A) was determined. 
Na Not applicable, ND Not done 
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3. 2. 4. Intradermal Growth Characteristics of A375 and 
A375/NUPR1 In Nude Mice. 
Tumor cells were prepared as described above except that Ix 106 cells were 
injected intradennally using a fine bore needle. If no tumor take was observed the 
mice were killed 12 weeks after injection of the tumor cells and gross necropsies were 
performed to determine if spontaneous metastasis had occurred. No macroscopic 
tumor growth was detected in any organ. Developing tumors were resected when the 
tumor measured 0.5-1.0 cm mean diameter and the tumor tissue was then divided into 
a number of portions for either reinjection. in vitro culture. histology or snap 
freezing. Results are shown in table 3. 5. for experiments 1 and 2 respectively. The 
growth rate of melanoma cells injected intradermally was determined as described 
previously (materials and methods). Growth rates and spontaneous metastasis rates 
were comparable between the two experiments and although the growth rate for 
intradennal growth was slightly higher the rate of spontaneous metastasis was 
comparable to that observed with subcutaneous injection and growth. 
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Table 3. 5. 
Growth potentials of A375 and A375/NUPRl human malignant melanoma cells in 
nude mice following intradermal injection: Experiments 1 and 2. 
Cell line 
A375 
A375/NUPRl 
Number of mice 
with tumor 
growth/number 
injected 
618 
(10/11) 
7/8 
(11/15) 
Tumor Number of 
doubling time mice showing 
1.9 ± 0.5 
(2.1 ± 0.4) 
1.7 ± 0.4 
(1.6 ± 0.2) 
spontaneous 
metastasisa 
2 
(None) 
None 
(None) 
Results of experiment 2 are shown in brackets. 
Number of 
metastasesb 
2, 1 (L) 
(Na) 
Na 
(Na) 
aSpontaneous metastasis was determined 12 weeks after tumor resection 
b The number of spontaneous metastases present in the skin (S), lungs (L) and 
abdominal organs (A) was determined. 
N a not applicable. 
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3. 2. 5. Intravenous Injection of a Series of Cutaneous 
Melanoma Cell Lines as a Measure of their Experimental 
Metastatic Potential In Nude Mice. 
Experimental metastasis assay 
Subconfluent cultures were detached using 2 mM EDTA, resuspended in 
Dulbecco's medium containing 10 % FeS, centrifuged at 400 g for 6 minutes and 
then resuspended in ice-cold PBS. Cells used in these studies were >95 % viable as 
determined by trypan blue exclusion, and adjusted to a fmal concentration of 1x107 
cells/ml by the addition of ice -cold PBS; mice (4-6 weeks old Balb/c nudes) received 
1x106 viable cells in 0.1 ml into the lateral tail vein. Animals were killed 12 weeks 
post inoculation by cervical dislocation following etherisation and subjected to gross 
necropsies. Lungs were fixed in neutral buffered formal saline and the extent of lung 
colonisation determined, the number of surface colonies was generally low and were 
quantified macroscopically. All cell lines showed a low experimental metastatic 
potential in nude mice, results are shown in table 3. 6. Overall A375/NUPRl 
appeared to show a higher incidence of lung colonisation than A375 when injected 
intravenously. 
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Table 3. 6. 
Experimental metastatic potentials of a series of human malignant melanoma cells in 
nude mice. 
Cell line Number of mice with lung Number of lung 
metastases/number injected metastasesb/mouse 
A375 3/28 2,3,5 
A375/NUPRla 15/31 2, 4, 6, 1, 1, 1, 1, 3, 2, 7, 
1,2, 3, 1, 10, 
DX.3c 1/5 6 
DX.3 LT 5.1c 3/9 12,8,7 
G361c 0/16 Na 
a This assay was performed 3 times on the flfst two occasions the results were 6/8 and 
7/8 however on the third assay the result was 2/15, a level similar to A375. The 
increased metastatic propensity of A375/NUPRI was not reproducible and may be 
due to the fonnation of homotypic tumor emboli or other artifacts which may be 
involved in the establishment of this assay. 
b The presence of metastases in the skin, peritoneal cavity and abdominal organs was 
also determined and found to be negative. 
c Results of a single experiment 
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3. 3. DISCUSSION. 
Melanoma metastases represent a major clinical problem, since the therapeutic 
approaches so far tested have, in the main, failed to improve the prognosis of 
melanoma patients. Following the initial report of the development of an experimental 
model for tumor growth in nude mice, several studies have indicated that human 
melanoma tissue shows a high tumor take rate when xenottansplanted subcutaneously 
into nude mice (Giovanella et al., 1974; Sharkey et aI., 1978). Many highly malignant 
human tumors do not form metastases when xenottansplanted into nude mice (Fidler, 
1986; Fidler et al., 1984; Giovanella and Fogh, 1985; Sordat et al., 1982), however, 
a few exceptions have been reported (Sharkey et al., 1978; Sordat et al.,1982; Neulat-
Duga et al., 1984; Kozlowski et al., 1984). This benign, localised growth of tumor 
cells is one of the limiting factors to the use of the nude mouse for testing therapeutic 
modalities on human metastases. 
The aims of this study were to assess the tumorigenic and metastatic ability in 
nude mice of a series of primary uveal melanoma tumor tissues and short-term 
cultures of human uveal melanoma. Comparisons with other patient parameters were 
also attempted, an in-depth description of these investigations is given in chapter 5. A 
series of five cutaneous melanomas were also studied with respect to their 
experimental metastatic potential in nude mice following tail vein injection. Two cell 
lines were chosen for further study of both their in vivo and in vitro characteristics ( 
see chapters 4 and 6). Furthermore, attempts were made to establish tumor cell 
sublines from both spontaneously and experimentally metastatic human cutaneous 
melanoma lesions in nude mice as celllines. The growth kinetics and spontaneous 
metastatic potential of two related human melanomas, A375 and A375/NUPR1, 
implanted at different sites, subcutaneous and intradermal, in nude mice was also 
studied. 
Initial studies using human uveal melanomas, both fresh tissue and short term 
cultured cells, showed them to have a low tumorigenic potential when injected 
subcutaneously into nude mice. subsequent studies used uveal melanoma tissue 
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injected intradennally. Of the 24 ocular melanomas tested. five were tumorigenic after 
subcutaneous injection and one was tumorigenic following intradermal injection, but 
none displayed growth in nude mice further than three in vivo transplantations. 
Likewise, spontaneous metastases were observed only once following subcutaneous 
injection and never following intradermal injection. These results are in agreement 
with the reports from other groups who describe a low incidence of tumor growth and 
metastasis, observing either no tumor take with fresh tissue or only a benign localised 
lesion. Reports by Fidler (1990) describing an increased incidence of tumor take and 
spontaneous metastasis following intradermal injection of tumor cells cannot at this 
stage be verified. however, it should be noted that one of the two tumors injected 
intradermally grew as a detectable lesion. Further studies involving an increased 
number of tumors are needed to confum these initial observations. 
Analysis of the characteristics of the primary uveal melanoma tissue, which 
successfully grew in nude mice, revealed a number of trends which are interesting. 
However, due to the low numbers in this study these observations should be treated 
with caution until they are either verified or found to be false following completion of 
a more extensive study. Despite this, these preliminary results will be discussed in the 
context of other investigations. Kerbel et al. (1984) reported an association between 
the metastatic cat'acity and tetraploidy of a human melanoma cell line. The ploidy 
values and karyotypes of the uveal melanomas from the present study were also 
assessed. When compared with the growth and metastasis of this tumor type in mice it 
was found that three of the six tumors displaying growth in nude mice were diploid, 
two were diploid with an aneuploid subpopulation and one was diploid with a 
tetraploid population; the metastatic tumor, was diploid with an aneuploid 
subpopulation. It cannot be confirmed that the findings of Kerbel et al (1984) apply to 
uveal melanoma. As will be discussed later (chapter 5), uveal melanoma, has both 
similarities and differences to cutaneous melanoma. 
The tumors which grew when implanted at subcutaneous or intradermal sites in 
nude mice were MEL 20, 23, 40, 50, 52 and 62. There appears to be no obvious 
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correlation with patient status and tumor growth upon implantation (see table 3. 7). 
This lack of correlation between patient status and growth in nude mice was also 
observed with respect to spontaneous metastasis in nude mice. 
The location of the primary tumor within the eye did appear to be related to the 
ability of the tumor tissue to grow in mice, with tumors orignating from primary 
tumors involving the choroidal or the choroid and ciliary body, no tumors which were 
solely of ciliary body origin grew or metastasised in nude mice. Furthermore, tumor 
cell type is used as an indicator of tumor aggression. Two cell types are recognised, 
spindle and epithelioid, and mixtures of the two cell types are frequently observed 
(Callender, 1931). Epithelioid cell tumors have the worst prognosis followed by 
mixed cell tumors and pure spindle cell tumors which have the most favourable 
prognosis (Callender, 1931). We observed that five of the six tumors growing in mice 
were of mixed cell composition, the remaining tumor was epithelioid. 
Alterations in chromosomes I, 3, 6, and 7, which have been reported in other 
primary and metastatic malignant melanoma biopsies or cell lines (Balaban et al., 
1984), do not appear to be closely associated with uveal melanoma tumorigenic o~ 
metastatic potential in nude mice, although alterations in chromosome 3 were 
frequently observed (a complete list of tumor karyotypes and a more comprehensive 
discussion of this area is present in chapter 5). 
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Table 3. 7. 
Comparison of patient status and uveal melanoma growth in nude mice with 
karyotypic abnonnalities. 
Tumors displaying vertical 
growtha 
20 
23 
40 
50 
52 
62 
Karyotypeb 
Na 
Na 
Na 
Na 
-3 +iSq del llq t (1.10) 
-3 +8 +iSq 
aDetennined by macroscopic analysis of the tumor lesion. 
bResults obtained by collaboration with K. Sisley. 
cClinical details kindly provided by I. O. Rennie. 
dpathological analysis of lung nodules by Dr M. A. Parsons. 
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Patient statusC 
Alive 
Alive 
Alive 
Alive 
Alive 
Alive 
Further studies are needed to establish which genotypic or phenotypic 
characteristics are associated with the growth of uveal melanomas in nude mice, and 
the clinical relevance of such findings. Orthotopic implantation, the implantation of 
tumor tissue or cells directly into the eye is a possible approach, however, due to the 
severity of this type of experiment this option has not been taken at the present time. 
Intrasplenic injection of tumor tissue has been reported to produce in vivo growth of 
melanoma in nude mice (Nicolson, 1987). Since the site of metastasis in 60-70 % of 
patients with uveal melanoma is the liver (Char, 1989), intrasplenic injection of tumor 
cells may aid in the development of a metastatic model for uveal melanoma. Initial 
results would suggest that this may be an appropriate site of injection since MEL17 
formed metastatic lesions in the liver when injected via an intrasplenic route. However 
additional experiments are needed to confirm this initial result. 
The cutaneous melanoma cell lines used in this study, A375 and A37.5INUPRl, 
when titrated, were found to be capable of subcutaneous tumor formation when the 
total number of cells injected per mouse was lxl05 although this was higher upon 
repeat experiments. The incidence of spontaneous metastatic potential for the two cell 
lines was low, only 3 out of 24 mice showed metastasis; the numbers of metastases 
were also of a low magnitude typically one or two lesions were detected upon 
macroscopic analysis. Spontaneous metastasis was not detected in a second 
experiment 
Intradermal injection of A375 or A375lNUPRl tumor cells followed by tumor 
resection and subsequent observation of the mice for longer than 12 weeks showed 
that although the doubling time for the tumors was reduced to approximately 2 days, 
when compared to subcutaneous injection (approximately 3.5 days), the incidence of 
spontaneous metastasis was not significantly different from that observed following 
subcutaneous injection; again the intradermal growth rates of the parent line (A375) 
and subline (A375/NUPR1) were not significantly different. 
The experimental metastatic potential of these tumor lines, when injected into the 
lateral tail vein, was low, and the number of metastases detected in individual animals 
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was minimal. typically only 1-15 exclusively pulmonary located lesions. In vitro 
experiments detennined that there were differences in gelatinase expression and its 
modulation by peptide regulatory factors between the different melanoma cell lines 
(see chapter 4). The two cell lines, A375 and A375/NUPRl, were analysed further. 
Both the constitutive expression of MHC class I, IT and ICAM-l was determined as 
was the response of the cells to the cytokines IL-l and TNFa (see chapter 6). 
There is now considerable evidence that alteration in gene expression by genetic or 
epigenetic processes can lead to the acquired phenotypic alterations in tumor cells 
which confer upon a minority of them a selective or competitive growth advantage. 
Host selective pressures may ensure the preferential survival and outgrowth of these 
cells, which would then become the progenitors of new and more aggressive clones. 
Analysis of such a dynamic evolutionary process involving the emergence and decline 
of succesive new clonal subpopulations' known as clonal dominance (Kerbel et al., 
1988) has been attempted through the use of endogenous or radiation induced 
cytogenetic markers (Hu et al., 1987; Talmadge and Fidler, 1982), drug resistance 
markers (Kerbel et al., 1982), by the use of X-linked isoenzyme mosaicism 
(Ootsuyama et al., 1987) or by the use of transferred DNA markers (Kerbel et al .• 
1988). This study showed that primary tumors have a tendency to become rapidly 
overgrown by the progeny of a small number of clones. In our own study, the cell 
line A375/NUPRl was found to display an increased level of cellular homogeneity 
when compared to the parent tumor, A375, and in one experiment to have an 
increased growth rate in nude mice when injected subcutaneously. Whilst our study is 
too limited to draw deflnite conclusions as to the nature of clonal selection within a 
primary tumor, it is probable that A375/NUPRl is an example of a selected 
subpopulation of the primary tumor which has an increased growth rate, possibly due 
to altered responsiveness to host microenviromental factors, compared with other 
clones, and has achieved dominance within the tumor. In in vitro experiments 
A375/NUPRl was found to react differently when exposed to cytokines. and this 
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alteration in susceptibility to the cytokines IL-1 and TNFa may be a result of in vivo 
passage (see chapter 7). 
In our hands the A375 melanoma did not metastasise following intravenous 
injection at the level reported in the literature (Kozlowski et al., 1984). This may 
however be due to genotypic and/or phenotypic alterations which may have occurred 
following in vitro passage of this cell line. It should be noted that the in vitro growth 
medium used in our study differed from that used by Kozlowski et al. (1984). In the 
present study cells were maintained in Dulbecco's minimal essential medium 
supplemented with 10 % FCS, whereas Kozlowski et al. (1984) maintained their 
cultures in Eagle's minimal essential medium supplemented with 10 % FCS. sodium 
pyruvate, nonessential amino acids, I-glutamine and 2-fold vitamin solution. This may 
have introduced a selective growth advantage for a particular subpopulation of tumor 
cells thereby altering the metastatic potential of the total population. 
The ability to extravasate is dependent upon the destruction of some of the major 
constituents of the basement membrane. The basement membrane is a dense scaffold 
of type IV and V collagen, laminin. entactin and heparan sulphate proteoglycan. The 
type IV collagenolytic (gelatinase) activity of these tumors is investigated in chapter 
four of this thesis. Hendrix et al. (1990a) have shown that the measurement of 
gelatinase activity or the ability of tumor cells to traverse reconstituted basement 
membrane may be good predictors of in vivo metastatic properties. In addition there is 
increasing evidence of an association between intercellular adhesion molecule 1 
(ICAMl) expression and melanoma progression (Holzman et al .• 1987; Johnson et 
al., 1988; Johnson et al., 1989; Natali et al., 1990). These studies report that ICAM-1 
is expressed at higher levels on successfully metastatic melanoma cells than on th~ 
cells in the primary tumor or precancerous lesions, suggesting that lCAM-1 may play 
a role in the metastatic process. Furthermore. Feldman et al. (1988) and Kushtai et al. 
(1988) have correlated major histocompatability antigen expression with metastatic 
propensity. These aspects are considered in the subsequent studies on uveal and 
cutaneous melanomas 
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CHAPTER 4 
INTRODUCTION: GELATINASE 
EXPRESSION AND METASTASIS. 
4. 1. INTRODUCTION: GELATINASE EXPRESSION AND 
METASTASIS. 
Tumor invasion, the process of the removal of the extracellular matrix surrounding 
the tumor, allowing cell migration and tumor growth, is an initial event in the 
metastatic cascade. The removal of the extracellular matrix is thought to occur through 
the action of a variety of degradative enzymes which are produced by either the tumor 
(Review: Tryggvason et al., 1987) or stimulated host cells (Basset et al., 1990). 
Tumor invasion may occur by a number of different mechanisms, which are not 
mutually exclusive, and may involve active locomotion (Strauli and Haemmerli, 
1984). Three theories of invasion have been proposed: 
1) the mechanical theory (Eaves, 1973) 
2) the enzymatic theory (Review: Tryggvason et al., 1987) 
3) the migratory theory (Strauli and Haemmerli, 1984) 
In addition to invasion of the interstitial matrix, the tumor cell must invade the 
vascular wall or lymphatic channels during dissemination if it is to successfully 
metastasise to a distant organ or tissue. The major structural barrier to invasion of 
these vessels is the basement membrane, a specialised extracellular matrix, produced 
by epithelial cells, endothelial cells, and many mesenchymal cells, whose functions 
include molecular sieving, impeding the passage of cells from one tissue compartment 
to another and cell attachment, growth and differentiation (Review: Farquhar, 1981). 
Liotta et al. (1986), suggested a three step theory for invasion. The ftrst step involves 
attachment of tumor cells to basement membrane components, typically laminin and 
type IV collagen (Kramer et al., 1989; Ramo, et al., 1990), followed by secretion of 
proteolytic enzymes to cause degradation of the extracellular matrix (Turpeenniemi-
Hujanen et al., 1986), and fmally tumor cell migration into the area of degradation. A 
number of studies have reponed these steps to be closely linked, for example, 
attachment to laminin induces increased enzyme expression (Turpeenniemi-Hujanen et 
al., 1986) which is itself a chemotactic stimulant for the tumor cells (Terranova et al., 
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1989), as indeed are the degraded basement membrane components (ferranova et aI., 
1989). 
Animal studies have indicated that that tumor cell invasion and metastasis are not 
random events, but arise from tumor cell subpopulations expressing a higher 
metastatic potential (Fidler and Hart, 1982). Many studies have focussed on 
biochemical and genetic markers of the invasive phenotype, which would allow 
patients at greater risk of developing metastatic disease to be identified. 
A major group of enzymes associated with matrix degradation during tumor 
invasion are the proteases (Goldfarb and Liotta, 1986), which can be subdivided into 
exopeptidases (peptidases) and endopeptidases (proteinases). Proteinases which 
appear to be the more important group, are classified according to their active sites, as 
serine-, cysteine-, aspartic- and metalloproteinases (McDonald, 1985). 
Tumor cells capable of metastasis have been shown to produce proteinases capable 
of degrading basement membrane type IV collagen (fryggvason et al., 1987; 
Turpeenniemi-Hujanen et al., 1986; Garbisa et al .• 1987; Nakajima et al., 1987), and 
the production of these enzymes constitutes an important mechanism by which 
migrating tumor cells degrade basement membrane components. Gelatinase enzymes 
are meta110proteinases capable of degrading type IV collagen (Collier et al., 1988; 
Fessler et al., 1984; Liotta, 1986; Murphy et al., 1989) and there is evidence to 
suggest that the type IV collagenase is a gelatinase (Review: Woessener, 1991; Collier 
et al., 1988; Murphy et al., 1985; Seltzer et al .• 1981). Two molecular forms of 
progelatinase have been identified, a 72 kDa species, expressed by connective tissue 
cells and tumor cells (Collier et al., 1988; Murphy et al., 1989; Seltzer et al., 1981; 
Yamagata et al., 1988; Yamagata et al., 1989), and an immunologically distinct 
glycosylated 92 kDa species, mainly expressed by monocytes. macrophages, 
polymorphonuclear leukocytes (Murphy et al., 1989) and tumor cells (Yamagata et 
al .• 1988; Yamagata et ai., 1989). Both molecular species of gelatinase are secreted as 
latent proenzymes which require modification prior to attaining their active state 
(Stetler-Stevenson et al., 1989). 
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The expression of the 92 kDa gelatinase has been shown to be induced by ras 
oncogene transfection (Ballin et al .• 1988) and has been correlated with increasing 
metastatic potential (Yamagata et al .• 1988; Yamagata et al .• 1989) in a number of 
malignant cell types. In addition. 92 kDa gelatinase expression was shown to 
correlate with the metastatic phenotype in transformed rat embryo cells (Bernhard et 
al .• 1990). 
The investigations described in this chapter have involved the study of the 
modulation of gelatinase by a number of cytokines. growth factors and extracellular 
matrix components. It is possible that a metastasising tumor cell may encounter these 
factors during the metastatic process which may subsequently influence the metastatic 
propensity of the cell. 
The cytokines used in this study were the interleukins: IL-la and ~. IL-2. IL-4. 
and IL-6; transforming growth factor beta 2 (TGF~2); interferons alpha (IFN ex) and 
gamma (IFNy); insulin like growth factors 1 (IGF 1) and 2 (lGF 2), epidermal 
growth factor (EGF). platelet derived growth factor (PDGF) and acidic fibroblast 
growth factor (aFGF). In addition to these soluble mediators of cell communication a 
number of extracellular matrix components were also studied. these were laminin. 
fibronectin. and collagen types I and IV • Later studies involved combinations of 
factors to determine possible inhibitory or synergistic actions. The combined 
literature on these factors is extensive and only their reported effects on gelatinase 
expression shall be discussed in this introduction. 
The structures of the genes (Huhtala et al .• 1990; 1991) and the cDNA sequences 
(Collier et al .• 1988; Wilhelm et al .• 1989) for human 72 kDa gelatinase and 92 kDa 
gelatinase respectively are known. The S' regulatory region of the 72 kDa gelatinase 
gene contains neither a TATA. TPA responsive element (TRE) or CAAT box. but 
there are however two putative SPI binding sequences (GC rich regions) and one 
potential AP-2 consensus sequence. In contrast. the 92 IDa gelatinase promoter 
region contains a TATA-like sequence (TIAAA). no CAAT motif and only one GC 
box. Two putative TREs are present as is a TGF13 inhibitory element (TIE). 
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Both the activity of 72 kDa gelatinase (Salo et al., 1985) and the mRNA levels 
(Salo et al., 1989) have been reported to be increased by phorbol esters in human 
fibroblasts. TNFa has been reported to stimulate the production of both active 
gelatinase and collagenase and to cause de novo expression of an 80 kDa gelatinase 
in carageen-induced granulation tissue in organ culture. However, granulation tissue 
contains a number of different cell types including many immunocytes, and the cell 
type(s) responsible for the production of this enzyme was not given (Nakagawa et 
al., 1987). A recent study, published during the present investigations, reported that 
92 kDa gelatinase was induced and stimulated by TNFa whereas 72 kDa gelatinase 
expression was unchanged (Okada et al., 1990). In addition this group reported that 
IL-la, PDGF, EGF, bFGF and TGF~ had no effect on gelatinase expression. In 
Contrast to this report Wilhelm et al. (1989) reported that EGF and IL-l~ were 
inducers for a 92 kDa gelatinase in SV 40-transformed human lung fibroblasts. 
Although expression of the 92 kDa gelatinase may be an important indicator of 
malignancy, it cannot be considered to be the only determinant for metastatic 
propensity, since upregulation or alteration of a number of different phenotypic traits 
have been correlated with metastatic cells. 
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4. 2. RESULTS. 
4. 2. 1. Zymographlc Analysis of Protelnases Constitutively 
Expressed by Cutaneous and Uveal Melanomas In Tissue 
Culture. 
To investigate proteinase expression in human melanoma cell lines, zymograms of 
gelatin and/or casein embedded polyacrylamide gels were used for the qualitative 
analysis of enzymes (Heussen and Dowdle, 1980). Serum free medium or celllysates 
are dissolved in a sample buffer containing SDS and are separated by electrophoresis. 
The technique of zymography or substrate gel electrophoresis (Heussen and Dowdle, 
1980) presents a number of advantages over classical assays for enzymatic activity 
using either natural or synthetic substrates, but principally its ability to detect different 
molecular species of enzymes and enzyme-inhibitor complexes. SDS was found to 
activate both serine proteinases (Granelli-Piperno and Reich, 1978) and proMMP-2 
(72 kDa progelatinase) without changing their apparent Mr (Collier et al., 1988) and to 
diSSociate and subsequently activate the proMMP-9 present in proMMP-9-TIMP 
complexes (Wilhelm et al .• 1989). but not to dissociate those formed between active 
MMP-9 (92 kDa gelatinase) and TIMP (Murphy et al .• 1989). Furthermore, it has 
been shown to reactivate several serine proteinase-inhibitor complexes without 
diSSOCiating them (Granelli-Piperno and Reich. 1978). 
When 24 hour serum free conditioned medium was analysed on gelatin 
zymograms, proteinases of apparent molecular weights 92 kDa and 72 kDa were 
detected as clear bands. The cutaneous melanoma cell lines A37S, and SK23 
expressed only one gelatinolytic activity. which had an apparent molecular weight of 
72 kDa whereas the cutaneous melanomas A37S/NUPR1, DX3 and LTS.l in 
addition constitutively expressed the 92 kDa species. A37SlNUPRl expressed a 92 
kDa gelatinolytic activity at a low level, so that whilst this enzyme could easily be 
detected in 10 fold concentrated conditioned medium, it was rare to detect this species 
in unconcentrated medium. The same pattern of enzyme activities was found in the 
Triton X-loo cell-lysates (table 4. 1). 
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Fifteen short tenn (1-5 passage levels) posterior uveal melanoma cell lines were 
qualitatively analysed for gelatinolytic and caseinolytic proteinase activity. All fifteen 
cell lines secreted a gelatinolytic metalloproteinase, with an apparent molecular weight 
of 72 kDa, into protein free culture media; and nine of these secreted an additional 
gelatinolytic metalloproteinase with an apparent molecular weight of 92 kDa; neither 
species had the ability to degrade casein. The results are shown in table 4. 2. 
Table 4.1. 
Identification of gelatinase activities constitutively expressed by a series of 
human cutaneous melanoma cell lines. 
Cell linea 
A375 
A375/NUPR1 . 
DX3 
LT5.1 
SK23 
gelatinase species (kDa) 
Cellularb 
72 
72 (92)C 
7292 
7292 
72 
Extracellular 
72 
72 (92) 
7292 
7292 
72 
a Subconfluent cell cultures were washed twice with PBS for 1 hour then incubated 
for 24 hours at 370 C in serum free medium. The medium was centrifuged for 5 
minutes at 15000 g prior to analysis, or storage at -7fPC. 
b Celllysates were prepared in 0.25 M Tris-HCl pH 7.4 containing 200 mM NaCl, 5 
roM CaCl2 and 0.1 % Triton X-100. 
c 92 kDa gelatinase was expressed at the limit of detection, however it was clearly 
present in 10 fold concentrated medium. 
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Table 4.2. 
Identification of gelatinase activities constitutively expressed by a series of uveal 
melanoma cell lines. 
gelatinase species (kDa) 
Cell linea Cellu1mb Extracellular 
MELt 4 72 72 
MELt 7 7292 7292 
MEL22 7292 7292 
MEL30 7292 7292 
MEL35 7292 7292 
MEL37a 72 72 
MEL37b 7292 7292 
MElAO 72 72 
MEL 44 72 72 
MElA7 7292 7292 
MEL50 7292 7292 
MEL52 7292 7292 
MEL55 7292 7292 
MEL56 72 72 
MEL57 7292 7292 
aSubconfluent cell cultures were washed twice with PBS for t hour at 370C then 
incubated for 24 hours at 370 C in serum free medium. The medium was centrifuged 
for 5 minutes at 15000 g prior to analysis, or storage at -700C. 
bCelllysates were prepared in 0.25 M Tris-HCl pH 7.4 containing 200 mM NaCl, 5 
111M CaCl2 and 0.1 % Triton X-tOO. 
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4. 2. 2. Proteinase Inhibitor and Enzyme Activation Studies. 
The 72 kDa and 92 kDa enzyme species, present in supernatants or celllysates, 
did not appear when the chelating agents EDTA, a general divalent cation chelator, or 
1,10, phenanthroline, a preferential zinc chelator, (both used at 10 mM) were added 
to the incubation buffer. However PMSF, a general serine proteinase inhibitor, (2 
mM), Net-MAL, a general cysteine proteinase inhibitor, (10 mM) and E-64, an 
inhibitor specific for cathepsins, (10 mM) did not inhibit enzyme activity (Fig. 4. 1). 
In addition, all the observed gelatinase species were activated by incubation with 1 
mM p-APMA suggesting that constitutively expressed species are latent 
metalloproteinases. Fig. 4. 2 shows the presence of an additional lower molecular 
weight activation band following treatment of the serum free A375 melanoma cell 
Conditioned growth medium with p-APMA. When casein was used as a substrate, 
bands of degradation comparable to those seen with gelatin were not apparent (Fig. 
4. 3) indicating that the enzyme activities were not due to stromelysins (Chin et a/., 
1985). These results infer that the gelatinases produced by melanoma cell cultures are 
latent gelatinolytic metalloproteinases with apparent Mr values similar to those 
reponed for proMMP-2 and proMMP-9 respectively. 
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Fig 4. l. 
Zymography inhibitor studies. 
EDTA(lOmM) 
+ 
LANE 1 LANE 2 
kDa 
LANE 1 LANE 2 
92 92 kOa 
72 72 kOa 
1, 10 Phenanthroline 
+ 
kDa 
LANE 1 LANE 2 LANE 1 LANE 2 
92 
92 kOa 
72 72 kOa 
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Fig 4. 1. continued. 
Zymography inhibitor studies. 
PMSF(2mM) E-64(10 mM) 
LANE 1 LANE 2 LANE 1 LANE 2 
92 kDa 92 kDa 
72 kDa 72 kDa 
Net-MAL (10 mM) 
LANE 1 LANE 2 
92 kDa 
72 kDa 
Serum free conditioned medium from LT 5.1 and A375 cell cultures was analysed 
by gelatin zymography on 7.5% w/v polyacrylamide gels, following electrophoresis, 
the gels were washed and incubation buffer as previously described. Inhibitors 
~pecific for the different mechanistic classes of proteinases were included in the 
Incubation buffer: Control gels were incubated in buffer plus the appropriate solvent, 
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Fig 4.2. 
Activation of progelatinase by p-APMA. 
LANE 1 LANE 2 
72 kDa 
+ 
APMA 
A375 melanoma cell conditioned medium containing constitutively expressed 
progelatinase species was incubated with 1 mM p-APMA for 4 hours at 370 C. The 
samples were analysed by zymograpby on 7.5 % w/v polyacrylamide minigels 
containing 1 mg/ml gelatin. Lane 1, A375 conditioned medium; Lane 2, A375 
conditioned medium incubated with p-APMA as described above. 
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Fig 4.3. 
Expression of caseinolytic enzymes. 
kDa 
97 
66 
45 
29 
Serum free conditioned medium containing gelatinolytic enzyme species was 
analysed by casein zymography. Casein zymograms contained 1 mg/ml casein co-
polymerised in 7.5 % (w/v) polyacrylamide minigels. Lane 1, A375 conditioned 
medium; Lane 2, A375/NUPRl conditioned medium; Lane 3, LT5.1 conditioned 
medium; Lane 4, DX3 conditioned medium; Lane 5, SK23 conditioned medium. 
Zymography was as previously described. 
11 4 
4. 2. 3. Cellular Location of 72 kDa Progelatlnases In A375 
and A375/NUPR1 as Determined by Triton X-114 Phase 
Separation. 
Celllysates were prepared as previously described: typically 1X107 cells were 
lysed on ice in 1 ml of 50 mM Tris-HCl pH 7.4 containing 200 mM NaCl, 5 mM 
CaC12 and 0.1 % Triton X-114. Integral membrane proteins fonn mixed micelles with 
nonionic detergents, and it is possible to isolate them from hydrophilic proteins by 
phase separation above the cloud point of the detergent. Phase separation of integral 
membrane proteins was perfonned by the method of Bordier, (1981). As a control 
ovalbumin, a hydrophilic protein, was phase extracted in parallel with the sample. The 
resulting aqueous and detergent phases were analysed by gelatin zymography or in the 
case of the ovalbumin control on an 7.5 % polyacrylamide SDS containing gel which 
was coomassie brilliant blue R 250 stained. The 72 kDa progelatinase species were 
found both in the detergent and aqueous phases suggesting that the enzymes exist as 
both integral and either intracellular or peripheral membrane proteins (Fig. 4. 4a and 
b). 
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Fig. 4. 4a. 
Phase separation of A375 and A375/NUPRI Triton X -114 celllysates. 
kDa 
97 
66 
45 
29 
LANE 1 LANE 2 LANE 3 LANE 4 
Cell lysates were prepared using a Triton X-114 containing lysis buffer as 
previously described and the samples phase separated using the method of Bordier, 
1981. Aqueous and detergent phases were analysed by zymography on 7.5 % Wjv 
polyacrylamide minigels containing 1 mg/ml gelatin. Lane 1, A375 aqueous phase; 
Lane 2, A375 detergent phase; Lane 3, A375/NUPRI aqueous phase; Lane 4, 
A375/NUPRl detergent phase. 
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Fig. 4. 4b. 
Phase separation of ovalbumin-Triton X -114 solution. 
kDa LANE 1 LANE 2 LANE 3 LANE 4 LANE 5 
97 
66 
45 
29 
As a control to determine if phase separation was occurring when the method of 
Bordier, 1981 was used a 0.5 mglml solution of ovalbumin was prepared using Triton 
X-114 containing lysis buffer. This solution was phase separated in parallel with cell 
lysate preparations. The respective detergent and aqueous phases were separated on 
7.5 % w/v polyacrylamide gels and the proteins stained using coomassie briliant blue 
R 250. Lane 1, blank; Lane 2, detergent phase; Lane 3, aqueous phase; Lane 4, 
aqueous phase; Lane 5, detergent phase. 
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.4. 2. 4. Cytoklne Modulation of Progelatlnase Expression In 
Melanomas by IL-1a, IL-2, IL-6, IFNa, IFNy, TNFa, and TGF~2. 
The cytokines IL-1a. and ~, IL-6, IFNa., IFNyand TNFa were used at a final 
concentration of 1000, 100, and 10 U/ml against nine melanoma cell lines (table 4.3); 
TGF~2 was used at a final concentration of 100, 50, 10, I, and 0.1 ng/mt When 
added as single activating agents, none of these cytokines, with the exception of 
TNFa. and IL-I a. and ~, altered the pattern of progelatinase expression by any of the 
cel11ines used in the study. However, a pronounced and consistent response to TNFa. 
was shown by A375, and A375/NUPRI melanoma cells (table 4. 3). 24 hour 
exposure to TNFa induced a 92 kDa progelatinase in a dose dependent manner in 
both of these related cell lines, detectable in both celllysates and conditioned medium 
(Fig. 4. 5). IL-Ia. and ~ induction of the 92 kDa progelatinase was observed with 
A375/NUPR1 cells but not A375 cells following a 24 hour exposure (table 4.3). 
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Fig 4. 5a. 
Dose dependent stimulation of the secretion of 92 kDa progelatinase by the A375 
human melanoma cultures in response to 24 hour TNFa treatment. 
10 o 100 o 1000 o 
kDa 
97 
66 
45 
30 
(TNF 
u/ml) 
Conditioned medium was collected from subconfluent A375 melanoma cultures 
stimulated with TNFa, 1000, 100, and 10 U/ml, for 24 hours. An aliquot (20 ~l) was 
electrophoresed on 1 mg/ml gelatin, 7.5 % w/v crosslinked polyacrylamide minislab 
gels and analysed by zymography (48 hours incubation) as described earlier. 
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Fig. 4. 5b. 
Dose dependent stimulation of the cell associated expression of 92 kDa progelatinase 
by the A375 human melanoma cultures in response to 24 hour TNFa treatment. 
kDa 
97 
66 
45 
30 
(TNF 
U/ml) 
10 o 100 o 1000 o 
Ceillysates were prepared from subconfluent A375 melanoma cultures stimulated 
with TNFa, 1000, 100, and 10 U/ml, for 24 hours. An aliquot (20 JlI) was 
electrophoresed on 1 mglml gelatin, 7.5 % w/v crosslinked polyacrylamide minislab 
gels and analysed by zymography (48 hours incubation) as described earlier. 
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Table 4. 3. 
Modulation of progelatinase activities by tumor necrosis factor ex and interleukin one 
a and J3 
Progelatinase activities (kDa) 
Cell line Controla TNFab 
A375 72 72 92 72 
A375lNUPRl 72 (92)d 72 92 72 92 
DX3 7292 7292 7292 
LTS.l 7292 7292 7292 
SK23 72 72 72 
MEIA7 7292 7292 7292 
MEL52 7292 7292 7292 
MEL56 72 72 72 
MEL57 7292 7292 7292 
a Subconfluent cultures were washed twice for 1 hour at 370 C, then incubated in 
serum free medium for 24 hours at 370 C. 
b TNFex treated cultures were washed as described and exposed to 1000 Vlml of 
TNFex for 24 hours. 
c lL-lwJ3 treated cultures were washed and incubated as described and exposed to 
1000 Vlml of IL-l ex for 24 hours 
d 92 kDa progelatinase was expressed at the limit of detection, however, it was clearly 
present in 10 fold concentrated medium. 
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4. 2. 5. Neutralisation of the Cytoklne Modulation of 92 kOa 
Progelatlnase Expression Using Specific Antl-Cytoklne Anti-
sera. 
Specific neutralising antibodies were used to block the effects ofTNFa and IL-la 
on 92 kDa progelatinase induction. TNFa (1000 U/ml) and IL-Ia (100 U/ml) were 
incubated with sufficient specific anti-sera to neutralise the effect of the cytokine 
present in serum free medium for 1 hour at 37°C prior to addition of the serum free 
medium to cell cultures. The conditioned medium was collected after 24 hours and 
analysed using gelatin zymography. Controls with and cytokine and anti-sera were 
perfonned in parallel. The effect of TNFa on A375 melanoma cell cultures and the 
effects of TNFa and ~-la on A375/NUPRI cell cultures were blocked by the 
respective anti-sera (shown in fig.4. 6). These results infer that TNFa and TI...-Ia 
exen a direct effect upon A375 and A375/NUPRI melanoma cell cultures. 
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Fig. 4. 6. 
Neutralisation of TNFa. and IL-l induction of 92 kDa gelatinase expression. 
kDa 
97 
66 
45 
29 
Specific neutralising antibodies were used to block the effects of TNFa. and IL- la. on 
92 kDa progelatinase induction. TNFa. (1000 U/ml) and IL-la. (100 U/ml) were 
incubated with specific anti-sera to neutralise the effect of the cytokine present in 
serum free medium for 1 hour at 37°C prior to addition of the serum free medium to 
cell cultures. The conditioned medium was collected after 24 hours and analysed using 
gelatin zymography as previously described. Lane 1, A375/NUPRI incubated with 
1000U/ml TNFa. for 24 hours; Lane 2, As lane 1 except the serum free cytokine 
Containing medium was incubated with 110 neutralising units of anti-TNFa. antibody 
for 1 hour prior to addition to the cells; Lane 3, A37S/NUPRl incubated with 100 
U/ml IL-l a. for 24 hours; Lane 4, As lane 3 except the serum free cytokine containing 
medium was incubated with 11 neutralising units of anti-TNFa. antibody for 1 hour 
prior to addition to the cells. 
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4. 2. 6. Time Course Studies to Determine the Minimum Time 
of Exposure of Melanoma Cells to TNFa. and IL-1 a. Necessary to 
Induce Expression of 92 kDa Progelatlnase. 
Time course studies, in which A375 cells were incubated with TNFa. (1000 U/m!) 
for various time periods, 1,4, 8, 16, and 24 hours, showed that the minimum time of 
exposure required to induce the 92 kDa progelatinase using A375 melanoma cells was 
4 hours (Fig. 4. 7), and 16 hours for A375/NUPRI (summarised in table 4. 4). 
Further studies revealed that IL-la. and ~ (both were used at 100 U/ml) induced the 
expression of 92 kDa progelatinase in A375/NUPRI but not A375 cells, the time 
periods used were 1,4,8,16, and 24 hours, the enzyme activity was first detectable 
in conditioned medium at the 16 hour time point (results are summarised in table 4.4). 
4. 2. 7. Time Course Studies to Determine the Duration of 92 
kDa Progelatlnase Expression Following 24 Hour Exposure to 
TN Fa. and IL-1a.. 
Additional time course studies established that, following a 24 hour exposure of 
A375 cells to TNFa. (1000 U/ml), the enzyme was still strongly expressed, in both 
celllysates and conditioned medium, 72 hours after removal of exogenous TNFa. by 
washing. 
A375/NUPRI treated with TNFa. displayed similar longevity of expression, 
however, activity was undetectable at 96 hours post TNFa. stimulation; in contrast IL-
lCt./p (100 U/ml) stimulated cells still expressed 92 kDa gelatinase activity at 96 hours 
post stimulation, results are summarised in table 4. 5. 
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Fig. 4. 7. 
Time course studies using the A375 melanoma to determine minimum exposure 
times for induction of 92 kDa gelatinase by TNFa.. 
kOa , 
97 
66 
45 
(TNF' 
u/ml) 
1000 o 
1 1 
1000 o 1000 o 
4 4 6 6 
A375 melanoma cell cultures were incubated with TNFa. (1000 U/ml) for the 
indicated time periodsand the medium removed, the cells were washed twice with 
PBS for 5 minutes and incubated for the reminder of the 24 hour period in serum free 
medium. The serum free conditioned medium was analysed using gelatin 
zymography. 
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Table 4. 4. 
Modulation of 92 kDa progelatinase by the cytokines IL-l a./(3 and TNFa. 
Time Controla TNFab IL-lac IL-l (3c Controla TNFab IL-lac IL-l(3c 
(hours) 
A375 A375/NUPRl 
1 72 72 72 72 72 (92) 72 (92) 72 (92) 72 (92) 
4 72 72 92 72 72 72 (92) 72 (92) 72 (92) 72 (92) 
12 72 72 92 72 72 72 (92) 72 (92) 72 (92) 72 (92) 
16 72 72 92 72 72 72 (92) 72 92 72 (92) 72 (92) 
24 72 72 92 72 72 72 (92) 72 92 72 92 72 92 
a Cells were seeded at a concentration of 4xlQ4 cells/cm2, allowed to settle for 24 
h?urs in serum containing medium and washed for 1 hour twice with PBS prior to 
stimulation with cytokines. The conditioned medium and celllysates were prepared as 
previously described. 
~ Cells were exposed to TNFa at a concentration of 1000 U/ml for the designated 
tlme period, washed with PBS twice for 5 minutes and incubated in serum free 
medium for the duration of the experiment. The post TNFa stimulation incubation 
medium was assayed for enzyme expression by zymography. 
C C.ells were exposed to IL-t at a concentration of tOO U/ml for the designated time 
penod, washed with PBS twice for 5 minutes and incubated in serum free medium for 
the duration of the experiment.The post IL-t stimulation incubation medium was 
assayed for enzyme expression by zymography. 
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Table 4.5. 
Duration of 92 kDa progelatinase expression following stimulation by the cytokines 
IL-ICX/~ and TNFcx for 24 hours. 
Tune Controla TNFab IL-Icxc UrI pc Controla TNFab Urlac n..-I~C 
(hours) 
A375 A375/NUPRl 
24 72 7292 72 72 72 (92) 7292 7292 7292 
48 72 7292 72 72 72 (92) 7292 7292 7292 
72 72 7292 72 72 72 (92) 7292 7292 7292 
96 72 72 72 72 72 (92) 7292 7292 7292 
a Cells were seeded at a concentration of 4x1()4 cells/cm2 allowed to settle for 24 
h<?urs in serum containing medium and washed for 1 hour twice with PBS prior to 
Stimulation with cytokines. Following completion of the experiment the conditioned 
medium and cell lysates were prepared as previously described and assayed by 
zymography. 
b Cells were exposed to TNFa at a concentration of 1000 U/ml for 24 hours, washed 
with PBS twice for 5 minutes and incubated in serum free medium for the duration of 
the experiment. 
c ~ells were exposed to UrI at a concentration of 100 U/ml for 24 hours, washed 
WIth PBS twice for 5 minutes and incubated in serum free medium for the duration of 
the experiment. 
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4. 2. 8. Effects of Simultaneous Co-Stimulation of A375 with 
Multiple Cytoklnes. 
Investigations into the possible synergistic or inhibitory actions of multiple 
cytokines were performed to determine if the expression of the 92 kDa progelatinase 
could be modulated by the simultaneous co-stimulation of A375 with TNFa plus 
another cytokine. TNFa was used at a constant concentration of 500 U/ml and the 
cytokines IL-1a, IL-2, IL-4, IL-6, IFNa, and IFNy were titrated at final 
concentrations of 1000, 100, and 10 U/ml, TGFJ32 was used at final concentrations of 
100,50, 10, I, and 0.1 ng/ml. These combinations were found to be without effect 
except for TNFa and TGFJ32, where TGFJ32 caused an upregulation of the 92 kDa 
proenzyme expression, detected as an increase in the size of the band. Epidermal 
growth factor when used at fmal concentrations of 1000, 100, and 10 U/ml with 
TNFa was also ineffective in altering progelatinase expression. 
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4. 2. 9. Synergistic Effect of TN Fa and TGFJ32 on both 
Cutaneous and Posterior Uveal Melanoma Cell Lines. 
Studies were undertaken to investigate the possible synergistic action of TNFa 
and TGFJ32 on progelatinase production. A375 tumor cells were exposed to TNFa at 
1000, 100, and 10 U/ml together with TGFJ32 at 100, SO, 10, 1, and 0.1 ng/ml. This 
caused an apparent increase of 92 kDa progelatinase secretion (Fig. 4. 8) at all 
concentrations ofTGFJ32 used. There was no quantitative or qualitative change in the 
secretion of the 72 kDa gelatinase by the A375 melanoma cell line as a result of co-
stimulation with TNFa with TGFJ32. Similar results were obtained with 
A375/NUPRl (table 4. 6). In further studies it was shown that exposure of SK23 and 
MEL56 to TNFa and TGFJ32 resulted in the detection of a 92 kDa progelatinase both 
in the cell lysate and conditioned medium (table 4. 6). Neither TNFa. nor TGFJ32 
alone induced this molecular weight species of progelatinase in SK23 nor MEL56 
cells. 
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Fig 4.8. 
Synergistic action of TNFa and TGFj32 on the secretion of 92 kDa progelatinase by 
the human melanoma A375. 
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Subconfluent A375 melanoma cultures were stimulated with TNFa (1000 U/ml) 
and TGFj32, at 100, 50, 10, 1, and 0.1 ng/ml either singularly or in combination for 
24 hours. The conditioned medium and celllysates were electrophoresed on 1 mg/ml 
gelatin, 7.5 % W Iv polyacrylamide minigels and analysed by zymography as described 
previously. 
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Table 4.6. 
Modulation of progelatinase activities by tumor necrosis factor alpha and transfonning 
growth factor beta 2. 
Progelatinase activities (kDa) 
Cell line TNFab 
A375 72 7292 7292d 
DX3 7292 7292 7292 
LT5.1 7292 7292 NT 
SK23 72 72 7292 
MEIA7 7292 7292 7292 
MEL52 7292 7292 7292d 
MEL56 72 72 7292 
MEL57 7292 7292 NT 
a Subconfluent cultures were washed twice for 1 hour at 370 C, then incubated in 
serum free medium for 24 hours at 370 C. 
b TNFa treated cultures were washed as described and exposed to 1000 U/ml of 
TNFa for 24 hours. 
C TNFa + TGF~2 treated cultures were washed and incubated as described but 
Contained 10 ng/ml ofTGF~2 in addition to 1000 U/ml TNFa. 
d An apparent upregulation of the 92 kDa progelatinase was obselVed. 
NT Not tested 
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4. 2. 10. Activation of Induced Progelatlnase Activities by p-
APMA. 
Progelatinase-containing conditioned medium was incubated with p-APMA for 
varying periods of time (1-24 hours) to determine if the cytokine induced enzyme 
species were active or latent forms of gelatinase. Activation was determined to have 
occurred if there was a decrease in apparent molecular weight of the enzyme of 
approximately 6-8 kDa. This was observed following 4 hour incubation of the 
supernatant with 1 mM p-APMA (Fig. 4. 10), but total loss of the 92 kDa enzyme 
Could not be achieved at any time point studied. The reason for this is at present 
unknown. 
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Fig 4.9. 
Activation of progelatinase by p-APMA. 
LANE 1 LANE 2 LANE 3 LANE 4 
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Serum free conditioned medium containing constitutively expressed and induced 
progelatinase species were incubated with I mM p-APMA for 4 hours at 370 C. The 
samples were analysed by zymography on 7.5 % W Iv polyacrylamide minigels 
containing 1 mg/ml gelatin. Lane 1. A375 conditioned medium; lane 2. A375 
Conditioned medium following incubation with p-APMA; Lane 3, A375 conditioned 
medium following incubation with TNFa (1000 U/ml) for 24 hours; Lane 4, A375 
conditioned medium following incubation with TNFa (1000 U/ml) for 24 hours and 
Subsequently activated with p-APMA for 4 hours. 
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4. 2. 11. Modulation of Progelatlnase Expression In the A375 
Melanoma by Growth Factors: IGF 1, IGF 2, ACIDIC FGF, PDGF, 
and EGF. 
The growth factors, Insulin like growth factors 1 and 2, acidic fibroblast growth 
factor, platelet derived growth factor and epidermal growth factor were added as 
single activating agents to subconfluent serum free A375 cell cultures for 24 hours. 
Insulin like growth factors 1 and 2 were used at final concentrations of 1000, 500, 
100, 10 and 1 V/ml, epidermal growth factor, acidic fibroblast growth factor and 
platelet derived growth factor were used at final concentrations of 10,000, 1000, 100 
and 10 V/ml. Following exposure to these growth factors in serum free conditions for 
24 hours at 370 C no qualitative or quantitative alterations in progelatinase expression 
Were observed (summarised in table 4. 7); similarly no induction of caseinolytic 
enzymes was observed. 
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Table 4.7. 
Modulation of 92 kDa progelatinase expression in the A375 melanoma by growth 
factors. 
Progelatinase activities (kDa) 
Controla IOF 1b IOF2c POOP<! aFOpe EOpf 
72 72 72 72 72 72 
a The appropriate control was used for each growth factor, this was the solution in 
which the growth factor was reconstituted added to the serum free medium, no 
modulation of progelatinase expression was observed for any control solution used. 
Subconfluent melanoma cell cultures (4x104 cells/cm2) were washed twice with PBS 
for 1 hour and incubated with growth factor containing or control medium for 24 
hours at 370 C. The conditioned medium was collected and celllysates were prepared 
as previously described. 
b IGF 1 was used at final concentrations of 1000, 500, 100, 10 and 1 U/ml. 
~ IGF 2 was used at final concentrations of 1000, 500, 100, 10 and 1 U/ml. 
PDGF was used at fmal concentrations of 10,000, 1000, 100 and 10 U/ml. 
~ aFGF was used at final concentrations of 10,000, 1000, 100 and 10 U/ml. 
EGF was used at final concentrations of 10,000,1000, 100 and 10 U/ml. 
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4. 2. 12. Extracellular Matrix Component Modulation of 
Progelatlnase ExpressIon by Melanomas. 
The extracellular matrix components collagens type I and IV, fibronectin and 
laminin were used to coat the growth surface of tissue culture flasks as described 
previously (materials and methods). Tumor cells were then seeded at a density of 
1xl06 cells/2Scm2 flask and allowed to attach and grow for 24 hours prior to washing 
with PBS twice for 1 hour at 370 C. The cell cultures were incubated for 24 hours in 
serum free medium, which was collected and stored as previously described. The 
conditioned medium was analysed by gelatin and casein zymography. Seeding of the 
cell lines A37S, DX3, LTS.l and SK23 onto the extracellular matrix components 
listed was without effect on progelatinase expression in this experimental system 
(table 4. 8). No caseinolytic enzymes were observed. 
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Table 4.8. 
Modulation of Progelatinase expression by extracellular matrix components. 
Cell linea 
A375 
DX3 
LT5.1 
SK23 
Controlb 
72 
7292 
7292 
72 
Progelatinase activities (kDa) 
Collagen 
type IC 
72 
7292 
7292 
72 
Collagen Fibronectine Lamininf 
typeIVd 
72 72 72 
72 92 72 92 72 92 
72 92 72 92 72 92 
72 72 72 
a Subconfluent melanoma cell cultures (4 x 1()4 cell5/cm2) were washed twice with 
PBS for 1 hour and incubated in serum free medium for 24 hours at 37°C. The 
Conditioned medium was collected and cell lysates were prepared as previously 
described. Cell counts were performed at the end of the experiment and cell numbers 
were found to be similar for each matrix component, All cell lines appeared to attach 
~ual1y well to each matrix component over the 24 hour equilibration period. 
b Tissue culture flask growth surfaces treated with the solution in which the 
extracellular matrix component was dissolved were used as controls. 
c Collagen type I was used at final concentrations of 5. 10 and 15 Jlg/cm2• 
d Collagen type IVwas used at final concentrations of 5. 10 and 15 llg/cm2. 
e Fibronectin was used at final concentrations of 1. 5 and 10 Jlg/cm2• 
f Laminin was used at fmal concentrations of 1. 2.5 and 5 Jlg/cm2. 
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4. 2. 13. Modulation of Progelatlnase Following Co-
Stimulation of A375 Melanoma Cells with both Lamlnln and 
Cytoklnes. 
The basement membrane component laminin was used to coat the growth surface 
of tissue culture flasks at a concentration of 5 Jlg/cm2• Tumor cells were then seeded 
at a density of Ix 106 cells/25 cm2 flask in serum free medium and allowed to attach 
and grow for 48 hours prior to washing with PBS twice for 1 hour at 370 C. The cell 
cultures were incubated for 24 hours in serum free medium or serum free medium 
containing either TNFa (1000 U/ml). TGF132 ( 10 ng/ml) or both TNFa and TGF132 
combined (concentrations as before), which was collected and stored as previously 
deScribed. The conditioned medium was analysed by gelatin and casein zymography. 
Seeding of the melanoma cell line A375 onto laminin and subsequent co-stimulation 
with the listed cytokine combinations failed to affect progelatinase modulation by 
cytokines in this experimental system (table 4. 9). 
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Table 4.9. 
Modulation of A375 progelatinase expression by co-stimulation with cytokines and 
laminin. 
Progelatinase activities (kDa) 
NoLaminin Laminina 
Controlb TNFac TGF13d TNFa+ Controlb TNFac TGF13d TNFa+ 
TGF13e TGF13e 
72 7292 72 7292 I 72 7292 72 7292 
a Plates were coated with 5 J.1g/cm2 of laminin, uncoated plates were treated with an 
identical volume PBS •. 
b Control cultures were incubated in serum free medium as previously described. 
C TNFa was used at a final concentration of 1000 U/ml. 
d TGF13 was used at a fmal concentration of 10 ng/ml. 
e TNFa and TGF13 co-stimulated cultures were exposed to 1000 U/ml of TNFa and 
10 ng/ml TGF13. 
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4. 3. DISCUSSION. 
An important characteristic of malignant tumor cells is their ability to invade 
foreign tissues and form metastatic foci at distant locations in the body. In the initial 
stages of tumor metastasis, the tumor cells become detached from the primary tumor 
and migrate into the surrounding tissues. In most cases the invading cells reach 
lymphatic or blood vessels from which they can spread to secondary organs, 
extravasate and form metastases (Poste and Fidler, 1980). 
The influence of host factors on tumor metastasis due to the modulation of the 
expression of tumor products is of considerable interest, and studies by Dabbous et al. 
(1988) have demonstrated that cytokines could stimulate invasion in an in vitro assay. 
Akedo et al. (1989) reported that preculture of rat ascites hepatoma cells with rat 
macrophages enhanced both their in vitro and in vivo invasion, as did TGFp and 
activated platelets. This group suggested that the potentiation of invasive ability was 
mediated by oxygen radicals which caused aggregation of the tumor cells. It is also 
POssible that a contributory factor in the potentiation of invasion is the activation of 
latent metalloproteinases by an oxidative mechanism (Review: Van Wart and Birkedal-
Hansen, 1990). In addition, activated macrophages are known to produce a number of 
cytokines including TNFa and TGFp, it is possible that these cytokines may 
influence tumor cell behavior. Host cells, including platelets, endothelial cells and the 
various imrnunocytes which are known to be associated with tumors are capable of 
secreting a number of cytokines and growth factors. An aim of this study was to 
determine which, if any. of these factors were capable of modulating gelatinase 
expression. Basement membrane and interstitial matrix components were also studied, 
in order to provide a comprehensive appraisal of agents which may alter proteinase 
Production and influence metastatic potential. 
Wilhelm et al. (1989) using SV40 transformed fibroblasts demonstrated that the 
mRN A for a 92 kDa progelatinase could be induced by exposure of the cells to IL-l, 
EGF and TPA. In contrast, Turpeenniemi-Hujanen et al. (1986) reported that 
expression of type IV procollagenase by the A20S8 melanoma was down regulated by 
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EGF. Furthermore, Okada et al. (1990) demonstrated that TNFa is a potent inducer 
of 92 kDa progelatinase expression in a variety of sarcoma cell lines, although a 
number of cytokines and growth factors: IL-la, PDGF, EGF, bFGF and TGFI3 
failed to influence the progelatinase profile of the cells. In the present study the effect 
of a number of cytokines, IL-la, ll..-2, ll..-6, IFNa, IPN-y, TNFa and TGF132 and 
growth factors, IGP 1 and 2, aFGP, POOP and EGP on progelatinase expression by 
melanomas was investigated. In agreement with previous studies (Okada et al., 1990) 
these factors were found to be without effect except for TNFa. Differences between 
our studies and those of Wilhelm et al. (1989) may reflect tissue or cell type 
differences between the cells studied, or differences in the response of cells 
transformed with other agents e.g. SY40, or responses which are tumor tissue 
specific. 
Initially TNFa was reported to cause haemorhagic necrosis of murine tumors 
(Carswell et al., 1975), suggesting that it may be of value in patient therapy. 
However, a consistent anti-tumor effect in cancer patients could not be achieved (Frei 
and Spriggs, 1989). The therapeutic action ofTNFa in animal models is thought to be 
due to a combination of biological effects and, in part, due to its cytotoxic and/or 
cytostatic potential (Sugarman et al., 1985), and its ability to cause activation of anti-
tumor immune surveillance mechanisms (Palladino et al., 1987). Recent! y TNFa has 
been reported to have multiple effects on both tumor and host cell behaviour, 
including the stimulation of angiogenesis (Frater-Shroder et al., 1987), osteoclastic 
bone resorption (Bertolini et al., 1986), tumor cell invasion and metastasis of human 
oVarian carcinoma xenografts (Malik et al., 1989), enhanced experimental metastasis 
in mice (Malik and Balkwill, 1991), and most recently in the induction of 92 kDa 
gelatinase in osteosarcoma and fibrosarcoma cells (Okada et al., 1990). TNPa may 
therefore play an important role in modulating the invasive properties of tumor cells, 
and the results of the present study are consistent with this hypothesis 
Reports by Yamagata et al. (1988; 1989) have correlated expression of the 92 kDa 
gelatinase with increased metastatic potential in a number of tumor types, and our 
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results using the A375 melanoma show that exposure to TNFa can induce the 
expression of this molecular weight species of enzyme. A recent study by Overall et 
al. (1989), reported that progelatinase production by fibroblasts was stimulated by 
TGFp, although the results of the present study show that human melanoma cells are 
unaffected by the addition of TGFp2. TGFp2 was found to synergise with TNFa to 
increase progelatinase detection in A375 and to induce the expression of the 92 kDa 
progelatinase in SK23 and MEL56. These results suggest that some melanoma cells 
either do not require TGFP as a co-stimulant to regulate enzyme production, or that 
they may constitutively release TGFp2, thereby requiring only exogenous TNFa to 
induce gelatinase gene expression. Analysis of TGFp2 production by the tumor cell 
lines used in this study would be beneficial in determining if this is a possible 
mechanism. Whether tumor cells in vivo may be affected by TNFa secreted from 
infiltrating mononuclear cells is not yet known, although cell-cell communication 
(between tumor and host cells) is likely to influence tumor cell behaviour. The A375 
melanoma has been shown to be capable of inducing TNFa secretion from a 
monocyte cell line in vitro (Sabbatini et al., 1990), suggesting the production of this 
cytokine is regulated by tumor cell signals, and this in turn could serve to increase the 
invasive and metastatic capacity of cells, through the induction and/or increase in 
gelatinase activity. 
In this study a subpopulation of the A375 melanoma (A375/NUPRl), selected by 
in vivo passage in nude mice, was sensitive to the action of IL-l a and p whereas the 
total (parental) tumor population shows no detectable induction of the 92 kDa 
gelatinase. TNFa and IL-laJP treatment of A375/NUPRl cells both result in the 
detection of the 92 kDa progelatinase species, however the time of detection is 
markedly different. It is possible that IL-l may act indirectly by inducing TNFa 
expression by the tumor cells, resulting in autocrine stimulation of progelatinase 
expression. Further studies are needed to investigate this possibility. A discussion of 
the respective gelatinase promoter structures and their possible role in explaining these 
observations is present in the general discussion chapter of this thesis. 
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Phase separation studies revealed the presence of a membrane associated 72 kDa 
progelatinase species in both A375 and A375/NUPR1, in addition a hydrophilic 
species was also detected. Zucker et al. (1985a, 1987a, 1987b, 1990) reported the 
presence of membrane associated gelatinases, and elucidating the importance of 
membrane associated enzymes versus secreted enzymes is of intense interest to 
enzymologists. Sas et al. (1986) reported that degradation of extracellular matrix 
fibronectin, laminin and type IV collagen occurred only beneath or along the path of 
the tumor cell migration, indicating that degradation was due to cell surface associated 
rather than secreted proteinases. In addition, Chen and Chen, (1987) have reported 
that degradation of fibronectin by rous sarcoma virus-transformed fibroblasts occurs 
only at the sites of cell-substrate contact and a 150 kDa metalloproteinase was 
extracted from the cell membrane of transformed but not normal cells. However, 
melanoma cells have been reported to secrete high levels of gelatinase relative to 
enzyme concentrations in the plasma membranes (Zucker et al., 1990). Whilst it is 
recognised that there are advantages to the membrane localisation of proteinases, 
namely protection from proteinase inhibitors and co-localisation of the enzyme and its 
substrate, membrane localisation may represent merely a transient situation prior to the 
shedding of membrane vesicles (Zucker et al., 1987c). It is not known if the 
extracellular activities observed in this study are soluble or located within vesicles. 
It is interesting to note that both cutaneous and posterior uveal melanomas express 
the 72 kDa and 92 kDa species of progelatinases, and the activities are modulated by 
the same cytokines. However, the expected sites of metastasis for these types of 
melanoma are differenL Whilst progelatinase expression is associated with the 
metastatic phenotype it may not determine the secondary site for metastasis. This may 
be dependent upon cell-cell, cell-substratum interaction via adhesion molecules, or due 
to the specific organ microenviromenL 
Gelatinase, in addition to its role in basement membrane invasion is thought t~ 
have a synergistic relationship with interstitial collagenase in the degradation of type I 
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collagen. Enhanced matrix degradation could be a contributing factor for increasing 
the in vivo growth rate of tumors. 
Turpeenniemi-Hujanen et al. (1986), demonstrated that laminin could increase the 
expression of type IV collagenase from malignant cells and Emonard et al. (1990) 
confIrmed the effect of laminin on type IV collagenase expression using trophoblasts. 
In our studies,laminin was found to be without effect on melanoma cells, however, 
other melanoma cell lines have been reported to be responsive to laminin: the A2058 
melanoma, B16 FlO melanoma and the fibrosarcoma cellline HT 29. Laminin is 
known to have a number of cell binding sites (Review: Humphries, 1990) and it is 
possible that the human melanoma cells used in this study may not express the 
receptor associated with an increase in type IV collagenase expression. 
The level of active enzyme is dependent upon enzyme: inhibitor ratios, whilst this 
qualitative study has identified progelatinase expression patterns further studies to 
quantitate metalloproteinases and their inhibitors would be informative. 
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CHAPTER 5 
INTRODUCTION: POSTERIOR UVEAL 
MELANOMA: PROGNOSTIC INDICATORS 
·5. 1. INTRODUCTION: POSTERIOR UVEAL MELANOMA: 
PROGNOSTIC INDICATORS. 
Uveal melanoma is a rare cancer (Deves et al., 1987), but it holds considerable 
interest because of the rapid and unexplained rise in incidence of the related but more 
Common melanomas of the skin (Cutler and Young, 1975). They represent 
approximately 80 % of all non-cutaneous melanomas (Scotto et al., 1976). The 
etiology of uveal melanoma is at present uncertain, possible causes including viral 
infection (Albert, 1979), chemical agents (Albert et al., 1980) and malignant 
transformation of benign nevi of the choroid. Although uncommon in the context of 
general neoplasia, uveal melanomas of the ciliary body and choroid, are the most 
common primary adult intraocular malignancy, they frequently metastasize. and 
approximately half of the patients die from their disease within 15 years of enucleation 
(Egan et al .• 1988). Metastatic disease is responsible for virtually all tumor-related 
deaths. However, not all tumors have the same metastatic potential; some tumors have 
little or no metastatic capabilities whereas others metastasise readily. Once metastases 
Occur the prognosis is extremely poor, with a median survival time of six months 
(Seddon et al., 1983), and despite recent advances in treatments, including many 
directed at preserving the eye. the overall prognosis has remained unaltered 
(Zimmerman and McLean, 1984). Traditional prognostic indicators rely heavily on the 
assessment of the morphological and histological appearances of the tumor; the tumor 
location and size are of prognostic significance. Generally "posterior" uveal 
melanomas located anterior to the equator have a less favorable prognosis than ones 
located posterioraly (Shammas and Blodi, 1977). In addition, large tumors (tumor 
diameter greater than 10 mm) have a less favorable prognosis than small tumors 
(Shammas and Blodi, 1977). 
Histologically, uveal melanomas may be classified as: spindle cell, epithelioid cell 
or mixed cell tumors. Pure spindle cell tumors generally have a favourable prognosis 
with a five year survival rate of approximately 80 %, whereas mixed and epithelioid 
tumors fare less favourably, with pure epithelioid cell tumors having a five year 
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survival of only 40 % (Paul et al .• 1962). Calculation of the inverse standard deviation 
of the nucleolar area has been assessed as an indicator of survival (John et al., 1977). 
In addition to metastatic potential. the relative growth rates of the primary tumors 
may also vary (Augsburger et al .• 1984; Friberg et al., 1983). Flow cytometry enables 
the rapid analysis of single cell suspensions by virtue of the light scatter properties of 
cells, which mayor may not be stained with DNA or protein specific fluorochromes. 
It has been shown to be a reliable quantitative method of determining the DNA content 
of tumor cells (Freidlander et al .• 1984); and from such analyses, details of the cell 
cycle kinetics, the percentage of cells undergoing division (those cells in G2IM and S 
phase of the cell cycle relative to those in GciGl) and ploidy (total DNA content) of 
the tumor cell population can be obtained. The presence of non-diploid (aneuploid) 
cells in some human tumors may infer a poor prognosis (Freidlander et al .• 1984). 
Prior to our studies, flow cytometric studies of uveal melanomas have been limited to 
analysis of histological material recovered from paraffin embedded specimens 
(Meecham and Char, 1986; Shapiro et al .• 1986). Meechan and Char (1986) 
retrospectively correlated ploidy and clinical outcome, and found that hyperploidy 
correlated with poor prognosis. Due to the reponed technical difficulties encountered 
When using parrafin embedded material for flow cytometry (Lawry et al .• 1987), 
namely formal saline fixation induced artefacts, including reduced fluorescent intensity 
and high levels of cellular debris which make histogram interpretation difficult 
(Shapiro et al., 1986), we have used flow cytometry in a prospective study to 
determine the cellular DNA content in fresh tumor tissue obtained from 49 uveal 
melanomas. Initial studies were published (Rennie et al., 1989) and these together 
with the results of further studies are included in this chapter. In addition to providing 
I 
a ploidy index for the tumor tissue, this technique permits us to obtain an index of cell 
proliferation by studying the percentage of cells in each phase of the cell cycle. The 
results and their relationship to various tumor parameters including, anatomical 
location, tumor size and histological cell type are discussed. For many biological 
studies of tumor cell characteristics, it is necessary to establish in vitro cell cultures. 
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Thus, a lack of an economically acceptable culture system which pennits the routine in 
vitro growth of uveal melanomas from biopsy specimens has hindered the study of 
the basic properties of this tumor type. 
The ability to grow human uveal melanoma in vitro enables the investigation of a 
number of diverse phenotypic properties which may be involved in both 
tumorigenesis and metastasis. The fll'st reported attempt to grow uveal melanoma cells 
in vitro was that of Kirby (1929). A number of studies demonstrated that uveal 
melanoma cells can survive in culture for periods of several months if passage of the 
cells is not attempted (Pomerat et al., 1956; Barishak et al., 1960). The culture 
medium shown to be optimal for growth was a modification of Hams F12. 
Albert et al. (1984) described a long term in vitro culture system for these tumors 
which relied upon tumor cell migration from explants which were seeded onto a 
fibroblast feeder layer, in addition they used 12-0-tetradecanoyl-phorbol-13-acetate 
(PMA) to inhibit the growth of fibroblasts and keratinocytes. This group detennined 
that for long term culture of uveal melanoma the following factors were important: 
1) the use of Hams F12 basal medium. 
2) the use of the human fibroblast cell line MRC-5 as a feeder layer. 
3) addition of epidermal growth factor, and cholera toxin to the medium. 
4) a combination of fetal bovine serum and horse serum. 
5) a high concentration of glucose which seemed to increase the longevity of the 
cultures. 
Albert et al., (1984) used a high concentration of epidermal growth factor (10 
)J.g/ml) in their culture system, but in the present study the routine use of this 
concentration of EGF was found to be too expensive; cholera toxin and PMA were 
Omitted from the growth medium as were fibroblast feeder layers, where a high risk of 
fibroblast overgrowth could occur. The use of different basal medium, and 
supplements was studied. In addition a variety of extracellular matrix components and 
tissue culture plastics were used as growth substrata. 
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Tissue cultures were identified as being abnormal by cytogenetic analysis (Sisley 
et al., 1990), which has allowed examination of a number of different phenotypic and 
genotypic parameters associated with this tumor type with the aim of developing new 
prognostic indicators for this tumor type. Using the described tissue culture procedure 
it has been possible to grow successfully 80 % of tumors for periods of up to 3 
months, and for several in vitro passages. Sucessful establishment of tumor cell lines 
was dependent upon the quantity of tumor material available as was the duration of the 
cell line in tissue culture. 
In spite of their importance in the context of ocular neoplasia, little information is 
available on the cytogenetics of uveal melanomas. Rey et al. (1985) and Griffin et al. 
(1988) reported on single cases, however more recent studies have reported non-
random abnormalities of chromosomes 3, 6, and 8 (Horsman et al., 1990; Prescher et 
al., 1990; Sisley et al., 1990), most of the published work on melanocytic tumors 
being confined to cutaneous melanomas (Pathak et al., 1983; Balaban et al., 1984; 
Cowan et aI., 1986; De Lucca et al., 1988). 
The overall ability of uveal melanoma to produce metastases is high, but it is 
recognised that metastatic potential varies from tumor to tumor, some having little or 
no metastatic potential, whereas others readily metastasise, and in part, these 
differences are reflected by the histological appearances of the tumor (Paul et al., 
1962). Tumor invasion and metastasis are complex interrelated multistage events 
which involve detachment and migration of tumor cells from the primary tumor mass 
into the surrounding tissues followed by spread to distant sites via the vasculature or 
lymphoid system. A major barrier to intravasation is the vascular basement membrane, 
a similar membrane is found around the lymphoid channels, this membrane is 
synthesised and lined by a layer of endothelial cells. If tumor metastasis is to occur, 
the tumor cell must attach to either the endothelial cells or to denuded basement 
membrane should this option be available, possibly as a result of fenestrations or 
damage to the endothelial ceUlayer. In the first situation the endothelial eels must be 
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stimulated to retract allowing the tumor cells access to the basement membrane, once 
this has occurred basement membrane degradation may proceed. Alternatively tumor 
cells may stimulate endothelial cells to alter the balance between synthesis and 
degradation of the basement membrane. 
Intra-ocular tumors, because of the lack of lymphatics, metastasise to distant sites 
exclusively via the blood stream, which implies that tumor cells must be capable of 
traversing blood vessel walls, including the basement membrane, and it is likely that 
tumor or host derived proteinases are major participants in this process. Expression of 
a number of different enzymes by tumor cells has been found to correlate with tumor 
invasion and/or metastasis: (a) metalloproteinases including interstitial collagenase 
(Liotta et al., 1982; Wooley, 1984), stromelysin (Matrisian et al., 1986) and 
gelatinase/type IV collagenase (Liotta et al., 1982); (b) serine proteinases including 
plasminogen activator (Quax et al., 1991), elastase (Kao et al., 1982) and mast cell 
chymase (Chiu and Lagunoff, 1972); (c) cysteine proteinases including cathepsins B, 
Hand L (Sloane and Honn, 1984; Murnane et al., 1991), and (d) glycosidases 
(Bernacki et al., 1985) including hyaluronidases (Fiszer-Szaforz and Gullino, 1970) 
and heparanases (Nakajima et al., 1984). In the reports cited above it should be noted 
that each tumor type has a specific enzyme proflle. One of the aims of this study was 
to identify the enzyme proflle associated with uveal melanomas which enables some 
tumors to metastasise and not others. 
Evidence has accumulated suggesting that a proteinase cascade involving serine 
and/or cysteine proteinase activation of one or more metalloproteinases, is pivotal to 
the breaching of basement membranes; in part due to the ability of these enzymes to 
degrade type IV collagen (Nakajima et al., 1987; Fessler et al., 1984; Liotta et al., 
1982). 
The metalloproteinase family of enzymes includes interstitial collagenase 
(Goldberg et aI., 1986), 72 kDa gelatinase (type IV collagenase) (Collier et al., 1988)~ 
92 kDa gelatinase (Wilhelm et al., 1989), stromelysin-l (Wilhelm et al., 1987), 
stromelysin-2 (Muller et al., 1988), stromelysin-3 (Basset et al., 1990), and Pump-l 
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(Quantin et al., 1989).The metailoproteinase enzymes are secreted as zymogens which 
require modification to their structure prior to attaining enzymic activity (Stetler-
Stevenson et al., 1989). Several studies have implicated these enzymes, and in 
particular stromelysin and type IV collagenase, in basement membrane degradation at 
the tumor cell-host interface; this process represents one of the key events in the 
invasive process (Nakajima et al., 1987; Fessler et al., 1984; Liotta et al., 1982). 
Yamagata et al. (1988; 1989), used zymography to compare the properties of two 
gelatinases (60 and 95 kDa forms), secreted in the conditioned media of murine 
fibroblasts, macrophages and various tumor cell lines, and demonstrated that cell lines 
with the greatest metastatic potential secreted the highest amount of the 95 kDa 
gelatinase (Yamagata et al., 1988; 1989). Furthermore, the present study has shown 
that in both cutaneous and posterior uveal melanoma cell lines, gelatinase production 
is influenced by the presence of certain cytokines and growth factors, particularly 
TNFa and TGF13 (Cottam et al., 1991). 
In this chapter, the expression of metalloproteinase enzymes in short term (1-5 
passages) cultures of human uveal melanomas is reported, and the expression of 
enzyme subtypes by these tumors are assessed in relation to other prognostic features 
of these tumors. 
Tumor cell invasion of the vascular basement membrane and the extracellular 
matrix is thought to occur by the synergistic action of a number of proteinases (Reich 
et al., 1988; Mignatti et al., 1986). In addition to gelatinase, posterior uveal 
melanomas were found to express tissue-type plasminogen activator (tPA). 
Plasminogen activator expression and its relationship with tumor malignancy and 
other prognostic indicators was investigated. High levels of expression of tP A have 
been associated with cutaneous melanomas (Wilson et aI., 1980) but the expression of 
plaSminogen activators by posterior uveal melanomas has received little attention. In 
this study the expression of plasminogen activators in a series of short term posterior 
uveal melanoma cell cultures was established and compared to the level of expression 
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of tP A in a series of established cutaneous melanoma cell lines. A recent report by 
Tsuboi and Rifkin (1990) suggested that a high level of expression of plasminogen 
activator may inhibit invasion rather than increase invasion of a denuded amniotic 
membrane due to the weakening of cell substratum contacts. However tP A has a 
number of functions which may augment metastasis rather than inhibit the process. 
tP A has a platelet binding site (Vaughan et al., 1989) which may, upon the formation 
of heterotypic platelet-melanoma cell emboli, facilitate the localisation of this enzyme 
in a similar way to the cell surface UK receptor. tPA is also reported to have a role in 
both platelet activation (Ohlstein et al., 1987; Niewiarowski et al., 1973) and platelet 
inhibition (Niewiarowski et al., 1973) and to cause platelet disaggregation (Loscalzo 
et al., 1987; Niewiarowski et al., 1973); this variety of actions appears to be the result 
of the concentration of plasmin produced as well as the duration of exposure to a 
given plasmin concentration (Loscalzo et al., 1987; Niewiarowski et al., 1973). The 
secretion of a number of platelet associated growth factors is linked with these events 
(Poggi et al., 1988). Thus platelets may contribute to successful haematogenous 
Spread by (1) forming a protective barrier between the tumor cells and the immune 
system following platelet aggregation, (2) causing release of platelet associated growth 
factors and (3) expression of platelet adhesion molecules which may enable attachment 
to basement membrane or endothelial cells (Albelda and Buck, 1990). In addition tPA 
is involved in stimulating endothelial cell migration (Inyang et al., 1990) and in 
fibrinolysis (Astrup et al., 1947), both of these actions may be important in allowing 
tumor cells access to the basement membrane. Subsequent basement membrane 
degradation may occur due to the action of tPA alone or by the synergistic action of 
tPA and gelatinases. Uveal melanomas, in addition to haematogenous spread, may 
invade locally through the sclera, which is composed of a mixture of proteoglycans, 
associated with fiber forming collagens. Whilst neither PA nor gelatinase can directly 
degrade the interstitial collagen triple helix, gelatinase is thought to have a synergistic 
action with interstitial collagenase in the degradation of these collagen types and 
plaSmin is known to degrade the telopeptide link regions between collagen fibers. This 
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suggests an important interrelationship between gelatinase and PA, which could 
potentiate tumor cell invasion. 
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5. 2. RESULTS. 
5. 2. 1. DNA Ploidy and Rate of Proliferation of Posterior 
Uveal Melanoma Cells. 
Based on the finding of this study, one publication has arisen and another is under 
review, a summary of the findings is given below. 
5. 2. 1. 1. Patient Details 
Forty nine tumors were analysed by flow cytometry, of the 49 patients. there were 
27 males (55 %) and 22 females (45 %) with a mean age of 61.5 years (range 21-90 
years). The mean period of follow up was 20.7 months (range 0-47 months). During 
this time four patients died, two had proven metastatic disease. one had suspected 
metastatic disease and for the other.patient no details were available. Mean survival 
times for these patients were 16.2 ± 10.9 months (range 8 to 32 months). 
5. 2. 1. 2. Pathological Details of the Tumors. 
Thirty one patients had choroidal melanomas (63 %). four patients (8 %) had 
Ciliary body tumours and fourteen patients (29 %) had tumors which involved both the 
choroid and ciliary body. Forty two tumors were classified as large (86 %) and seven 
were medium (14 %). 
Two tumors were classified as spindle (4 %). 34 as mixed (69 %) and 11 as 
epithelioid (22 %). no data was available on 2 tumors. Lymphocyte infilration was 
described as low. 
5. 2. 1. 3. Flow Cytometry. 
Flow cytometric analysis of 49 posterior uveal melanoma tumors showed that 47 
(96 %) had a diploid cell population. of these 2 (4 %) had a tetraploid subpopulation 
and 12 (24 %) had an aneuploid subpopulation. 3 (6 %) tumors were purely aneuploid 
(representative histograms are shown in figure S. 1). 
The percentages of cells in GYM and S phases in the 32 pure diploid tumors were 
summed to provide an index of cell proliferation. the percentage of cells in G2fMJS 
Was 7.3 ± 4.1 % (range 1.9 to 18.2 %). 
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The flow cytometric results for pure diploid tumors were then compared with 
histological cell type. The proportion of cells in G2fMjS for the 22 mixed cell tumors 
was 7.5 ± 4.6 % and for the 6 epithelioid cell tumors it was 7.5 ± 3.6 %, the 2 diploid 
spindle cell tumors had a value of 4.5 ± 1.2 %, cell type data was not available for 
two diploid tumors (results are summarised in table 5. 1). 
Whilst proliferation rates could not be determined for non-diploid tumors 
comparisons with the cell type classification were performed. Of the 2 diploid tumors 
which contained a tetraploid subpopulation 1 was mixed, data was not available on the 
other. Of the 12 diploid tumors with aneuploid subpopulations 3 were epithelioid, 8 
were mixed and 1 was spindle. 2 of the aneuploid tumors were mixed cell and 1 was 
epithelioid. There appeared to be a link between epithelioid cell type of the tumor and 
aneuploidy. 
There appeared to be a difference in the percentage of cells in G2fMlS between 
medium (5.8 ± 1.6 %) and large (7.8 ± 4.7 %) tumors. In agreement with our earlier 
report we found that there was no statistically significant difference between tumor 
location in the eye and the percentage of cells in G'lfMIS. The proportion of cells in 
G2fMlS was 6.8 ± 6.4 % for ciliary body tumors, 7.0 ± 4.2 % for choroidal tumors 
and 7.9 ± 4.3 % for tumors involving both the ciliary body and choroid. The three 
patients who died of proven metastatic disease had mean G2fMlS phase values of 11.5 
± 1.6 % (range 9.6 to 14.7 %). The coefficient of variation (CV) of the G(}I'GI peaks, 
which is a measure of sample quality was low, 7.5 ± 2.3 % (range 3.3 to 13.5 %). 
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Table 5. 1. 
Comparison of cell type with respect to mean percentage cells in the G'lfM/S phases of 
the cell cycle. 
Cell typea 
Spindle 
Mixed 
Epithelioid 
N 
2 
22 
6 
4.5 
7.5 
7.5 
Std. Dev 
1.2 
4.6 
3.6 
Minimum Maximum 
3.6 
1.9 
3.0 
5.4 
16.8 
11.3 
a Determined using the cell type classification system of McLean et al. 1983. 
b Determined by flow cytometric analysis of digested fresh uveal melanoma tissue (Rennie 
et al., 1989). 
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Fig. 5. 1. 
A series of representative Facs analyses. 
Uveal melanoma samples were analysed using flow cytometry as previously described 
and their ploidy values were determined in comparison to a lymphocyte control sample 
which represented a diploid population of cells. 
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Fig. S.l. continued 
MEL52. Diploid and aneuploid populations within the tumor. 
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5. 2. 2. The Development of a Short Term Culture System for 
Posterior Uveal Melanoma. 
Preliminary investigations to determine the most efficient tumor digestion protocol 
resulted in the following procedure: mincing of the tumor tissue with scalpels until the 
tissue fragments were less than Imm3 and the suspension of them in a digestion 
cocktail containing collagenase type II (0.025 %), pronase E (0.05 %) and 
dithiothreitol (0.5 JlM) in PBS; the digested tumor tissue was seeded onto a number of 
different growth surfaces in a variety of growth media. The optimum combination of 
factors was determined using different tumors. Less comprehensive studies were 
performed using individual tumors to 'fine tune' the protocol but these usually had a 
negligible effect upon successful melanoma cell culture establishment and longevity of 
the culture in vitro and shall not be discussed. As a consequence of the diversity of 
tumor cell phenotype the tumor was routinely suspended in 10 ml of growth medium 
and seeded onto two 25 cm2 tissue culture flasks, if the tumor was exceptionally large 
or small this would be increased or decreased accordingly. Whilst this study has not 
fully elucidated the optimum growth conditions for uveal melanoma celJ culture it has 
provided a reliable culture system enabling investigation of the in vitro characteristics 
of this tumor type. Photographs of uveal melanoma cells in culture are shown in 
figure 5.2. 
Study One. 
Determination of optimal growth medium for cell attachment and 
growth. 
Freshly digested uveal melanoma cells were suspended at a concentration of 1 
xl()6 cells/ml in seven different growth media and seeded onto tissue culture plastic 
using a volume to growth area ratio of 1 ml of cell suspension/5cm2 of growth surface 
(5 x106 cells/25 cm2 tissue culture flask). The cells were allowed to attach for 4 days 
at which point the medium was replaced with fresh growth medium. Growth medium 
was subsequently changed every 4 days until the end of the experiment. The different 
growth media were compared for their ability to allow successful attachment, growth 
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and their ability to support continued cellular growth over extended periods of time. 
The optimum growth medium was found to have a Hams F12 base supplemented with 
15 % FeS, 5 % Donor horse serum, glucose (2 gil) and epidermal growth factor (2 
ng/ml) (results are summarised in table 5. 2). 
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Table 5. 2. 
Detennination of optimal growth medium for cell attachment and growth. 
Growth Medium 
RPM! 1640 + 
10 % FCS 
RPM! 1640 + 
20 % FCS 
Dulbecco's + 
10% 
Dulbecco's + 
20% 
HamsF12 
+ 10 % FCS 
HamsF12 
+20 %FCS 
Oc. Mel Mediad 
Attachmenta 
+ 
+ 
+ 
+ 
++ 
++ 
+++ 
+ 
++ 
+++ 
Longevity of the 
Culturec 
+ 
+ 
+++ 
a Cell cultures were assessed by eye and the percentage of attached cells to the 
percentage of floating cells detennined and results recorded as follows: + low (0-30 % 
attachment), ++ medium (30-60 % attachment), +++ high (60-100 % attachment) 
b Indicates the comparative time required to reach confluence (90 % of the growth area 
covered by the cell monolayer) and results are represented as follows: - no growth, + 
low proliferation (the culture reaches confluency after 1 month), ++ average 
proliferation (the culture reaches confluency after 2·3 weeks), +++ high proliferation 
rate (the culture reaches confluency after 1-2 weeks). 
C Indicates the comparative number of in vitro passages for the culture to senescence 
(no detectable inl."Tease in cellular confluency for 2-3 weeks) and is represented as 
follows: - no initial growth, + low growth potential (reaches passage 1·2), ++ 
medium growth potential (reaches passage 3), +++ high growth potential (reaches 
passage 4-5). 
d Composition: Hams F12 basal medium supplemented with 15 % FCS, 5 % Donor 
horse serum, glucose (2 gil) and epidermal growth factor (2 ng/ml). 
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Study Two. 
Determination of optimal growth substratum for cell attachment and 
growth. 
Freshly digested uveal melanoma cells were suspended at a concentration of lxl()6 
cells/ml in ocular melanoma growth media and seeded onto six different growth 
surfaces using a volume to growth area ratio of 1 ml of cell suspension/5cm2 of 
growth surface (5xl()6 cells/25 cm2 tissue culture flask). The cells were allowed to 
attach for 4 days at which point the medium was replaced with fresh growth medium. 
Growth medium was subsequently changed every 4 days until the end of the 
experiment. The different growth surfaces were compared for their ability to allow 
successful attachment, growth and their ability to support continued cellular growth 
over extended periods of time. The optimum growth substrata were found to be 
collagens type I and IV and Costar vented tissue culture flasks the reason for the 
difference between the two different costar tissue culture flasks is unknown but may 
be due to improved circulation of C02 (results are summarised in table 5. 3). For 
simplicity Costar vented tissue culture flasks were routinely used. 
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Table 5. 3. 
Detennination of optimal growth substratum for cell attachment and growth. 
Growth surface 
Collagen type I 
Collagen type N 
Fibronectin 
Laminin 
Costar tissue 
culture flasks 
Costar vented 
tissue culture flasks 
Attachmenta 
+++ 
+++ 
++ 
++ 
++ 
+++ 
Longevity in 
Culturec 
+++ +++ 
+++ +++ 
+++ ++ 
+++ +++ 
++ ++ 
+++ +++ 
a Cell cultures were assessed by eye and the percentage of attached cells to the 
percentage of floating cells determined and results recorded as follows: + low (0-30 % 
attachment), ++ medium (30-60 % attachment), +++ high (60-100 % attachment) 
b Indicates the comparative time required to reach confluence (90 % of the growth area 
covered by the cell monolayer) and results are represented as follows: - no growth, + 
low proliferation (the culture reaches confluency after 1 month), ++ average 
proliferation (the culture reaches confluency after 2-3 weeks), +++ high proliferation 
rate (the culture reaches confluency after 1-2 weeks). 
c Indicates the comparative number of in vitro passages for the culture to senescence 
(no detectable increase in cellular confluency for 2-3 weeks) and is represented as 
follows: - no initial growth, + low growth potential (reaches passage 1-2), ++ 
medium growth potential (reaches passage 3), +++ high growth potential (reaches 
passage 4-5). 
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5. 2. 3. Cytogenetic Analysis of Short Term Posterior Uveal 
Melanoma Cultures. 
In a collaborative study (with Miss K. Sisley), who analysed short term cell 
cultures for cytogenetic abnormalities, the karyotypes of sixteen posterior uveal 
melanomas were analysed. Cytogenetic analysis of lymphocyte preparations showed 
that all patients had a normal constitutional chromosome complement. The results of 
the analysis are summarised in table 5. 4 and representative karyotypes are shown in 
figure 5. 3. Based on the cytogenetic findings of this study, one publication has arisen 
and another has been accepted for publication, a summary of genetic characteristics is 
given below. 
No cytogenetically detectable abnormalities were detected in two cases (MEL17 
and MEL61). 3 patients showed the loss of a sex chromosome, the Y chromosome 
(cases MEL22, MEL35 and MEL60). Nine tumors (MELll, MEL22, MEL30, 
MEL35, MEL37, MEL53, MEL47, MEL59 , and MEL63) showed structural 
anomalies of chromosome 6, which took the form of a deletion of the long arm, or 
trisomy of the short arm. Seven ciliary body tumors (MELlO, MEL30, MEL35, 
MEL37, MEL52, MEL57 and MEL63) had monosomy of chromosome 3 with one or 
two copies of i (8q). In MEL52 and MEL62 there was evidence of clonal evolution 
with some cells demonstrating increased dosage of the long arm of chromosome 8. 
One ciliary body tumor (MEL53) had monosomy of chromosome 3 but no associated 
i(8q), and one choroidal melanoma (MEL59) had trisomy 8 but no corresponding loss 
of chromosome 3. Three tumors (MEL52, MEL47. and MEL62) had deletions of the 
long arm of chromosome 11. Other abnormalities involved chromosome 1 (MELl!, 
MEL22 and MEL52), two of these were deletions of the short arm (MELlI and 
MEL22) and chromosome 13 was abnormal in MEL53 and MEL59. Trisomy 7 was 
observed in MEL22 and MEL35 and monosomy 16 in MEL30 and MEL35. In 
MEL22 two derivative chromosomes 22 were present with material possibly of Y 
origin, but it was not possible to perform C-banding to confirm this. A marker 
chromosome was present in MEL30, but could not be identified as a derivative of the 
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missing chromosome 13. Two clones were evident in MEL60 and MEL52 
demonstrated several sub clones. 
Table 5. 4. 
Karyotypes of a series of short tenn cultured uveal melanoma cell lines: major 
changes. 
Cell linea Chromosomal alterationsb 
MEL 10 NormaV+6p 
MEL 11 -3/+ i8q 
MEL 22 +7/ deleted chromosome 1 der 6q 
MEL 27 Nonna! 
MEL 30 -3/+ i8q (6.9) 
MEL 35 -3/+iSq i6p 
MEL 37 Normal/-3 +i8q 
MEL 47 der 6. 19. 22. 
MEL 52 -3/+i8q delllq t(1.10) 
MEL 53 -3. der 6. (9./17.) 
MEL 57 Normal/ -3 +8q 
MEL 59 t(6. 13) -13, 22 
MEL 60 NormaV-y 
MEL 62 
-3 +8, +i8q 
MEL 63 der (6) 
The following tumors had apparently nonnal karyotypes: MEL17, MEL36, and 
MEL61. 
a Chromosomal analysis obtained in collaboration with K. Sisley. 
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Fig. 5.3. 
Representative uveal melanoma karyotypes. 
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Karyotypes of MELlI and MEL22 showing the loss of chromosome 3 and an 
additional isochromosome 8q in MELlI. In contrast MEL22 shows no obvious 
detectable cytogenetic alterations. 
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5. 2. 4. Progelatlnase Expression by Posterior Uveal 
Melanomas In Short Term Culture. 
A series of posterior uveal melanomas have been studied to establish the pattern of 
gelatinase production (described in chapter 4) and this has been compared with other 
established prognostic indicators to assess its value in the prediction of both local 
invasion and metastasis. Histologically, eleven (78.6 %) tumors were of mixed cell 
type and three were found to be composed of purely epithelioid cells (21.4 %). 
Evidence of overt extrascleral spread was noted in five specimens (36 %) (see table 5. 
5. for patient details). By zymography all melanoma cell lines released an enzyme of 
approximately 72 kDa molecular weight, and 10 cell lines secreted an additional 92 
kDa progelatinase (summarised in table 4. 2). All enzyme activities detected could be 
activated with p-APMA, suggesting that the enzymes were latent metalloproteinases 
(examples of p-APMA activation are shown in Figs. 4. 2. and 4. 9). Enzyme activity 
in supernatants from all tumor cells could be completely inhibited by the inclusion of 
EDTA or 1, 10 phenanthroline in the incubation buffer, but PMSF, Net-MAL and E-
64 had no effect on enzyme activity, thus suggesting that substrate degradation was 
not due to serine or cysteine proteinase activities (examples shown in fig. 4. 1). No 
caseinolytic activities could be detected in any of the supernatants infering that the 
observed metalloproteinase activities were not due to stromelysins (examples shown 
in fig. 4. 3). This study is contained in chapter 4. 
There was no statistically significant difference (p=<O.05) between the mean ages 
of patients secreting both molecular weight species of metalloproteinase (mean age 
63.8 ± 9.2 years) and for those expressing only the 72 kDa progelatinase (mean age 
68.4 ± 14.2 years). Although the numbers are too small to permit a reliable statistical 
comparison, there does not appear to be any correlation between either location of the 
primary tumor, cell type or development of metastatic disease with progelatinase 
enzyme production. However, it is of interest to note that all four tumors with overt 
extrascleral spread secreted both 72 kDa and 92 kDa progelatinases. 
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Table S. S. 
Patients details. 
Patient Sex Age Tumor location Histological 
cell type 
MEL14a M 52 Choroid Mixed 
MEL17 M 64 Choroid Mixed 
MEL22 M 79 Ciliary Body + Mixedc 
Choroid 
MEL30a M 80 Ciliary Body + Mixedc 
Choroid 
MEL35 M 66 Ciliary Body Epithelioid 
MEL37a F 90 Ciliary Body + Mixedc 
Choroid 
MElAOb F 48 Choroid Mixed 
MElM M 76 Ciliary Body + Mixed 
Choroid 
MEIA7 M 67 Choroid Mixed 
MEL50 F 48 Ciliary body + Mixedc 
Choroid 
MEL52 F 72 Ciliary body + Mixed 
Choroid 
MEL55 M 72 Ciliary body + Epithelioidc 
Choroid 
MEL56b M 58 Ciliary Body + Epithelioid 
Choroid 
MEL57 F 63 Ciliary Body + Mixed 
Choroid 
M= male F= female 
a Deceased 
b Local resection, the eye was not removed surgery involved only removal of the 
tumor and the tissue contained within the resection margins which were typically 3-5 
mm from the tumors edge. 
c Evidence of extrascleral spread. 
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.5. 2. 5. Plasminogen Activator Expression by Posterior Uveal 
Melanomas In Short Term Culture. 
Attempts have been made to correlate PA activity with patient status for the uveal 
melanomas, and a series of cutaneous melanoma cell lines have been included for 
comparison. Histologically, eight (80 %) tumors were of mixed cell type and two 
were found to be composed of pure epithelioid cells (20 %). Evidence of overt 
extrascleral spread was noted in four specimens (44 %), evidence of extraocular 
spread was also noted in three specimens (see table 5. 5). By zymography all 
melanoma cell lines released an enzyme of approximately 70 kDa molecular weight, 
and most celllines expressed an enzyme species or enzyme inhibitor complex with a 
molecular weight of approximately 110 kDa. MEL37b and MELSO expressed an 
additional enzyme species with a molecular weight of SO-6O kDa; these activities had 
the ability to degrade casein only if plasminogen was co-polymerised in the gel (Fig. 
S. 5). Zymographic analysis of conditioned medium derived from cutaneous 
melanoma cell cultures displayed similar patterns of plasminogen-dependent 
degradation with bands of lysis of apparent molecular weights of 70 and 110 kDa 
respectively. There were no lower molecular weight species of plasminogen activator, 
as observed in MEL37b and MEL50, and no plasminogen-independent lysis of casein 
was detected. 
Using a chromogenic assay specific for plasminogen activators, the cell lines were 
found to express only fibrinogen fragment-dependent plasminogen activator activity, 
which is most probably tissue-type plasminogen activator (tPA). However, the 
activities detected in uveal melanoma cell supernatants were 10 fold lower than those 
detected in cutaneous melanoma cell supernatants, values were expressed as the mean 
± the standard deviation; 33.3 ± 25.5 mIU/ml (range 0-85 mIU/ml) and 469 ± 245 
mIU/ml (range 256-737 mIU/ml) for the uveal melanomas and cutaneous melanomas 
respectively. 
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The patterns of plasminogen activator expression were compared with the 
morphological and histological characteristics of the primary tumors as summarised in 
table 5. 6. The tP A activity secreted by uveal melanma cell cultures did not correlate 
with tumor location, cell type or ploidy values. However, there was a correlation 
between tumors which secreted the highest levels of tP A and extrascleral spread; these 
twnors also co-expressed the 92 kDa progelatinase species. 
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Table 5.6. 
Comparison of the morphological and histological characteristics of the primary tumor 
with expression of tissue plasminogen activator. 
Patient tPA activitya ploidyb extrascleral 92kDa 
(mIU/ml) spread progelatinase 
expression 
MEL30 46 ± 1.6 Diploid Yes Yes 
MEL35 19 ± 2.3 Aneuploid No Yes 
MEL37a 19 ± 1.0 Diploid Yes No 
MEL37b 65± 14 Diploid Yes Yes 
MEL40 26 ± 2.0 Diploid No No 
MElA4 20 ± 0.6 Diploid No No 
MEL47 0±0.4 Diploid No Yes 
MELSO 86 ± 6.4 Diploid! Yes Yes 
Aneuploid 
MELS2 20 ± 5.0 Diploid! No Yes 
Aneuploid 
MEL55 32 ± 9.4 Diploid! Yes Yes 
Aneuploid 
A375 737 ±25 Na Na No 
LT5.1 256± 85 Na Na Yes 
SK23 416 ± 57 Na Na No 
aThese values are the mean of two separate triplicate detenninations using the 
chromogenic assay of Leprince et aI. 1989. 
bAs determined by Facs analysis of the digested tissue. 
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Fig. 5. 5. 
Examples of uveal melanoma plasminogen activator expression patterns. 
97 kOa 
67 kOa 
45 kOa 
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 
The conditioned medium was analysed by zymography on 7.5 % w/v polyacrylamide 
gels containing 1 mg/ml casein and 60 ~g/ml plasminogen, control gels containing 
casein without plasminogen were run in parallel. Lane 1, MEL30; Lane 2, MEL50; 
Lane 3, MEL37b; Lane 4, MEL4O; Lane 5, MEL 47. 
171 
5. 3. DISCUSSION. 
Not all tumors give rise to populations of cells endowed with the ability to 
metastasise and successfully establish tumors in secondary organs. Genotypic and 
phenotypic properties are important in allowing tumor cells to traverse basement 
membranes and endothelial cell barriers, to survive the hostile enviroments of the 
blood (escaping host immune defence systems) and to colonise and grow at distant 
sites of the body (Fidler, 1990). Although certain clinical and histological criteria are 
associated with tumor progression, there are as yet no definitive markers of the 
invasive phenotype. 
A number of studies of cutaneous melanoma (Barlogie et al., 1980; Hansson et 
al., 1982; Sondergaard et al., 1983) have shown an increased incidence of aneuploidy 
amongst patients who died early of metastatic disease; the incidence of aneuploidy in 
cutaneous melanoma has been reported to be high (70-89 %). Two previous studies 
(Meecham and Char, 1986; Shapiro et al., 1986) involving the estimation of DNA 
ploidy in uveal melanomas reported that the incidence of aneuploidy was 36 % and 77 
% respectively. In contrast we observed a much lower level of aneuploidy (15.8 %) 
(Rennie et al., 1989), and have extended our initial study to show that with increased 
numbers the incidence of aneuploidy is 6 %; 12 tumours (24 %) were shown to have 
both diploid and and aneuploid cell populations. This latter observation may indicate 
that these tumours are undergoing clonal expansion of an aneuploid subpopulation, 
which is linked Vlith increasing malignancy (Shapiro et al., 1986). If these tumours 
are combined with the purely aneuploid tumours the incidence of aneuploidy is 30 % 
which is comparable to that observed by Meecham and Char (1986). At this time it 
cannot be confirmed that hyperploidy is linked to poor patient prognosis, since the 
only patients to have died of metastatic disease had diploid tumours. 
In the present study four patients with solely diploid cell profiles have died, two 
with proven metastatic disease and one with probable metastatic disease. When the 
rate of cell turno'/er within the diploid group was determined by summation of the 
total number of cc:lls counted in G2fM and S phases it was found that the patients with 
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metastatic disease all had values greater than 9.S % for their G1fMIS phase 
populations. This value should be interpreted with caution since the tumor will contain 
a number of non-tumor cell types, including vascular endothelial and stromal cells, 
which may be undergoing cellular division. However since this cell division may be 
stimulated by tumor derived growth factors and related to tumor-induced 
angiogenesis, it is unlikely to significantly influence the results. In addition to the 
fibrovascular population of the tumour it is probable that immunocytes will be present 
within the tumour, as has been reported by Hansson et al. (1982), however little or no 
infiltrate was observed in the tumors described in this study. 
We have previously found the percentage of cells in G2fMlS phases to be 
significantly lower than the 30 % reported by Shapiro et al. (1986), in the present 
study this ranged between 1.9 % and 18.2 % (7.3 ± 4.1 %). Shapiro et at. (1986) 
used paraffin fixed material whereas fresh material was analysed here. The results of 
this enlarged study are in agreement with our previous observations that spindle cell 
neoplasms have a lower cell turn over rate than epithelioid and mixed cell tumours, 
4.5 ± 1.2,7.5 ± 3.6 and 7.5 ± 4.6 respectively (table 5. 1). In contrast to the earlier 
observations there appears to be a difference between the rate of cell tum over and 
tumor size, medium and large tumours having values of 5.8 ± 1.6 % and 7.8 ± 4.7 % 
respectively. Obviously these values represent the rate of cellular turnover at the time 
of enucleation and it has been reported that choroidal melanomas are capable of rapid 
growth following periods of quiescence (Char et al., 1983). 
In the light of this larger study of ploidy and proliferation rates in posterior uveal 
melanomas, the initial observations (Rennie et al., 1989) can be confmned; however, 
two new trends hve become apparent, that of an apparently higher rate of cellular 
turnover in large tumours as compared to medium sized tumours and the correlation 
between high diploid tumour cell turnover rates and metastatic disease. Whilst this 
study is biased towards large and medium sized tumours due to current patient 
management it has relevance to uveal melanoma metastasis since it is these large 
tumours which pose the greatest threat to patients. 
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There are few investigations of the chromosomal changes associated with 
posterior uveal melanoma, mainly due to the rarity of this tumor type. Cytogenetic 
studies by our laboratory have confIrmed the non-random abnormalities described by 
Griffin et al. (1988) and Rey et al. (1985) involving chromosomes 3, 6, and 8. 
However our study has analysed 16 tumors, compared with only a single tumor in the 
studies by Griffin et al. (1988) and Rey et al. (1985). Grifrm et al. (1988) observed a 
single abnormality, trisomy of 6p, in one uveal melanoma and Rey et al. (1985) found 
structural anomalies of chromosomes 6 and 8, in the form of i (6p) and +8p which 
was virtually trisomic for 8q, in a uveal melanoma metastatic to the brain. Recently 
Prescher et aI. (1990) also demonstrated a non-random association of chromosomes 3 
and 8 in a series of fourteen tumors. Associated abnormalities between chromosomes 
3 and 8 have been observed in both renal cell carcinoma and lung adenocarcinoma 
(Drabkin et al., 1985; Miura et al., 1990), and involvement of c-myc and erb-A proto-
oncogenes have been suggested (Drabkin et al., 1985; Wong et al., 1986; Rabbitts et 
al., 1989). Tucker (1985) demonstrated an increased risk in adult males with uveal 
melanoma for the development of lung cancer. Hence it is possible that as 
abnormalities of erb-A and c-myc are shared by cancers such as renal, lung and 
posterior uveal melanoma. Whilst both cutaneous and uveal melanomas are 
melanocytic tumors, abnormalities of chromosomes 3 and 8 are rarely observed in 
cutaneous neoplasms (Limon et al., 1988) but appear to be common in uveal 
melanoma, thus indicating that uveal melanomas are genotypically distinct from their 
supposed cutaneous counterparts. In addition, these abnormalities appear to be 
characteristic of tumors arising in the ciliary body. Only one choroidal tumor had 
trisomy of chromosome 8 and no corresponding abnormality of chromosome 3. 
Monosomy of chromosome 3 and i (8q) may be uniquely associated with a subset of 
uveal melanomas. 
Another common abnormality of both cutaneous and uveal melanoma are 
rearrangements of chromosome 6, resulting in either deletions of the long arm or 
trisomies of the short (Cowan et al., 1986; Limon et al., 1988; Prescher et al., 1990; 
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Sisley et al., 1990). It has been suggested that abnormalities of chromosome 6 are 
linked with tumor progression, rather than genesis (Limon et al., 1988), and a recent 
study (Trent et al., 1990) demonstrated that introduction of chromosome 6 into human 
melanoma cell lines could reverse the the malignant phenotype. Thus structural 
changes of chromosome 6 may be an integral part of melanocytic transformation. 
Our studies are in agreement with those of Prescher (1990) who found structural 
abnormalities of chromosomes I, 11 and 13 in both ciliary body and choroidal 
tumors. We found rearrangements of chromosome 1 in 3 cases; this is a common 
feature of many solid tumors (Mitelman, 1988) which may reflect tumor progression 
(Limon et al., 1988; Dracopoli et al., 1989). In addition to these previously reported 
abnormalities, we have detected abnormalities in chromosomes 11 and 13. Three 
cases, 10, 12 and 15, showed deletions of the long arm of chromosome 11. No 
breakpoint was common to all, but two tumors did have a breakpoint in the region 
l1q23, which is in agreement with a tumor from Preschers (1990) series of fourteen 
uveal melanomas which also had a breakpoint at llq23. Several proto-oncogenes 
have been identified on the long arm of chromosome 11, including ets-lat llq23-24 
and hst, bel-I, int-2 and sea at llq13. Both deletions of llq23 in this study were 
found in tumors with choroidal involvement, and may therefore may be a 
characteristic feature associated with these tumors. The deletion of llq13 in case 15 
was not found in all cells examined and may therefore reflect tumor progression. Two 
cases, 11 and 14, had abnormalies of chromosome 13. Monosomy of chromosome 13 
was found in case II, while in contrast case 14 displayed a translocation between 
chromosome 6 and 13. Prescher (1990) observed both monosomy and structural 
rearrangements of tumors in his series of uveal melanomas. In addition to the presence 
of various oncogenes on chromosome II, the genes for both interstitial collagenase 
and stromelysin are present on the long arm of chromosome 11 (Spurr et al., 1988) 
Whilst the gene for 72 kDa gelatinase is located on 16q21 (Huh tala et al., 1990), the 
location of the gene for 92 kDa is not known.lt is interesting to note that we found no 
evidence for the expression of interstitial collagenase or stromelysin in the uveal 
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melanomas studied. There are currently few reports of abnormalities of chromosome 
13 in cutaneous melanomas, and this chromosomal abnormality may be a 
distinguishing feature of uveal melanomas. 
One important aspect of tumor cell metastasis is the ability of cells to migrate 
across basement membranes, a mechanism associated with the production of enzymes 
expressing gelatinolytic activity (Liotta et al., 1982; Fessler et al., 1984; Nakajima et 
al., 1987). In an attempt to further understand the association between such enzymes 
and tumor cell invasion, a series of uveal melanomas, propagated in vitro for 1 to 5 
passages, have been assessed for their ability to produce differing molecular weight 
species of enzymes with gelatinolytic activity. Approximately ftfty percent of patients 
undergoing surgical removal of their ocular melanomas will succumb to metastatic 
disease, commonly to the liver, within a ftfteen year period. Thus any property of the 
tumor which may predict metastasis would be valuable in determining the prognosis, 
and assist in patient management 
This study identifted two molecular weight forms of gelatinolytic enzymes, (72 
kDa and 92 kDa) produced by posterior uveal melanoma cells upon short tenn culture. 
Both these enzyme species were able to degrade gelatin, but not casein. Stromelysin is 
known to degrade casein under the assay conditions used in the present investigation 
(Wilhelm et al., 1987), but no caseinolysis was seen, and it is therefore unlikely that 
the active enzymes released from uveal melanoma cell cultures are stromelysins. There 
are however, several proteinases capable of degrading basement membrane and 
intercellular matrix components, including the plasminogen activators (Mackay et al., 
1990). One possibility is that the synergistic action of these two proteinase groups 
may contribute to the invasive properties of the tumor. 
Although, it is of academic interest to identify the production of a 92 kDa 
gelatinase in posterior uveal melanomas and speculate on its potential role in tumor 
invasion, the relatively small sample size and short follow up periods prevent any ftrm 
conclusions being drawn as to its clinical signiftcance. A long tenn longitudinal study 
of the pattern of proteinase secretion and its clinical correlate is currently in progress. 
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The acquisition by a tumor cell of an invasive malignant phenotype is in part due 
to the increased expression, or altered control of a number of proteases (Dano et a/., 
1985). Plasminogen activator expression has been shown to be involved in cellular 
invasion (Mignatti et a/., 1986; 1989; Yagel et al., 1988; 1989). Varani et al. (1987) 
found high levels of PA activity in the culture medium of malignant cells including 
Illalignant cutaneous melanoma cell lines. To the best of our knowledge the type and 
level of plasminogen activators expressed by uveal melanomas in short term culture 
has not been reported, and the present study demonstrates that posterior uveal 
Illelanoma cells secrete tissue-type plasminogen activator (tP A) into their culture 
Illedium at a level which is low (approximately 10 fold lower) in relation to a series of 
cutaneous melanoma cell cultures. In addition, two other species of plasminogen 
activator were observed; a 110 kDa PA and a 50-60 kDa PA. The 110 kDa species 
may represent the tPA: inhibitor complex reported by Dano et al. (1985) and the 
molecular weight of the 50-60 kDa species corresponds to that of urokinase-type 
plasminogen activator, although no fibrinogen-independent plasminogen activation 
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was detected in these samples. This suggests that either no biologically active 
urokinase-type plasminogen activator was present, possibly as a result of complex 
formation with plasminogen activator inhibitors, although such enzyme: inhibitor 
complexes could not be detected as discrete bands by zymography or that the 
sensitivity of this assay is lower than that of zymography. Recent work by Quax et al. 
(1991) has identified expression of both tPA and UK by invasive cutaneous 
melanoma cell lines, and correlated this co-expression with the incidence of 
spontaneous metastasis in nude mice. 
Uveal melanomas, with the exception of one tumor which did not express PA 
activity, expressed tissue plasminogen activator at levels which varied between 19 and 
86 mIU/ml wherelS the cutaneous melanomas studied expressed tP A at levels between 
256 and 737 mIU/ml. Whilst differences in tissue culture growth conditions or cell 
proliferation rate could account for these differences; the uveal melanoma cell cultures 
proliferated at a slower rate than the cutaneous melanomas used in this study. It is also 
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possible that the level of active enzyme is lower as a result of increased plasminogen 
activator inhibitor production by uveal melanomas. Relatively high tPA activities in 
uveal melanomas was found to correlate with extrascleral invasion in four tumors 
(MEL30, 37, 50 and 55) from patients with either clinical or histological evidence of 
extrascleral spread at the time of surgery. Two of these patients (MEL30 and 37) 
subsequently died from metastatic disease, whilst the remaining two are alive and have 
no detectable metastatic disease at present. The expression of both 72 and 92 kDa 
progelatinases by these cell lines was also studied, and it was noted that the four cell 
lines which expressed the highest tP A activities all expressed both 72 and 92 kDa 
progelatinases. Although nine out of fifteen tumors expressed both species of 
gelatinase. only the four expressing tP A activity had invaded the sclera. It is therefore 
tempting to suggest that it is possible that the synergistic actions of these two enzyme 
groups is important in scleral invasion. The sclera, which is composed of a mixture of 
interstitial collagens and sulphate-containing proteoglycans, may be degraded by the 
combined action of metalloproteinases and plasmin. 
The role of ti3sue-type plasminogen activator in metastasis is complex. Plasmin, 
the product of th(: action of plasminogen activators on plasminogen, has been shown 
to activate endothelial cell migration (Jnyang et aI., 1990), to degrade type IV collagen 
(Mackay et ai., 1990), and to activate latent metalloproteinases (Werb et ai., 1977). In 
addition to these actions, which can be correlated directly with vascular and connective 
tissue invasion, the ability to modulate platelet function with respect to the de novo 
expression of platelet related growth factors may be important for tumor metastasis. In 
chapter 2 the modulation of both uveal and cutaneous melanoma gelatinase expression 
by a series of cytokines was studied and uveal melanomas were found to respond in a 
similar way to cutaneous melanomas when insulted with TNFa and TGFp2 either 
singularly or in combination. The site specific metastasis, which is characteristic of 
uveal melanoma is, if this fact is taken in isolation, independent of degradative enzyme 
expression. However the expression of a particular profile of enzymes may be a 
prerequisite for tumor cell invasion, either through the sclera or through the vascular 
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basement membrane, it is only after escape from the primary tumor site has been 
accomplished that the phenotypic determinants for liver metastasis would become 
important, assuming that such factors are different from those involved in tumor cell 
escape. 
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CHAPTER 6 
INTRODUCTION: MELANOMA CELL ( 
PHENOTYPIC PARAMETERS ASSOCIATED 
WITH THE METASTATIC PHENOTYPE AND 
THEIR REPORTED MODULATION BY 
SELECTED CYTOKINES 
6. 1. INTRODUCTION: MELANOMA CELL PHENOTYPIC 
PARAMETERS ASSOCIATED WITH 
PHENOTYPE AND THEIR REPORTED 
SELECTED CYTOKINES. 
THE METASTATIC 
MODULATION BY 
The in vivo growth characteristics of A375 and A375/NUPRI in nude mice and 
the expression of gelatinase and modulation of gelatinase expression in vitro by 
cytokines have been studied in chapters 3 and 4 respectively. The complexity of the 
metastatic cascade necessitates that a successfully metastatic tumor cell must express a 
wide range of gr.netic, biochemical, immunological and biological traits, such as 
altered morphology, growth properties, cell surface components and receptors, a 
resistance to therapeutic agents, and the ability to invade and metastasize. The 
expression of some of these phenotypic traits are investigated in this section, together 
with the modulatory effect of cytokines which were found to induce the expression of 
92 kDa gelatinase in A375 and A375/NUPRl. 
Melanoma cells share a number of antigenic determinants with lymphoid cells, 
amongst these are the Thy antigen (Hersey et al., 1983), lILA class II antigens 
(Winchester et al., 1978; Wilson et al., 1979) ICAM-l (Johnson et al., 1989) and the 
common acute lymphblastic leukemia antigen (CAllA) or COlO (Carel et al., 1983). 
The tenn cytokine was fIrst used by Dr S. Cohen in 1974 to describe any soluble 
substance produced by lymphoid and/or non-lymphoid cells that exercises specifIc 
effects in its target cells. This definition has been modified to " a class of inducible, 
water soluble, heterogeneous proteinaceous mediators of animal origin of molecular 
weight greater than 5000 that exercise specific, receptor mediated effects in target cells 
and/or in the mediator-producing cells themselves. Such effects are typically the 
normal physiological control of 
(a) mitogenes~s which is required for cell proliferation and thus tissue development 
and repair, and 
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(b) cell function which is required for the maintenance of homeostatic and defence 
mechanisms, and the integrated control of different physiological systems (Meager, 
1990). 
Whilst many types of animal cell do not normally divide, cells are often stimulated 
to proliferate during normal physiological processes such as tissue repair, 
angiogenesis and morphogenesis. Malignant cells are characterised by their accelerated 
and apparently uncontrolled growth rates, and for convenience these can be 
subdivided into four distinct stages in the cell division cycle Gl, S, G2, and M. The 
fIrst stage, Gl is of 8-10 hours duration and involves cellular preparation for S phase, 
this typically involves synthesis of RNA and protein. S phase involves a period of 
DNA synthesis, RNA and protein synthesis also continue during this phase. The third 
stage, G2, is characterised by a cessation of DNA synthesis but RNA and protein 
synthesis continue for a further 3-4 hours. During the final stage, M phase, mitosi~ 
and cell division occur during which little or no DNA, RNA or protein synthesis takes 
place. Cells may either enter the cell cycle or become growth arrested, which is 
associated with entry into GO (O'Keefe and Pledger, 1983). 
Initially, TNFa was reported to cause haemorhagic necrosis of murine tumors 
(Carswell et al., 1975), suggesting its potential in therapy, but a consistent anti-tumor 
effect in cancer patients could not be achieved (Frei and Spriggs, 1989).The anti-
tumor activity of TNFa has been demonstrated both in vivo (Carswell et al., 1975; 
Helson et al., 1979; Watanabe et al., 1985a; Niitsu et al., 1988a) and in vitro 
(Watanabe et al., 1985b; Watanabe et al., 1988; Sugarman et al., 1985), and its action 
in animal models is thought to be due, in pan, to its cytotoxic and/or cytostatic 
potential (Sugarman et al., 1985), together with the ability to cause activation of anti-
tumor immune surveillance mechanisms (Palladino et al., 1987). Recently TNFa has 
been reported to have multiple effects on both tumor and host cell behaviour, 
including the stimulation of angiogenesis (Frater-Shroder et al., 1987), osteoclastic 
bone resorption (Bertolini et al., 1986), tumor cell invasion and metastasis of human 
ovarian carcinoma xenografts (Malik et al., 1989). TNFa has been reported to 
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modulate the expression of the cell surface molecules HLA class I and II which are 
involved in the generation and regulation of the immune response and cell-cell 
adhesion molecules such as intercellular adhesion molecule 1 (Maio et al., 1989), and 
to have an antiproliferative effect on human melanoma cells (Morinaga et al., 1989). 
The ability of 1NFa to lyse mouse fibroblasts during M phase is possibly due to its' 
ability to delay cell progression through G2 to M (Darzynkiewicz et al., 1984). Also it 
has been shown that A375 is capable of inducing 1NFa expression in monocytic cells 
following release of tumor derived GM-CSF (Sabatini et al., 1990). Also, TNFa is 
not equally cytotoxic to all tumor cells. and certain tumor cell types are resistant to its 
effect (Sugarman et al .• 1985; Shepard and Lewis. 1988). A suggested mechanism is 
that endogenous 1NFa production acts as a protective protein against the action of 
exogenous TNFa (Spriggs et al .• 1987; Niitsu et al .• 1988). Alternatively IL-6 
(Defilippi et al .• 1987). HER2/erb-B2 (Hudziak et al.. 1988) and the Mr 14.700 
protein of adenovirus E3 region (Gooding et al .• 1988) have been reported to act as 
protective factors. 
Recently expression of the TNFa gene has been reported to correlate with reduced 
tumorigenicity and reduced invasion in vivo (Vanhaesebroeck et al .• 1991). In 
contrast. Lollini et al. 1990 reported that murine B16 melanoma cells when treated in 
vitro prior to use in an experimental metastasis assay displayed enhanced lung 
colonisation in C57B1./6 mice. In related studies using ovarian cancer, Malik et al. 
(1989) showed that TNFa therapy promoted both peritoneal invasion and solid tumor 
formation of ovarian ascites in xenograft models. Later studies determined that cell 
expressing TNFa. following transfection with the TNFa gene. exhibited enhanced 
invasion and metastasis in nude mice Malik et al. 1990. 
Cellular exposure to n., 1 in vitro shows similarities to the effects of TNFa on 
tumor cells (Dinarello, 1989; Endo et al .• 1988) and has been reported to arrest A375 
melanoma cells in the Go-G 1 stage of the cell cycle (Morinaga et al., 1990). IL-6 has 
been reported both to contribute to the anti proliferative effect of n., 1 by acting as an 
autocrine factor (Morinaga et al., 1989) and also to have a strong inhibitory effect 
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itself (Heinrich et al., 1990; Kohase et al., 1986). In vivo intravenous administration 
of a-I prior to cell injection resulted in increased lung colony fonnation of the A375 
melanoma (Giavazzi et al., 1990) and daily intraperitoneal treatment increased the 
incidence of spontaneous lung and liver metastases following footpad tumor 
innoculation of B 16-BL6 melanoma cells (Bani et al., 1991). However this effect was 
only observed with cell lines which had previously been shown to be metastatic in 
nude mice and did not endow non-metastatic cell lines with the ability to metastasise. 
Activation of endothelial cells by cytokines has been shown to augment metastasis 
(Belloni and Tressler, 1989; Nicolson, 1988; Barbera-Guillem et al., 1989) possibly 
as a result of the de novo expression of adhesion molecules involved in the binding of 
malignant cells (Dejana et al., 1988; Lauri et al., 1990; Rice and Bevilacqua, 1989); 
this could result in site specific metastasis due to organ specific endothelial cell 
phenotypes. 
Modulation of HLA class I expression by tumor cells may influence T-cell or 
natural killer cell recognition of tumor cells (Elliott et al., 1989). An increase in class I 
MIle expression can be associated with a loss of susceptibility of some tumor cell 
lines to NK-mediated lysis. In addition class I MHC molecules have a role in 
intercellular adhesion (Bartlett and Edidin, 1978), contact inhibition of epithelial cell 
movement (Curtis and Rooney, 1979), and the control of endothelial cell clustering in 
vitro (Birkby et al., 1988). Class II:MIlC antigens playa role in the processes of cell 
proliferation and differentiation, the majority of the evidence for this being derived 
from studies on B cells (Cambier and Lehmann, 1989; Forsgren et al., 1984). Cross-
linking class IT molecules expressed on B cells has been shown to trigger elevation of 
intracellular calcium and cAMP, as well as nuclear translocation of cytosolic protein 
kinase C (Cambier et al., 1987). 
The majority (approximately 70 %) of melanomas in long term culture express 
HLA class IT antigens (Herlyn et al., 1980; Pellegrino et al., 1981; Houghton et aI., 
1982), which appears to be unrelated to their establishment from either primary 
tumors or metastases or to their growth characteristics in nude mice (Reynier et al., 
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1984; Welch et ai., 1991). However, Feldman et ai. (1988) and Kushtai et ai. (1988) 
have shown that expression of class I and II histocompatibility antigens correlates 
with the metastatic propensity of murine tumors. 
Intercellular adhesion molecule 1 (ICAM-l) is frequently found on cells of the 
melanocytic lineage, transformed cells showing a higher incidence of expression 
(Johnson et ai., 1989; Natali et ai., 1990). The expression of ICAM-l in primary 
lesions from stage 1 melanoma patients has been shown to correlate with tumor 
thickness (Johnson et al., 1989; Natali et ai., 1990), which is itself a prognostic 
indicator. The frequency of expression is higher in metastases than in primary lesions, 
indicating a possible selective process. Alternatively, this phenomena may be due to 
the effect of immunocyte derived cytokines (Matsui et ai., 1987; Pober et ai., 1986; 
Dustin et ai., 1986; Rothlein et al., 1986; Dustin et al., 1988; Maio et al., 1988).The 
high frequency of lCAM-1 expression in metastases is interesting, since lCAM-1 has 
been shown to be a ligand for lymphocyte function antigen-1 (LFA-l) in T cell 
mediated cytotoxicity (Makgoba et al., 1988) although LFA-1, LFA-3 and ICAM-1 
were reported not to be the major adhesion ligands for LAK cell mediated lysis on a 
series of target tumor cell lines none of which were melanoma cell lines (Quillet-Mary 
et al., 1991). 
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,6. 2. RESULTS. 
6. 2. 1. Modulation of the Proliferation Rates and Cell Cycle 
Kinetics of A375 and A375/NUPR1 by TNFa and IL·1 a. 
The effects of TNFa (1000 U/ml) and IL-la (100 U/ml) on cell proliferation, 
when used both as single agents or in combination for 24 hours, was investigated 
using 3H thymidine uptake. The results shown in Figures 6. 1 and 6. 2 represent the 
mean value ± the SD of 3 experiments. Both TNFa and IL-Ia were able to decrease 
3H thymidine uptake; this decrease was statistically significant (p<O.05. Student's t-
test). This effect was more pronounced with ll..-Ia and the magnitude of this effect 
could be further increased by co-stimulation with TNFa. The effect of TNFa and IL-
Ia on cell cycle kinetics, was investigated following staining of cellular DNA with 
propidium iodide and subsequent analysis by flow cytometry. 
Figures 6. 3 and 6. 4 show changes in the cell cycle distribution which occurred in 
treated and untreated A375 and A375/NUPRI cells. The percentage of cells in S/G2/M 
appeared to decrease in both A375 and A375/NUPRl cell lines in the presence of both 
Cytokines either individually or in combination. 
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Fig. 6. 1. 
3H thymidine incorporation by the A375 melanoma, used as a measure of cellular 
proliferation: modulation by lNFex and IL-I ex 
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Melanoma cells were seeded onto 96 well plates at a concentration of 4x104 cells/well, 
and allowed to equilibrate for 24 hours at 370 C in Dulbecco's medium containing 10 
% FCS in an atmosphere of 5 % C<h in air. Following two 1 hour washes with PBS 
at 370C, the cells were incubated in serum free medium containing cytokines (the 
concentrations used were: TNFex at 1000 U/ml; IL-1ex at 100 U/ml), either used alone 
or in combination, for 24 hours in the conditions described previously. Cells were 
pulsed with 3H thymidine, harvested and assayed as previously described in materials 
and methods. Values are the mean value ± the standard deviation of 3 experiments. 
* Statistically significant decrease (p<O.05, Student's t-test). 
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Fig. 6. 2. 
3H thymidine incorporation by the A375/NUPR1 melanoma. used as a measure of 
cellular proliferation: modulation by TNFa and IL-1 ex. 
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Melanoma cells were seeded onto 96 well plates at a concentration of 4Jf1Q4 cells/well. 
and allowed to equilibrate for 24 hours at 370 C in Dulbecco's medium containing 10 
% FCS in an atmosphere of 5 % C<h in air. Following two 1 hour washes with PBS 
at 370C. the cells were incubated in serum free medium containing cytokines (the 
concentrations used were: TNFa at 1000 U/ml; IL-la at 100 U/ml), either used alone 
or in combination, for 24 hours in the conditions described previously. Cells were 
pulsed with 3H thymidine, harvested and assayed as previously described in materials 
and methods. Values are the mean value ± the standard deviation of 3 experiments. 
• Statistically significant decrease (p<O.05, Student's t-test). 
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Fig. 6.3. 
Cell cycle distribution of A375 cell cultures: modulation by TNFa and IL-la. 
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The cell cycle kinetics of the A375 melanoma was determined using a DNA 
analysis kit (Becton Dickinson Ltd., Oxford, England); the kit was used by following 
the manufacturers instructions. Alterations in cell cycle kinetics due to cytokine 
treatment was studied as described in materials and methods. The cell cycle was 
analysed using an orthocyte benchtop flow cytometer attached to a PC computer and 
the % of cells in Go/Gt. S and G2/'M phases of the cell cycle was determined. The 
Go/G} peak channel number and the coefficient of variation (CV) of this peak were 
recorded and used to produce histograms. Samples with a CV greater than 10 
channels were considered to be of poor quality due to inadequate cellular or DNA 
staining and not used. 
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Fig. 6. 4. 
Cell cycle distribution of A375/NUPRl cell cultures: modulation by TNFa and IL-
Ia. 
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The cell cycle kinetics of the A375/NUPRl melanoma was detennined using a 
DNA analysis kit (Becton Dickinson Ltd., Oxford, England); the kit was used by 
following the manufacturers instructions. Alterations in cell cycle kinetics due to 
cytokine treatment was studied as described in materials and methods. The cell cycle 
was analysed using an orthocyte bench top flow cytometer attached to a PC computer 
and the % of cells in G<iGl. S and G2fM phases of the cell cycle was determined. The 
G(Y'GI peak channel number and the coefficient of variation (Cy) of this peak were 
recorded and used to produce histograms. Samples with a CV greater than 10 
channels were considered to be of poor quality due to inadequate cellular or DNA 
staining and not used. 
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6. 2. 2. The Influence of TNFa and IL-1 a on The Major 
Histocompatablllty Class I and II Antigens and Intercellular 
Adhesion Molecule-1 (ICAM-1) Expression by A375 and 
A375/NUPR1. 
The expression and modulation of class I and II major histocompatability antigens 
by cytokines in two related human cutaneous melanoma cell lines, A375 and 
A375/NUPRl was investigated in vitro. Both cell lines showed similar levels of 
expression of class I and II MHC, which was unaltered following 24 hour exposure 
to the cytokines IL-la and TNFa either as single agents or in combination (figures 6. 
5 and 6. 6). 
The expression and modulation of ICAM-l by cytokines in A375 and 
A375/NUPRl was investigated in vitro. Both cell lines showed similar levels of 
reAM-I. rL-la and TNFa was shown to increase ICAM-l expression, TNFa 
having a greater effecL Co-incubation of the cell lines with both cytokines failed to 
increase expression of ICAM-l to levels significantly higher than those acheived with 
TNFa alone. The magnitude of the TNFa induced increase in ICAM-l expression 
was 5 fold and 7 fold for A375 and A375/NUPRl respectively. IL-la caused 2.5 
fold and 5.4 fold increases for A375 and A375/NUPRl respectively; co-incubation 
causing 5 fold and 7.5 fold increases for A375 and A375/NUPRl respectively 
(figure 6. 7). 
This study was performed in collaboration with Mr M. Mesrl. 
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Fig. 6. 5. 
Expression of MHC class I on the related melanoma cell lines A375 and 
A375/NUPR1 and its modulation by TNFa and ll..-la. 
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Melanoma cells were seeded onto 25 cm2 tissue culture flasks at a concentration of 
1 x 106 cells/flask. and allowed to equilibrate for 24 hours at 370 C in Dulbecco's 
medium containing 10 % FCS in an atmosphere of 5 % C02 in air. Following two 1 
hour washes with PBS at 370C. the cells were incubated in serum free medium 
containing cytokines (the concentrations used were: TNFa at 1000 U/ml; ll..-la at 
100 U/ml). either used alone or in combination, for 24 hours in the conditions 
described previously. Following completion of the experimental protocol, the cells 
were harvested and stained with an excess of monoclonal antibody (MoAb) (W6/32. 
10 ~l as determined by titration assays) as described in materials and methods. The 
cells were resuspended and flxed in 1 % paraformaldehyde and analysed with an 
orthocyte bench top flow cytometer attached to a PC computer (Ortho Diagnostic 
Systems Ltd). Background fluorescence was assessed by including a control with no 
primary MoAb added. Mean fluoresence intensity was given as channel number on a 
linear scale from 1 to 2048. Results are the mean of 3 experiments ± the SD. 
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Fig. 6. 6. 
Expression of MHC class II on the related melanoma cell lines A375 and 
A375/NUPRI and its modulation by TNFa and IL-Ia. 
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Melanoma cells were seeded onto 25 cm2 tissue culture flasks at a concentration of 
1 x 106 cells/flask, and allowed to equilibrate for 24 hours at 370 C in Dulbecco's 
medium containing 10 % FCS in an atmosphere of 5 % CO2 in air. Following two 1 
hour washes with PBS at 370C, the cells were incubated in serum free medium 
containing cytokines (the concentrations used were: TNFa at 1000 U/ml; IL-Ia at 
100 U/ml), either used alone or in combination, for 24 hours in the conditions 
described previously. Following completion of the experimental protocol, the cells 
were harvested and stained with an excess of monoclonal antibody (MoAb) (Ill.A-
DR, 5 ~ as determined by titration assays) as described in materials and methods. 
The cells were resuspended and fixed in I % paraformaldehyde and analysed with an 
orthocyte bench top flow cytometer attached to a PC computer (Ortho Diagnostic 
Systems Ltd). Background fluorescence was assessed by including a control with no 
primary MoAb added. Mean fluoresence intensity was given as channel number on a 
linear scale from 1 to 2048. Results are the mean of 3 experiments ± the SD. 
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Fig. 6. 7. 
Modulation ofICAM-l expression in A375 and A 375/NUPR1 by TNFa and ll...-la. 
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Melanoma cells were seeded onto 25 cm2 tissue culture flasks at a concentration of 
1 x 106 cells/flask, and allowed to equilibrate for 24 hours at 370 C 'in Dulbecco's 
medium containing 10 % FCS in an atmosphere of 5 % CO2 in air. Following two 1 
hour washes with PBS at 370C, the cells were incubated in serum free medium 
containing cytokines (the concentrations used were: TNFa at 1000 U/ml; ll..-la at 
100 U/ml), either used alone or in combination, for 24 hours in the conditions 
described previously. Following completion of the experimental protocol, the cells 
were harvested and stained with an excess of monoclonal antibody (MoAb) (ICAM-l, 
20 Ill, as determined by titration assays) as described in materials and methods. The 
cells were resuspended and fixed in 1 % paraformaldehyde and analysed with an 
orthocyte bench top flow cytometer attached to a PC computer (Ortho Diagnostic 
Systems Ltd). Background fluorescence was assessed by including a control with no 
primary MoAb added. Mean fluoresence intensity was given as channel number on a 
linear scale from 1 to 4096. Results are the mean of 3 experiments ± the SD. 
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6. 2. 3. The Effect of Pretreatment With TNFa on the 
Experimental Metastatic Potential of A375. 
A375 cells pretreated by 24 hour incubation with TNFa were used in an 
experimental metastasis assay to determine the effect of TNFa on lung colonisation. 
The assay was performed as previously described, and animals were examined for 
lung colonies 12 weeks after injection. Control mice received A375 cells which had 
been placed in serum free conditions for 24 hours. TNFa was not found to increase 
experimental metastasis when this protocol was used; the results are shown in table 6. 
1. 
Table 6.1. 
The effect of preincubation of A375 tumor cells with TNFa prior to determination of 
experimental metastatic potential. 
Cell linea 
A375 
A375+TNFa 
number of mice with lung 
metastases/number 
injectedb 
0/16 
1/16 
Number of lung 
metastases/mouse 
Na 
1 (L) 
aSubconfluent cultures were washed twice for 1 hour at 370 C, then incubated in 
serum free medium for 24 hours at 370 C.TNFa treated cultures were washed as 
described and exposed to 1000 U/ m1 of TNFa for 24 hours. 
bMice were examined at autopsy for the macroscopic presence of lung (L), liver (Li). 
and peritoneal (P) metastases. 
Na Not applicable. 
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6. 3. DISCUSSION. 
The effects of TNFa. on a number of A375 melanoma cell phenotypic 
characteristics reported to be associated with the metastatic phenotype were studied 
and related to in vivo experimental metastatic potential in nude mice. The aims of this 
study were (1) to determine if pretreatment of A375 melanoma cells with TNFa. prior 
to intravenous injection could augment experimental metastatic propensity in nude 
mice; (2) to establish which, if any, of the phenotypic characteristics studied were 
modulated by TNFa. andlor IL-la. treatment. In this context, the differences in the 
expression, by A375 and A375/NUPR1, ofHLA class I and II molecules and ICAM-
1 in vitro and their modulation by exposure to TNFa. and IL-1a. were investigated. 
The effects of exposure to TNFa. and IL-la. for 24 hours on A375 and A375/NUPRl 
melanoma cell proliferation rate and cell cycle kinetics in vitro. 
There is increasing evidence of an association between intercellular adhesion 
molecule 1 (ICAM-l) expression and melanoma progression (Holzman et al., 1987; 
Johnson et al., 1988; Johnson et al., 1989; Natali et al., 1990). These studies report 
that ICAM-1 is expressed at higher levels on cells which have sucessfully completed 
the metastatic cascade of events than on the cells in the primary tumor or pre-
cancerous lesions, suggesting that ICAM-1 may playa role in the metastatic process. 
In addition Feldman et al. (1988) and Kushtai et al. (1988) have correlated expression 
of major histocompatability antigens with metastatic propensity; however in contrast, 
Rodolfo et al. (1988) found that HLA class I and II antigens did not correlate with 
metastatic ability in nude mice. 
Exposure of both cell lines to TNFa. and IL-la. alone caused a decrease in 
proliferation rate to occur, IL-1a. having the more pronounced effect. Co-incubation 
with both cytokines produced an increase in the magnitude of the growth inhibition 
relative to the effects of a single cytokine. This decrease in proliferation rate was 
linked with an decrease in the number of cells present in S/Ch and M phases of the cell 
cycle. 
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In addition, this study has shown that A375 and A375/NUPRI cells constitutively 
express similar levels of MHC class I and II and ICAM-I in vitro. Class I and II 
MHC expression on both cell lines was unaltered following 24 hour exposure to the 
cytokines IL-Ia and TNFa either as single agents or in combination. However. both 
IL-Ia and TNFa increased lCAM-1 expression, TNFa having a greater effect than 
IL-I a. Co-incubation of the cell lines with both cytokines failed to increase 
expression of lCAM-1 to levels significantly higher than those achieved with TNFa 
alone. The magnitude of the TNFa induced increase in lCAM-1 expression was 5 
fold and 7 fold, 2.5 fold and 5.4 fold for IL-Ia. Co-incubation caused 5 fold and 7.5 
fold increases for A375 and A375/NUPRI respectively. It is interesting to note that 
HLA class I expression was unaltered by treatment with TNFa andlor IL-Ia and 
therefore unaffected by the changes they induced in cell cycle kinetics and proliferation 
rate. In contrast lCAM-1 expression was increased by these cytokines and expression 
was found to be inversely related to the rate of proliferation; an increase in the number 
of cells in the S/02 and M phases of the cell cycle perhaps being indicative of 
increased ICAM-I expression in these phases of the cell cycle. This study has 
illustrated the complex changes in melanoma cell phenotype which may occur 
following exposure to TNFa andlor IL-Ia.ln vivo this may occur through contact 
with or close proximity to tumor inflltrating lymphocytes. tumor associated monocytes 
andlor other mesenchymal, endothelial or epithelial host cells. Growth inhibition and 
cytolysis of tumor cells is of obvious importance in cancer therapy but the associated 
changes in tumor cell phenotype, possibly creating a phenotype associated with 
successfully metastatic cells should not be overlooked. 
Intravenous injection of TNFa treated A375 melanoma cells did not increase 
experimental metastatic potential. The inhibitory effects of TNFa and IL-Ia on 
cellular proliferation rate may be responsible for the lack of an increase in experimental 
metastatic potential since this decrease in proliferation rate may preceed cytolysis, 
which although undetected in vitro may occur after arrest in the nude mouse. 
Alternatively the reduced rate of proliferation may inhibit growth at the secondary site. 
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It is possible that an increase in lCAM-1 expression may be irrelevant to increasing 
metastatic propensity. since it is a possibility that receptor: ligand interactions will not 
function due to the species barrier involved. or the immunodeficient status of the nude 
mouse. which enables successful xenografting to occur. may reduce the number of 
lymphocyte: tumor cell interactions and hence possible lymphocyte aided metastasis 
will be reduced. Alternatively other tumor cell: host cell interactions may be altered 
following exposure to cytokines resulting in tumor cells unable to interact effectively 
with host cells i. e. adherance to vascular endothelium. Recent reports (Mortarini et 
al .• 1991) have indicated that the integrin receptors VLA 1.2 and 6 were weakly 
expressed on primary tumors compared to metastases. The expression of these 
molecules and their modulation by cytokines was not studied in our investigation. 
hence. we have no information regarding their modulation by TNFa or IL-1a or their 
possible role in experimental metastasis in our model. 
However. it is interesting to speculate about the relative importance of adhesion 
molecule expression. MHC expression and rate of proliferation. to successful 
completion of the metastatic cascade. One could hypothesise that following 
intravenous injection of tumor cells. the first obstacle to overcome would be the hosts 
immune response. then attachment followed by degradation of the basement 
membrane and subsequent invasion into the interstitial stroma. The ability to 
proliferate and form a detectable lesion may then be the critical factor in the 
establishment of a metastasis. This scenario is in no way complete.We do not know 
the relative abilities of the two cell lines to withstand the mechanical trauma of the 
vasculature; if this is modulated by cytokines; whether in vitro lCAM-1 and gelatinase 
levels of expression are important in this model or the duration of the growth 
inhibition caused by TNFa. 
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CHAPTER 7 
GENERAL DISCUSSION 
CHAPTER 7 
GENERAL DISCUSSION 
Tumor metastasis is an extremely complex process involving many aspects of cell 
biology. Markers for metastasis have involved the study of ploidy values, genetic 
alterations, at both the molecular and cytogenetic levels, and the identification of 
phenotypic traits and alterations in cellular behavior possibly responsible for organ 
specific metastasis. The data contained in this thesis has been obtained by the use of a 
number of diverse and complimentary investigations of in vivo tumor growth 
characteristics, metastatic potential and also the study of specific molecules thought to 
be involved in invasion in vitro. It is pertinent to consider the implications of these 
fmdings for tumor metastasis. 
This thesis has addressed a number of potentially important questions relating to 
the nature of uveal melanoma and its similarities andlor differences to cutaneous 
melanoma. These have involved comparative studies in vivo (chapter 3) and in vitro, 
with particular emphasis on the expression and modulation by ·cytokines, of 
proteinases thought to be involved in invasion (chapters 4 and 5). A number of other 
phenotypic characteristics considered to be involved in determining the metastatic 
propensity of tumor cells by TNFa and IL·l were also studied (chapter 6). The 
influence of pretreatment of A375 melanoma cells with TNFa on experimental 
metastatic potential in nude mice was investigated. 
Uveal melanoma displays a characteristic pattern of metastasis, showing 
involvement of the liver in 97 % of cases (Jensen. 1963), and metastasis to regional 
lymph nodes is virtually unknown (Zimmerman 1980b), whereas cutaneous 
melanoma displays a different pattern of metastatic spread which frequently shows 
lymph node involvement (Nicolson, 1982). The reason for this disparity is unclear 
and it is unlikely that there is a single determining factor, although such a possibility 
cannot be excluded. Rather it may be the case that a number of contributory factors are 
involved. Using the seed-soil hypothesis (Paget, 1889), it is tempting to speculate that 
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there may be factors present in the liver that promote one or more of the following 
events: attachment, invasion into the organ parenchyma and growth and possibly 
inhibition of the development of lymph node metastases. 
In vivo studies of uveal melanoma growth and metastasis were performed in 
congenitally athymic nude mice and initial observations concluded that tumor growth 
was a rare event (21 %), and with the tumors that grew, the growth was slow (taking 
upto 12 weeks to form visible tumors) in comparison to the established cutaneous 
melanoma cell lines. This observation is in contrast to that of Phillips et al. (1989), 
who reported that ocular melanomas failed to grow in either nude or SCID mice. 
Ocular melanoma growth was infrequent and slow, and such tumors did not 
metastasise to the liver, this being the most frequent site of metastasis for uveal 
melanoma in patients (Jensen et al., 1963). Therefore, this system cannot be 
considered a model for uveal melanoma metastasis. Further studies could involve the 
use of SCID mice, and possibly intra-ocular implantation of melanoma tissue or cell 
lines (Harning and Szalay, 1987), or intra-splenic injection of dissociated tumor 
samples, which has proved a successful route for colon carcinoma (Kozlowski et al., 
1984). Intra-splenic injection has been used previously to select for melanoma 
subpopulations with increased liver colonisation potential (Sargent et al., 1988; 
Ladanyi et al., 1990) and this increase in liver colonisation has been shown to be due 
to growth stimulation of the tumor cells in the presence of hepatocytes (Sargent et al., 
1988). The applicability of animal studies to human cancer metastasis is contraversial 
since the introduction of human cells into a mouse immediately introduces an aspect of 
heterogeneity into any subsequent observation, in addition tumor growth in these 
models is frequently rapid which is in contrast to the growth of many human 
neoplasms in patients. 
It was interesting to note that the doubling time for cutaneous melanomas 
following intradermal implantation was lower than for subcutaneous implantation, the 
reason for this is at present unknown, but seeding of the tumor cells onto the 
basement membrane may be responsible, possibly because of the ability of the 
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basement membrane to stimulate and polarise cellular growth (Review: Farquhar, 
1981). However, a number of different explanations could be given to account for this 
observation such as, a reduction in the resistance that the growing tumor may 
encounter due to this site or a more generally suitable microenviroment for growth. 
Whilst the level of lung colonisation observed, following tail vein injection of a single 
cell suspension of either A375 or A375/NUPR1, showed that the experimental 
metastatic potential of A375/NUPRl was higher than that of A375, the incidence of 
spontaneous metastasis displayed by these cell lines was approximately equal and of a 
low magnitude. 
In attempts to explain this increase in experimental metastatic potential of 
A375/NUPR1 in nude mice, a number of parameters, thought to be involved in 
metastasis, were studied in vitro, these included, progelatinase expression (Yamagata 
et al., 1989; 1990), MHC class I and II (Van Muijen et al., 1991), ICAM-l 
expression (Johnson et al., 1989) and the relative rates of proliferation for the two cell 
lines. These were generally found to be of similar orders of magnitu~e; with the 
exception that A375/NUPR1 which constitutively expressed the 92 kDa progelatinase 
in vitro wheras the parent cell line did not; however, no data concerning the 
expression of this proteinase in vivo is available at present. It is unlikely that the 
increase in experimental metastatic potential observed for A375/NUPRl is solely due 
to the de novo expression of the 92 kDa progelatinase, and may be due to a number 
of, as yet undetermined, parameters. Further studies presented here examined the 
modulation of these factors by cytokines, and established that the two cell lines 
responded differently to TNFa and IL-l. The effect of IL-l on A375/NUPRl 
melanoma cell cultures was more pronounced than its effect on A375 cell cultures. 
MMP-9 (92 kDa gelatinase) was upregulated by IL-l in A375/NUPRl cells but not in 
A375 cells. Similarly, the magnitude of ICAM-1 modulation was greater in 
A375/NUPR1 than in A375 cells, suggesting that a sub-population may have been 
selected following in vivo passage of the parental cells.The different response to IL-l 
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is possibly due to altered signal transduction pathways. although the precise 
mechanism has still to be established. 
A large component of the study involved the identification of phenotypic 
characteristics common to uveal and cutaneous melanomas. These focussed on 
proteinase expression by these cell types. particularly MMP-9 and MMP-2 (92 and 72 
kDa progelatinases respectively). and tissue plasminogen activator. Not only did both 
types of melanoma express the same enzyme profiles. but they were also susceptible 
to modulation by the same agents. In situ hybridisation for mRNA and 
immunolocalisation of proteinase and proteinase inhibitor molecules may detennine 
whether their expression in situ is similarly controlled. 
The fact that melanoma cell cultures constitutively express progelatinase and 
secrete high amounts in vitro is interesting. The enzyme was found in a latent state. 
requiring loss of an amino-terminal peptide for activity. However. the mechanisms 
involved in the activation of the metalloproteinases are exquisitely complex. and much 
research is directed towards elucidating the details of this process (Review: V an Wart 
( 
and Birkedal-Hansen. 1990). The mechanism of activation of the metalloproteinases 
in vivo is generally accepted to be undefined. however. in vitro there appear to be 
differences in the control of activation between the different metalloproteinase groups. 
MMP-2 and MMP-9 (72 and 92 kDa progelatinases) are enzymes which display 
characteristics not yet observed in other proteinases to date. The 72 and 92 kDa 
gelatinases have been found to co-purify with TIMP-2 and TIMP-1 respectively, as 
stable proenzyme-inhibitor complexes with the inhibitor bound at a site other than the 
active site (Goldberg et al., 1989; Wilhelm et al., 1989). It is not known if these 
enzymes-inhibitor complexes are secreted as separate molecules which associate 
following secretion, or if the enzyme-inhibitor complex is assembled intracellularly 
and then subsequently secreted. This situation is in contrast to the majority of known 
enzymes which are capable of binding inhibitors only at their active sites when active. 
The 72 kDa gelatinase, once it has formed a complex with TIMP-2, has a reduced 
susceptibility to auto-activation (Howard et al .• 1991) and this stabilisation may be 
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important in vivo. Removal of TIMP from its complex with gelatinase results in auto-
activation and the production of a number of unstable but highly active enzyme 
fragments (Howard et al., 1991). Furthermore, once activated, they may be inhibited 
by TIMP. Interestingly this unusual complex formation of TIMP-1 with the MMP-9 
and TIMP-2 with MMP-2 has not been observed with the other matrixins, although 
TIMP-2 has been shown to preferentially inhibit type II matrixins (Howard et al., 
1991). This dual control of the enzyme (activational repression and inhibition) by 
TIMP suggests an important role for these enzymes in vivo. 
The study of in situ patterns of enzyme and inhibitor expression by different 
tumor types may prove to be useful in understanding invasive tumors, and it is 
interesting that this study found that melanoma, which is considered to be a highly 
metastatic tumor, constitutively expresses only the type II matrixins (gelatinases). The 
expression of type III matrixins (stromelysins) by melanomas has not been reported, 
and expression of type I matrixins (interstitial collagenases) although reported by one 
group (Smyth Templeton et al., 1990) awaits conflrmation. Neither type I or type III 
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matrixins were detected in the present study using gelatin and casein zymography. It is 
interesting to speculate about this pattern of enzyme expression and its association 
with melanoma: of the three matrixin families, the type II matrixins are the only 
enzymes which are thought to be capable of binding to their substrates prior to 
activation or as an enzyme-inhibitor complex. This most likely occurs because of the 
presence of a fibronectin-like collagen binding domain present in only the 72 kDa and 
92 kDa gelatinases (Goldberg et al., 1989). In addition an a2 (V) collagen-like 
domain is present in the 92 kDa gelatinase, the function of which is unknown, but 
which may be involved in the binding of this enzyme to type V collagen. In this study 
it was observed that high levels of gelatinase were secreted into the culture medium; 
should this occur in vivo and the enzyme be capable of binding to its substrate in an 
in vivo milieu, then subsequent degradation of associated TIMP-1 by elastase (Okada 
et al., 1988) may result in an autoactivated enzyme associated with its substrate in a 
way that may prevent inhibition by TIMP, due to the close proximity of the enzyme 
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and its substrate. This combination of factors: high levels of enzyme secretion; the 
ability of the enzyme to bind to substrate prior to activation to form an enzyme-
inhibitor complex and subsequent activation by removal of the stabilising inhibitor by 
proteolysis, suggests a scenario where enzyme/enzyme-inhibitor complexes attached 
to its appropriate substrate awaits activation by the appropriate stimulus. This stimulus 
may be the arrival of cells possibly by macrophages or neutrophils, secreting elastase 
(to degrade TIMP-l) or other proteinases capable of degrading TIMP-2 at this site, 
which may facilitate the rapid invasion commonly associated with melanoma. 
The in vitro experimental data presented in this thesis determined that certain 
cytokines. TNFa, TGF13 and IL-I a/13. are capable of altering melanoma cell 
phenotypic characteristics in such a way as to enhance the metastatic ability of these 
cells; however, other characteristics such as proliferation rate are decreased. When 
TNFa treated cells were used in an experimental metastasis assay in nude mice, their 
metastatic ability remained unaltered, suggesting that the factors which were 
upregulated were not rate limiting for successful experimental metastasis. The role of 
, 
TNFa and IL-l in tumor metastasis is an area of current interest. Lollini et al. (1990) 
reported that murine B16 melanoma cells when treated in vitro prior to use in an 
experimental metastasis assay displayed enhanced lung colonisation in C57Bl./6 mice, 
and Bani et al. (1991) studied the effect of intravenous injection ofIL-1 in nude mice 
on the experimental metastatic potential of the A375 melanoma, which was found to 
be increased. In related studies using ovarian cancer, Malik et al. (1989) showed that 
TNFa therapy promoted both peritoneal invasion and solid tumor formation of 
ovarian ascites in xenograft models. Later studies determined that cells expressing 
TNFa. following transfection with the TNFa gene, exhibited enhanced invasion and 
metastasis in nude mice (Malik et al. 1990). The study of Lollini et al. (1990) involved 
the use of murine melanoma cells in a murine system, and using a subline resistant to 
H-2 induction they provided evidence that the increase in experimental metastatic 
potential was due to the increase in H-2 expression associated with TNFa treatment. 
This study determined that in vitro treatment of A375 melanoma cells with TNFa did 
203 
not alter MHe expression or experimental metastatic potential in nude mice, therefore 
confirming the study of Lollini et al. (1990) but in a human xenograft model. The 
study by Bani eta!. (1991) involved analysis of the role ofIL-1 in the augmentation of 
experimental metastasis due to increased endothelial cell-tumor cell interactions caused 
by endothelial cell activation by IL-l. A more comprehensive study by Burrows et al. 
(1991) investigated the effect of melanoma cell secretion of IL-l on melanoma-
endothelial cell adhesive interactions, but did not investigate modulation of 
experimental metastatic potential. These two studies do not address the question of the 
effect of TNFa treatment on experimental metastasis but rather that of the effect of a 
cytokine with a similar spectrum of activities to TNFa (IL-l) on endothelial cells and 
their role in metastasis. Studies by Malik et al. (1989; 1990) provide evidence for the 
role of TNFa in the invasion and metastasis of ovarian cancer cells in nude mice. 
The differences observed in gelatinase modulation by the cytokines TNFa, IL-l 
and TGFI3 may possibly be explained by examining the differing promoter sequences 
of the two gelatinase genes. TNFa and IL-l have been shown to induce expression of 
c-fos and c-jun the components of the transcription factor AP-l (Lin and Vilcek, 1987; 
Conca et a!., 1989). AP-l is capable of stimulating gene expression following binding 
to TRE sequences in their promoter elements (Angel et al., 1981). The 92 kDa 
gelatinase promoter contains 2 TRE motifs but the 72 kDa gelatinase lacks such a 
sequence (Huh tala et al., 1990; 1991). Furthermore, the 92 kDa gelatinase promoter 
contains a TGFI3 inhibitory element (TIE), the 72 kDa gelatinase again does not 
contain this motif (Huhtala et aI., 1990; 1991). 
In the interstitial collagenase promoter there is a TPA oncogene responsive unit 
(TORU), composed of a TRE motif and a PEA3 binding sequence which act together 
to regulate the level of expression of the enzyme. If only the AP-l binding motif is 
occupied, basal expression of the enzyme results, but if both sites are fllled, maximal 
transcription occurs (Gutman and Wasylyk, 1990). It is possible that the AP-l 
binding sites and the TIE motif are acting in such a way as to regulate 92 kDa 
gelatinase gene transcription. Alternatively, rather than a direct effect of TGFI3 on 
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proteinIDNA binding, TGP13 may stimulate the de novo production of a factor which 
is capable of binding at a site in the promoter other than the TIE motif. Interestingly, 
the 92 kDa gelatinase promoter contains an Spi-l binding motif (5' GAGGAA 3') 
(Goebl, 1990) at -536 to -542 position 5' to the transcriptional start site (personal 
observation), which is one nucleic acid away from the 5' TRE sequence; it is possible 
that these two sequences may act together to regulate enzyme expression. The putative 
oncogene Spi-l has been reported to produce the PU-l transcription factor which may 
act as a lymphoid· specific enhancer, which has been detected in macrophage and B· 
cell but not in T·lymphocyte cell lines (review: Goebl, 1990). In addition, it is a 
member of the ets transcription factor family and may be able to bind to PU boxes in a 
similar way to that of the oncogene c·ets-l binding to PEA3 sites (Goebl, 1990). 
Synergy between TNFn and TGF13 has previously been observed in the induction of 
monocytic differentiation of the human promyelocytic leukemia cell line HL-60 (De 
Benedetti et al., 1990); furthermore, the induction of a 94 kDa gelatinase has been 
reported to occur during HL-60 differentiation (Davis and Martin, 1990); the role of 
Spi-l in this event has not been determined. 
Since the 72 kDa gelatinase lacks TRE sequences, it is not surprising that it is 
refractory to the action of AP-l inducing cytokines. However, the constitutive 
expression of the 72 kDa gelatinase by all melanoma cell cultures studied to date may 
indicate that melanomas, as a tumor type, either have a tumor specific transcription 
factor stimulating gelatinase expression, or have lost a constitutively expressed 
inhibitory factor. Further studies are needed to elucidate the exact mechanism of 
transcriptional regulation of the different gelatinases. 
Whilst all melanoma cell cultures studied expressed the 72 kDa progelatinase, only 
a proportion of them expressed the 92 kDa progelatinase. A recent report by Burrows 
et al. (1991) showed that high levels ofICAM-l expression on melanomas was due to 
endogenous ll..-1 production by the tumor cells, and a number of the cell lines used in 
the present study were also used in the study of Burrows et al. (1991). It will be 
interesting to determine if expression of the 92 kDa gelatinase by DX3 (a cell line 
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shown by Burrows et al. (1991) to secrete IL-1 and in this study to express 92 kDa 
progelatinase) can be inhibited by anti-IL-1 antibodies. Cell lines shown not to secrete 
ll..-1 (Burrows et al., 1991) were A375 and SK23, however, both A375 and SK23 
failed to express 92 kDa progelatinase at a detectable level. This study has not 
investigated the expression of cytokines by melanoma cell cultures, but further studies 
may address the expression of cytokines by melanoma cells and the modulation of 
tumor derived cytokine expression by the addition of exogenous cytokines. The 
production of cytokines such as TNFa and ll...-1 may profoundly affect the ability of a 
melanoma cells to metastasise, due to both autocrine effects and the influence of these 
cytokines on host cells such as endothelial cells. 
The studies in this thesis attempting to identify potential new prognosic indicators 
for uveal melanoma were: 
(i) analysis of the role of ploidy in metastatic spread. 
(ii) cytogenetic analysis of uveal melanoma tissue. 
(iii) studies involving the expression of proteinases such as gelatinases and 
, 
plasminogen activators by uveal melanomas. 
Analysis of tumor cell karyotypes has shown that cells exhibit increasingly altered 
karyotypes and ploidy values, as they progress from benign to malignant neoplasms 
(Yunis, 1983; Nowell, 1989). Therefore, as the tumor progresses it should exhibit an 
increased rate of genetic mutation, since cellular homeostatic mechanisms are likely to 
become altered or inactivated. Experimental evidence for this was provided by Cifone 
and Fidler (1982) who showed that highly metastatic cells were both phenotypically 
and genotypically more unstable than non-metastatic cells. In contrast, this study 
found that the majority of the tumors studied were diploid, and it was in this group of 
tumors that deaths due to metastasis occurred rather than in the aneuploid or tetraploid 
groups of tumors. Fidler and Talmadge (1986) demonstrated that a single tumor cell 
has the ability to form a metastatic lesion, and whilst the majority of tumor cells within 
a tumor were diploid, it is possible that a minor sub-population of tumor cells may be 
present and have a higher metastatic potential and associated alterations in ploidy 
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values. It is these tumor cells that may escape from the primary tumor mass and form 
the metastases. Unfortunately metastatic deposits were not available for analysis, so 
this hypothesis could not be proved. It is possible that this subclone, whilst it is 
adapted for invasion and metastasis, may not achieve dominance within the tumor due 
to growth inhibitory interactions (Kerbel et al., 1984). 
The observation that the uveal melanoma patients who died of metastatic disease 
all had tumors which had high numbers of cells, which were undergoing cell division, 
has important implications for invasion. Theories of how cells invade have included 
mechanical explanations (Eaves, 1973), which suggest that invasion may be 
accomplished solely by the build up of pressure due to tumor growth, which will 
eventually allow the tumor to force its way through the extracellular matrix and into 
the newly available tissue space. However, later theories included cyto-migration as 
an additional factor (Strauli and Haemerli, 1984), and finally active degradation of 
extracellular matrix (Tryggvason et al., 1987). It is reasonable to accept that such a 
combination of theories could explain tumor invasion. A high proliferation rate may be 
a basic requirement for tumor invasion and as such it may be responsible for certain 
forms of tumor invasion, especially when the tumor does not express degradative 
enzymes. However, if degradative enzymes are expressed by such tumors they may 
increase the rate of invasion. Furthermore, the products of matrix degradation have 
been shown to be chemotactic for tumor cells (Terranova et al., 1989), and as such 
may augment tumor invasion into the surrounding stroma by providing a strong 
chemotactic signal for the tumor cells to migrate to the periphery of the tumor, and into 
the surrounding stroma. The role of degradative enzymes in tumor invasion may be 
more complex than at first thought, due to the effects of both the enzymes and their 
inhibitors on host cell behavior (lnyang and Tobelern, 1990; Takigawa et al., 1990). 
Many of these studies presented here were possible due to the development of a 
short term in vitro culture system for uveal melanoma. Whilst a protocol for cell 
growth had been previously described by Albert et al. (1984), the media requirements 
were expensive and not feasible for the present study. Whilst the culture system used 
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failed to maintain cells in vitro for extended periods of time, it is possible to grow cell 
cultures for periods of 2-3 months and up to five in vitro passages. This provides 
sufficient uveal melanoma cells to perfonn selected experiments. Cytogenetic analysis 
of uveal melanoma cell cultures was performed at a passage level equal to or later than 
the cells used in other experiments, so verifying the cells as abnonnal (Sisley et al., 
1990; Sisley et al .• 1992 in press). A major problem in the continuing culture of uveal 
melanomas was the poor attachment of the cells following sub-culture. Although 
tumor cells may attach directly to plastic, such binding is generally considered to be 
non-physiological and cannot be disrupted by the agents commonly used in cell 
culture. Rather cells are considered to attach to matrix factors present in the serum or 
to factors produced by themselves (Review: Yamada. 1983). If we speculate that 
uveal melanomas lack expression or display reduced levels of expression of the 
receptors capable of binding to these matrix components. this may. in part. explain 
their site specific metastasis as a negative selection event. Whilst it is possible that 
liver associated extracellular matrix components or cell types express adhesion 
, 
receptors which allow specific attachment of uveal melanoma cells at this site. it is also 
possible that becf-use the liver does not have a basement membrane layer (Martinez-
Hernandez, 1984) it does not impede the extravasation of uveal melanoma cells as 
other sites may. In contrast to other organs the liver has a loosely organised basement 
membrane-like matrix which is found in the space of Disse and allows the hepatocyte 
direct contact with the blood plasma. This irregular organisation of extracellular matrix 
contains collagen type III (Geerts et al., 1986) and fibronectin (Martinez-Hernandez, 
1984) in addition to classic basement membrane components such as collagen type IV 
(Martinez-Hernandez, 1984), laminin (Maher et al., 1988) and heparin sulphate 
proteoglycan (Friedman et al., 1985) Recently a novel heparan sulphate proteoglycan 
has been reported to be present exclusively in liver extracellular matrix (Soroka and 
Farquhar. 1991). It is interesting that type m collagen which is not normally present 
in basement membranes has been detected in Bruch's membrane and the space of 
Disse (Geerts et al., 1988). Adhesion to this collagen type may be responsible for 
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arrest in the liver, since it is possible that the tumor cells may express receptors for 
this collagen type due to their previous close proximity in the eye to Bruch's 
membrane and the sclera (Zimmerman, 1985). However, at present little is known 
about the adhesion molecules expressed by uveal melanomas. Further studies would 
investigate this possibility, possibly using cryostat sections of the liver, and other 
organs to determine if specific adhesion occurs. Subsequent studies may involve the 
identification of cell-type specific or matrix specific binding. Alternatively, it would be 
informative to study in vitro adhesion molecule expression on uveal melanomas using 
specific anti-sera to adhesion molecules (such studies are currently underway in 
collaboration with Dr. I. R. Hart at the Imperial Cancer Research Fund, London). 
Complementary studies aiming to identify growth factors and cytokines capable of 
modulating uveal melanoma cell growth may be undertaken using tritiated thymidine 
incorporation and flow cytometry, as a measure of cell proliferation, Identification of 
factors capable of increasing the growth rate of uveal melanomas in vitro may help in 
determining factors important in vivo, especially if these factors were present at higher 
< 
concentrations in the liver (Sargent et al., 1988). This would offer a possible 
explanation for the site specific metastasis associated with this tumor type, that of 
growth potentiating factors present in the liver. 
Increasing genetic abnormality is associated with a tumor's progression from a 
benign to malignant neoplasm. Since few cytogenetic abnormalities were detected in 
uveal melanoma cells, they would be expected to have a low metastatic propensity. 
Only three patients out of forty nine patients have died of metastatic disease to date: 
and it has not been possible to correlate cytogenetic analysis with the development of 
metastatic disease. Whilst both cutaneous and uveal melanomas are melanocytic 
tumors, abnormalities of chromosomes 3 and 8 are rarely observed in cutaneous 
neoplasms (Limon et al., 1988; Grammatico et al., 1990) but appear to be common in 
uveal melanoma (Sisley et al., 1990; 1992 in press), thus indicating that uveal 
melanomas are genotypically distinct from their supposed cutaneous counterparts. In 
addition, these abnormalities appear to be a characteristic of tumors arising in the 
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ciliary body. Only one choroidal tumor had trisomy of chromosome 8 and no 
corresponding abnormality of chromosome 3 (Sisley et al., 1990; 1992 in press). 
Monosomy of chromosome 3 and i (8q) may be uniquely associated with a subset of 
uveal melanomas. Whilst there are a number of phenotypic similarities between 
cutaneous and uveal melanomas there are also significant genetic changes observed in 
uveal melanoma that have so far not been detected in cutaneous melanoma. These 
specific changes may, in some way, be linked with the characteristic pattern of 
metastasis observed in uveal melanoma. 
In common with cutaneous melanomas, uveal melanomas express tissue 
plasminogen activator as the major plasminogen activator species detected. 
Interestingly, a plasminogen activator with an apparent molecular weight similar to 
that described for urokinase type plasminogen activator was also expressed by cell 
cultures established from highly aggressive tumors. Quax et al. (1991) reported that 
expression of tissue and urokinase plasminogen activator correlated with 
spontaneously metastasis in nude mice. The in vitro levels of active enzyme were 10 
< 
fold lower than those secreted by the series of cutaneous melanomas studied. Whilst 
this observation may be due to incresed expression of PA by the cutaneous 
melanomas, equally the increased expression of PA inhibitors by uveal melanomas 
may be responsible. Although a plasminogen activator with a molecular weight 
comparable to urokinase was detected using casein/plasminogen zymography, no 
activity was detectable in the conditioned medium (chapter 6). Urokinase is thought to 
be more involved in tissue remodelling than tissue plasminogen activator, and as such 
has a receptor allowing the enzyme to remain active following binding to the cell. It is 
possible that if celllysates were assayed urokinase activity may well be detectable. 
These studies have shown that aggressive uveal melanomas express a number of 
degradative enzyme species which may act synergistically to degrade the components 
of the sclera and in so doing potentiate metastasis (Cottam et al., 1992 in press). 
Further studies to determine the in situ expression at the site of scleral invasion 
would be informative, and provide evidence for the production of these enzymes in 
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the patient. Therapeutic manipulation of the enzymes or the inhibitors may prove 
beneficial in the treatment of invasive neoplasms, however, localisation of the 
modulators at the site of the tumor may prove difficult A systemic reduction of 
proteinases or an increase in the expression of proteinase inhibitors would be 
disruptive to a number of physiological processes, for example, systemic decreases in 
tissue-type plasminogen activator may adversely affect fibrinolysis and wound healing 
and a reduction in the expression of gelatinase may affect wound healing, ovulation, 
uterine and breast involution (Mullins and Rohrlich, 1983). The role of these enzymes 
in physiology should be investigated extensively before therapeutic modulation is 
attempted. 
The major fmdings of the work in this thesis can be summarised as follows: 
Although uveal and cutaneous melanoma display different cytogenetic changes, in 
vitro, cell cultures of both melanomas express similar patterns of degradative 
enzymes, the 72 and 92 kDa gelatinases and tissue plasminogen activator. Expression 
of the 92 kDa gelatinase was found to be modulated in both melanoma types by the 
, 
cytokine TNFa and TGF13 was found to synergise with TNFa in the induction of the 
92 kDa gelatinase in some melanoma cell cultures. The uveal melanomas which 
expressed the highest levels of tissue plasminogen activator activity c<rexpressed the 
92 kDa gelatinase and were found to have invaded the sclera, suggesting a synergistic 
action between these enzyme families in the process of invasion. 
The related cutaneous melanoma cell lines A375 and A375/NUPRI showed 
different levels of experimental metastatic potential, but expressed similar levels of a 
number of melanoma associated markers, MHC class I and n and lCAM-I, and had 
similar proliferation rates in vitro and doubling times in vivo. ICAM-I expression was 
increased by TNFa and IL-l but MHC expression was unaltered. Differences in the 
magnitude of modulation were observed between the two cell lines, A375/NUPRI 
showing a greater response than A375. The proliferation of both cell lines was 
decreased following stimulation with both TNFa and IL-l. In vitro pretreatment of 
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A375 cell cultures with TNFcx prior to tail vein injection did not alter the extent of 
lung colonisation. 
Further analysis of the metastatic process aiming to reveal the underlying 
molecular mechanisms of metastasis will be likely to involve the study of matrix 
metalloproteinases and plasminogen activators. No doubt, the roles of these molecules 
and their inhibitors in this process will be extended to include their actions upon 
tumor and host cell behavior and the effects upon cell differentiation caused by 
alterations in the extracellular matrix induced by their action. 
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List of Abbreviations 
A, abdominal organs 
Ad-2 EIA, adenovirus 2 EIA 
AP-I, activator protein-l 
AP-2 activator protein-2 
Arg, , arginine 
BSA , bovine serum albumin 
CaCh calcium chloride 
cAMP, cyclic adenosine monophosphate 
CAT, chloramphenicol acetyl transferase 
cDNA, complementary deoxyribonucleic acid 
c-fos, cellular fos oncogene 
c-Ha-ras, cellular harvey ras oncogene 
c-myc, cellular myc oncogene 
Co, carbon dioxide 
C V: coefficient of variation 
del, deletion of 
der, derived chromosome 
DMSO, dimethyl sulphoxide 
DNA, deoxyribonucleic Acid 
DTNB, 5,5'-Dithiobis-(2-nitrobenzoic Acid) 
E-64. trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane 
EDT A, ethylenediaminetetraacetic acid 
EGF, epidermal growth factor 
Facs, fluorescence activated cell sorting 
FCS. fetal calf serum 
aFG F, acidic fibroblast growth factor 
bFGF, basic Fibroblast growth factor 
FITC. fluorescein-isothiocyanate 
GM-CSF, granulocyte macrophage colony-stimulating factor 
HCI , hydrochloric acid 
Hg, mercury 
i8q isochromosome 8q 
ICAM-I intercellular adhesion molecule-l 
i. d. intradermal 
IFNa interferon alpha 
IFNy interferon gamma 
IGF 1 insulin like growth factor 1 
IGF 2 insulin like growth factor 2 
I-KB inbibitor of NF-KB 
IL-l(a./(3) interleukin-l (aJphalbeta) 
IL-2 interleukin-2 
11.-4 interleukin-4 
IL-6 interleukin-6 
i. m. intramuscular 
IMP inhibitor of metalloproteinases 
IU international units 
i. v. intravenous 
KCL pottasium Chloride 
kDa kilodalton 
L lungs 
LAK lymphokine activated killer 
lb/sq in pounds per square inch 
LFA-l lymphocyte function antigen-l 
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LFA-3 
LIMP 
MBq 
MIlC 
MMP 
MoAb 
Mr 
mRNA 
Na 
NaC! 
NaOH 
NaSCN 
NBCS 
NO 
NEAA 
Net-Mal 
NF-lCB 
NIBSC 
NT 
PA 
p-APMA 
PBS 
PEA3 
PC 
POOP 
PI 
PMA 
PMN 
PMSP 
proMMP 
Pump-l 
pymiddle T 
RPM! 1640 
RNA 
rTIMP 
S 
s.c. 
SCID 
SD 
SDS 
SpI 
SV40 
t 
TEMED 
TGF(3 
TIE 
TIMP 
TIMP-l 
TIMP-2 
TNFa 
TORU 
tPA 
TPA 
TRE 
Tris 
UK 
lymphocyte function antigen-3 
large inhibitor of metalloproteinases 
megabequerels 
major histocompatability complex 
matrix metalloproteinase 
monoclonal antibody 
molecular weight 
messenger ribonucleic acid 
not applicable 
sodium chloride 
sodium hydroxide 
sodium thiocyanate 
new born calf serum 
not done 
non-essential amino acids 
n-Ethylmaleimide 
nuclear factor lCB 
National Institute for Biological Standards and Control 
not tested 
plasminogen activator 
para-aminophenylmercuric acetate 
phosphate buffered saline 
PEA3 oncogene 
personal computer 
platelet derived growth factor 
propidium iodide 
12-O-tetradecanoyl-phorbol-13-acetate 
polymorphonuclear neutrophil 
phenylmethylsulfonyl fluoride 
promatrix metalloproteinase (latent meta1loproteinase) 
punctuated metalloproteinase-I ' 
polyoma middle T oncogene 
Roswell Park Memorial Institute 1640 tissue culture medium 
ribonucleic Acid 
recombinant tissue inhibitor of metalloproteinases 
skin 
subcutaneous 
severe combined immunodeficiency 
standard deviation 
sodium dodecyl sulfate 
transcription factor Sp I 
simian virus 40 
translocation 
N. N. N. N-Tetramethyle4hylenediamine 
transforming growth factor beta 
transforming growth factor beta inhibitory element 
tissue inhibitor of meta1loproteinases 
tissue inhibitor of metalloproteinases type I 
tissue inhibitor of metalloproteinases type 2 
tumor necrosis factor alpha 
TPA and oncogene responsive unit 
tissue-type plasminogen activator 
12-O-tetradecanoy lphorbol I3-acetate 
TP A response element 
tris[hydroxy methyl]amino-methane 
urokinase-type plasminogen activator 
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Val 
VIA 
v-mos 
v-raf 
v-src 
v-myc 
valine 
very late activation antigen 
viral mos oncogene 
viral raf oncogene 
viral src oncogene 
viral myc oncogene 
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